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There are 350 million chronic carriers of the hepatitis B virus (HBV) worldwide who 
face increased risks of developing liver diseases such as cirrhosis and hepatocellular 
carcinoma (HCC). The severity of disease is associated with high replication 
efficiency of HBV, which is in turn dependent on the establishment of functional host-
pathogen interactions, as factors such as HBV pathogen genotype and host factor 
variability are predictors of infection outcomes. HBV infection is currently treated by 
boosting the immune system to aid viral clearance or inhibition of HBV polymerase 
function with nucleoside or nucleotide analogues. These have their limitations—the 
former is only efficacious in certain individuals while the latter have resulted in the 
generation of drug-resistant strains. Importantly, both are incapable of eliminating the 
virus. Therefore, there is a need to design novel strategies for the treatment of 
chronic HBV infection.  
The synthesis of infectious HBV particles depends on the activity of host binding 
factors regulating transcription at the HBV core promoter (HBVCP). Modulating the 
function of such transcription factors thus seems an obvious solution for combating 
HBV infection. Since infection outcomes differ greatly among individuals, it was 
hypothesized that subtle differences in these factors contribute significantly to the 
efficacy of HBV replication hence infection outcome.  
To understand how transcription at the HBVCP may be differentially regulated, a 
screen was performed at the HBVCP for binding factors in four cell lines whose 
ability to support HBV replication differ. The results show that only a handful of 
described host factors critically affect transcription at the HBVCP, including SP1, 
hnRNP K and HNF1, all of which serve vital functions in cells hence renders them 
unfavourable as therapeutic targets. The screen also discovered a novel binding site 





and this was subsequently shown to bind poly (ADP-ribose) polymerase 1 (PARP1), 
an enzyme involved in DNA repair and transcriptional regulation. Not only was 
PARP1 important for transcriptional activation at the HBVCP, its enzymatic activity 
was found to inversely correlate with the efficiency of HBV replication. This led to the 
discovery that a polymorphic variant with low enzymatic activity often expressed in 
HBV endemic areas accounts for high HBV replication efficiency. Since the ablation 
of PARP1 activity is not known to be lethal, PARP1 is a favourable therapeutic 
candidate for the treatment of chronic HBV infection.  
Even though PARP1 is known to be a transcription factor, its recognition motif has 
not been defined. This was resolved by studying how individual nucleotides 
contribute to transcription at the PARP1 binding site of the HBVCP. Surprisingly, in 
contrast to enzymatic activation by binding DNA strand-breaks during DNA repair, 
binding the PARP1 motif results in enzymatic inhibition. Exogenous expression of the 
PARP1 binding motif was sufficient to reduce cellular PARP1 enzymatic activity, 
leading to impaired DNA repair hence cytotoxicity with DNA damage induction. This 
was reproducible with replicative HBV, providing a mechanism for the association of 
high viral load and DNA damage accumulation leading to HCC. The novel 
phenomenon achieved by the PARP1 motif puts it in a new class of PARP1 inhibitors 
with therapeutic potential. 
This is the first report that PARP1 is an important transcriptional regulator in HBV 
replication. In addition, by studying the HBVCP, the PARP1 consensus binding motif 
was uncovered. The PARP1 binding motif was further demonstrated to inhibit PARP1 
enzymatic activity. Not only is this useful for cancer therapy, it also providing insights 





List of Tables 
 Title Page 
1 HBV products and their functions 6 
2 Treatment of chronic HBV infection 11 
3 PARP1 associated  diseases and outcomes of enzymatic inhibition 25 
4 Properties of liver-derived cell lines used 42 
5 Guidelines for indentifying therapeutic targets that bind the HBVCP 53 
6 Nucleotide positions critical for PARP1 motif binding 161 
7 Comparing the PARP1 binding motif and general PARP inhibitors 163 
8 List of RT-PCR primers 175 
9 List of primers for generating HBVCP deletion mutants 177 
10 Sequences of cloning primers 179 
11 Primer sequences for detecting HBV cccDNA and HBV transcripts 183 
12 List of 20bp DNA duplexes used in histone H1 modification assays 184 





List of Figures 
 Title Page 
1 HBV envelope proteins expression and secretion 37 
2 Generation of replicative HBV with the HBV-RFP construct 41 
3 HBV transcripts may only be expressed in certain cell lines 43 
4 Differential capabilities in expressing different HBV products 45 
5 Effect of URR deletions on the HBV core promoter 55 
6 Prediction of transcription factors binding to URR17 62 
7 Expression of HNF4α in different cell lines 66 
8 HNF4α is not the URR17-binder 69 
9 Oct-1 does not bind URR17 sequence 72 
10 PARP1 is novel transcriptional activator at HBV core promoter 74 
11 PARP1 binds the HBV core promoter in a sequence dependent manner 76 
12 PARP1 regulates transcription at HBVCP in motif dependent manner 77 
13 PARP1 regulates pgRNA and pcRNA synthesis 81 
14 PARP1 expression and knockdown 87 
15 Effect of PARP1 knockdown on HBV replication 89 
16 PARP1 inhibition enhances PARP1 dependent transcription 92 
17 PARP1 inhibition increase HBV replication 94 
18 PARP1 is expressed in all cell lines used 95 
19 HepG2 has low endogenous PARP1 enzymatic activity 96 
20 HepG2 and Huh-6 express the V762A mutant PARP1 98 
21 The V762A polymorphism and PARP1 function 100 
22 The PARP1 V762A polymorphism supports HBV replication 102 
23 Allelic frequency of the V762A SNP extracted from dbSNP 103 
24 The PARP1 recognition motif 110 
25 Confirmation of the PARP1 motif in different cell lines 113 




List of Figures 
 Title Page 
26 Describing validated PARP1 binding sites with novel PARP1 motif 114 
27 The PARP1 binding site is highly conserved across HBV genotypes 116 
28 Inhibition of PARP1 enzymatic activity by binding PARP1 motif 118 
29 HBV PARP1 binding motif impairs DNA damage repair 121 
30 PARP1 binding motif alone sensitizes cells to induced DNA damage 124 
31 HBx protein does not impair DNA damage repair 125 
32 Sensitivity to DNA damage with PARP1 motif is PARP1 specific 127 
33 Full-length genome of HBV genotype C results in greater DNA damage 130 
34 HBV genotype C has additional copy of PARP1 binding motif 132 
35 Increased apoptosis with HBV replication by induced DNA damage 135 
36 HBV mediated sensitization to etoposide induced cell death in Huh-7 136 
37 PARP1 motif enhances cytotoxicity by DNA damage inducers 137 
38 Enhanced apoptosis by PARP1 motif is PARP1 dependent 138 
39 Comparing the effect of PARP1 motif with clinical PARP inhibitors 142 




List of Illustrations 
 Title Page 
1 Variable outcome of HBV infection 2 
2 Worldwide distribution of HBV genotypes and severity of disease 3 
3 The replicative cycle of HBV with emphasis on genomic replication 5 
4 Organization of the HBV genome and transcripts 7 
5 The HBV core promoter 9 
6 Factors contributing to effective HBV replication 11 
7 Functional domains of PARP1 13 
8 PARP1 enzymatic activity 14 
9 PARP1 modification, activity modulation and its effects 15 
10 Role of PARP1 in DNA repair 19 
11 PARP1 regulates gene expression in many ways 23 
12 PARP1 inhibition and effects on disease states 27 
13 The replicative HBV construct 36 
14 Described binders of the HBVCP upper regulatory region 51 
15 The functional elements of the HBVCP basal core promoter 79 
16 PARP1 enzymatic activity shuts down transcription at HBVCP 149 
17 Potential roles of PARP1 enzymatic activity in HBV replication 154 
18 Rhythmic cycling of PARP1 enzymatic activity and HBV replication 156 
19 PARP1 binding motif as a novel class of PARP1 inhibitors 162 
20 Comparing therapeutic strategies against HBV 166 
21 Factors contributing to variable outcomes of HBV infection 169 
22 PARP1 V762A polymorphism, HBV replication and HCC 171 
23 Generation of HBVCP deletion constructs 176 





LIST OF ABBREVIATIONS 
 
3-AB  3-aminobenzamide 
BCP  Basal Core Promoter 
BER  Base-excision repair 
cccDNA Covalently closed circular DNA 
HBs  Hepatitis B virus surface antigens 
HBV  Hepatitis B Virus 
HBVCP HBV Core Promoter 
HCC  Hepatocellular carcinoma 
HNF4α Hepatocyte Nuclear Factor 4α 
hnRNP K Heterogeneous nuclear ribonucleoprotein K 
NMU  N-nitroso-N-methylurea 
NRE  Negative Regulatory Element 
PAR  Polymers of ADP-ribose  
PARP1 Poly (ADP-ribose) polymerase 1 
pgRNA Pre-genomic RNA 
rcDNA  Relaxed circular DNA 
RFP  Red Fluorescent Protein 
SNP  Single Nucleotide Polymorphism 
TF  Transcription Factor 






















1.1 THE HEPATITIS B VIRUS 
 
The hepatitis B virus (HBV) is a small virus from the Hepadnaviridae family that has 
infected a third of the world’s population1 (Illustration 1). The outcomes of primary 
infection are variable. While 95% of infections may be resolved and lead to recovery, 
0.5% of infections lead to fulminant hepatitis hence death. The remaining 350 million 
people who survive acute infection become chronic carriers of HBV, and unless they 
eventually recover, would face increasing risks of developing liver diseases such as 
cirrhosis and hepatocellular carcinoma (HCC) with prolonged infection. Importantly, 
the prognosis of HCC is poor as the 5-year survival rate is less than 5%. Amongst 
chronic carriers, the risk of developing HCC is much higher in males compared to 
females after accounting for confounding effects such as alcoholism2, 3. The varied 
outcomes of HBV infection indicate the multi-factorial nature of efficient persistent 




Illustration 1 Variable outcomes of HBV infection. Percentages of infected 
populations are indicated1. 
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where genotypes B and C predominate in states with rich Asian migrant presence 
while genotypes A and D are found in the Northern, Eastern and Southern states. 
Curiously, besides the high likelihood of infection with HBV genotype C, being of 
Asian descent is also a marker for poor response to hepatitis B treatment14. 
 
HBV Replication 
HBV is a small DNA virus which preferentially replicates in host hepatocytes15. The 
infectious 42nm HBV particle contains a core particle that is enveloped by a 
membrane containing three different types of surface antigens15-20. The core particle 
is made up of a partially double-stranded DNA (relaxed circular DNA, rcDNA) 
covalently attached to its polymerase (Illustration 3). The mechanism in which the 
virus enters a host cell, usually a hepatocyte, is currently unknown. Upon host cell 
entry, the rcDNA is released from the core particle into the nucleus and repaired by a 
mechanism yet to be defined to form covalently closed circular DNA (cccDNA) which 
can persist in the nucleus of a cell for extended periods of time even after “resolution” 
of infection21-24. This cccDNA is the template for the synthesis of all HBV transcripts, 
of which the most important is the pre-genomic RNA (pgRNA). pgRNA is a multi-
functional RNA template, acting not only as the mRNA template for the synthesis of 
HBV capsid proteins (HBc) as well as the HBV polymerase, but is itself also 
encapsidated and used as a precursor for the reverse transcription of the (-) strand of 
viral rcDNA25-27 in new core particles by the HBV polymerase. During rcDNA (-) 
strand synthesis, the encapsidated pgRNA is gradually degraded by the RNase H 
activity of the viral polymerase, leaving behind an RNA primer for the (+) strand 
synthesis based on the sequence of the completed (-) strand . The entire process of 
rcDNA synthesis can occur as the core particle is enveloped and ceases when the 
virion is secreted, accounting for the partially double-stranded genome. To maintain 
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 Depending on HBV genotype, HBV cccDNA is 3215bp to 3221bp in size, and 
sufficient to produce all viral products (Table 1), not all of which are essential to HBV 
replication or the components of the infectious virion. For example, HBx is produced 
such minute amounts that it is often not detectable, although it is reportedly 
associated with the development of HCC29-35. The secreted HBe antigen is 
associated with immune tolerance enabling stealthy but efficient HBV replication 
hence increased risk of developing HCC36-38. 
 
Table 1 HBV products and their functions 





Binds rcDNA Polymerase pgRNA z Synthesize rcDNA 
Capsid HBc pgRNA z Forms nucleocapsid 
Envelope 
proteins 
HBs (S) 2.1kb mRNA z Decoy sequestering anti-HBs 
Pre-S2 (M)  2.4kb mRNA z Unknown 
Pre-S1 (L) 2.4kb mRNA z Essential for viral envelope z HBV secretion 
Secreted HBe pcRNA z Regulates host cell pathways 
Host cell HBx 0.7kb mRNA z Regulates host cell pathways
29, 
33, 34, 39-42 
 
To accommodate the generation of at least 7 distinct protein products in the tiny 
genome, their coding sequences overlap extensively16, 19, 25, 43, 44 such that all 
nucleotides in the HBV genome are part of at least one coding sequence for a 
functional protein (Illustration 4). The compact genome contains 4 promoter regions 
and a single poly-adenylation (poly-A) signal, thus all HBV transcripts vary in size 
depending on the location of the promoter hence transcription initiation start site. 
Importantly, pgRNA initiated at the core promoter is in close proximity and upstream 
of the poly-A signal. Thus, to encompass the entire genome, pgRNA is synthesized 
such that at the first instance of encountering the poly-A signal it is read-through, 
resulting in pgRNA at 3.5kb being longer than the 3.2kbp genome. The redundancy 
of the core promoter sequence in the pgRNA is important for the generation of RNA 
secondary and tertiary structures (Illustration 3) that enable encapsidation45, 46 and 





Interestingly, this full-length transcript also codes for the viral polymerase and HBc 
capsid protein, making it convenient for the synthesis and assembly of the core 
particle. Another full-length (3.5kb) transcript pcRNA that codes for HBe is also 




Illustration 4 Organization of the HBV genome and transcripts. Promoter regions are 
highlighted in boxes. Grey lines indicate mRNA, with the coloured circle indicating the 
5’ cap and the arrowhead is the poly-A signal. pgRNA is indicated in black. X—X 
promoter; CP—Core promoter; S1—pre-S1 promoter; S2—pre-S2 promoter. 
 
Since pgRNA is transcriptionally controlled at the HBV core promoter (HBVCP), 
variability of properties in critical host factors that bind the HBVCP would affect the 
efficiency of pgRNA synthesis. Furthermore, preventing the activity of such factors 
required for pgRNA synthesis would shut down HBV replication and prevent disease 
progression. To achieve this, a better understanding of the host factors important for 


















The HBV Core Promoter 
The HBV core promoter54, 55 has been described to comprise of two major elements, 
the 5’ upper regulatory region (URR) and the 3’ basal core promoter (BCP) 
(Illustration 5). The BCP contains basal elements commonly found in eukaryotic 
promoters needed for basal transcriptional activity. It is therefore the site where RNA 
polymerase II would bind to, bringing about basal amounts of pgRNA synthesis. It 
possesses four TATA-like boxes56, of which the one at the 3’ end is used for the 
initiation of pgRNA54. Transcription of pgRNA and pcRNA may be uncoupled50-52, 54-57 
such that the three 5’ TATA-like boxes are used for the pcRNA synthesis hence 
accounting for pcRNA being of inconsistent length, all of which are slightly longer 
than pgRNA. How these TATA-like boxes may be differentially utilized and 
distinguished from the 3’ end TATA-like box for the initiation of pgRNA is not well-
understood. An element known as DR1 (Direct Repeat 1) involved in the synthesis of 
rcDNA is also found in the BCP19, 25-28. 
The URR is the region best studied for its role in regulating the activity of the BCP. 
Most host factors reported to be important for transcriptional activity at the HBVCP 
bind to the URR, including HNF4α58-60, HNF161, 62, HNF360, 63, 64, c/EBPα/β65, 66 and 
SP167, 68. While the URR is often referred to as conferring “liver-specificity” for HBV 
replication as it is associated “liver-specific” transcription factors, this description is 
not particularly accurate. Many of the “liver-specific” transcription factors such as 
HNF4α and HNF1 are also known to play vital roles in other tissues such as the 
pancreas, where their altered activities have been associated with diseases such as 
maturity onset diabetes of the young (MODY)69-73 and their deletion in mice is 
embryonic lethal74. Furthermore, ubiquitous transcription factors such as SP1 have 
also been reported to bind the URR specifically, enabling the transcription of pgRNA.  
Therefore, the reason for the preferential replication of HBV in livers remains 





development of therapeutics, as modulation of their activities would result in the 




Illustration 5 The HBV core promoter. The grey arrow indicates pcRNA initiation 
while the black arrow represents pgRNA initiation. Nucleotide positions relative to 
HBV genotype A are indicated. The relative positions of TATA-like boxes are 
indicated in circles, where the one in black is used to initiate pgRNA synthesis. 
URR—Upper Regulatory Region; BCP—Basal Core Promoter; NRE—Negative 
Regulatory Element. 
 
The URR is made up of several elements and regulatory boxes50, 54, 55, of which the 
broad classification of it being composed of an upstream negative regulatory element 
(NRE)59, 75-78 and a downstream enhancer II (En II) that partially overlaps the BCP is 
the best recognized. This suggests that host factors binding the NRE inhibit 
transcription at the HBVCP, while host factors that bind the enhancer II will result in 
enhanced transcriptional activities at the HBVCP. It is noteworthy that the effects of 
enhancer II are not restricted to the HBVCP, and can act in concert with another 

























promoters54, 55, 79. Thus, functional host-pathogen interactions at the HBVCP 
enhancer II result in efficient HBV replication. 
Most of what we know about the transcriptional regulation at the HBVCP is based on 
early studies of individual binding factors. There is a lack of update on recent 
development, and more importantly, no one has defined to what extent the described 
transcription factors are required for HBV replication. Therefore, to develop 
therapeutics aimed at preventing pgRNA synthesis, a thorough re-evaluation of the 
HBVCP to confirm the roles of host binding factors is required. 
 
Therapeutic Approaches to Treat HBV Infection 
Effective HBV replication manifests in chronic carriers as high viral load and HBV 
DNA, both of which are positively correlated with the severity of HBV associated liver 
diseases14, 80. Factors contributing to effective HBV replication include viral genotype, 
the ability of the virus to evade immunity44, 81-84, as well as the variability of host 
factors required for viral replication (Illustration 6).  
Current therapeutic strategies14, 85, 86 for hepatitis B act either by boosting host 
immunity to aid viral clearance or by inhibiting the viral polymerase with nucleoside or 
nucleotide analogues (Illustration 6 and Table 2). None are known to target the host 
factors required for pgRNA synthesis. Importantly, current therapeutic approaches 
cannot eliminate HBV and only minimize viral replication to reduce the risk of chronic 
carriers developing liver diseases. The suppressed virus can result in flares when the 
opportunity arises14, 87, 88. 
To address the problem of immune evasion, IFNα is given to stimulate the activity of 
immune cells such as cytotoxic T-cells that kill and clear infected cells14, 86. IFNα also 
induces the production of anti-viral proteins in infected cells to prevent further viral 
replication. However, as IFNα is a protein by nature, it has to be administered by 







































































































































genotypes A and B89-91. Not surprisingly, oral treatment with nucleoside or nucleotide 
analogues such as Lamivudine is eventually favoured over IFNα14. 
Nucleoside or nucleotide analogues work by competitive inhibition with intracellular 
nucleotides for the reverse transcriptase of the HBV polymerase, preventing the 
synthesis of (-) strand DNA86. Drugs such as Lamivudine are more effective in 
controlling HBV replication86. However, due to the poor proofreading capabilities of 
the HBV polymerase, prolonged therapy eventually generated resistant HBV strains 
that contained mutations within the reverse transcriptase domain92-96. This led to the 
development of several new nucleoside or nucleotide analogues such as Adefovir 
dipivoxil and Entecavir which also exhibited greater potency than Lamivudine86.  
Nevertheless, drug resistance by mutating other residues of the reverse transcriptase 
has already been reported97, 98.  As with organisms with high replication and mutation 
rates, it is apparent that targeting the viral polymerase or other viral component 
would lead to drug resistance. Therefore, new targets that prevent HBV replication 
need to be identified for the effective treatment of hepatitis B. Since transcription of 
pgRNA is the critical step for synthesis of virions, understanding how this may be 
achieved by studying host-pathogen interactions at the HBVCP would shed light on 
how HBV replication can be effectively controlled. 
 
1.2 PARP1 AND ITS FUNCTIONS 
 
PARP1 is a multi-functional protein that regulates several cellular pathways including 
DNA repair, transcription and cell death99-112. It comprises three functional domains109, 
112 (Illustration 7)—the N-terminal DNA-binding domain, a central dimerization and 
auto-modification domain, and the C-terminal catalytic domain. The two zinc fingers 
(Zn I and Zn II) located within the N-terminus have been well-characterized to bind 





been recently identified114 that functions to coordinate N-terminal DNA binding with 
C-terminal enzymatic activation115. This overlaps with the PADR1 domain, a domain 
conserved in poly (ADP-ribose) synthetases whose function is currently unknown. 
The WGR domain is another conserved amongst PARPs whose function has not 




Illustration 7 Functional domains of PARP1. Zn—Zinc-binding domains; NLS—
Nuclear localization signal; Casp—Caspase cleavage site; BRCT—BRCA1 C 
Terminus domain; Reg—Regulatory domain. 
 
PARP1 relies on its bipartite nuclear localization signal (NLS)116 within the DNA-
binding domain for entry into the nucleus where it mainly resides. Using the C-
terminal catalytic domain conserved in all PARP family members109, 112, 117, it acts as 
an enzyme that cleaves NAD+ for the ADP-ribosylation of protein acceptors thus 
modulates their activity by conferment of negative charges, in turn generating 
nicotinamide as a by-product106, 109 (Illustration 8).  
The BRCT (BRCA1 C Terminus) domain is responsible for PARP1 protein-protein 
interactions, such as with the transcription factors hnRNP K118 and Oct-1119, as well 
as for homo-dimerization. It is also required for “unfaithful” DNA repair during gene 
conversion to increase the repertoire of epitope-recognizing antibodies produced by 
maturing B-cells120. As the major acceptor of ADP-ribose121, PARP1 adds poly-(ADP-
ribose) chains (PAR) to its BRCT domain122, 123, forming extensive branching 
polymers that attract and assist the assembly of multi-protein complexes124-130. Both 
the extensive PAR chains as well as nicotinamide exert mild inhibitory effects on the 
enzymatic activity of PARP1131-137. PARP1 enzymatic activity is also modulated by 



















































































 activity is 











































Illustration 9 PARP1 modification, activity modulation and its effects. Casp—






















































































Perhaps the best studied PARP1 activator is nicked DNA. PARP1 enzymatic activity 
may also be stimulated by interacting partners such as phosphorylated ERK2144, 145. 
Post-translational modifications and interactions with inhibitory proteins add on to the 
complexity of enzymatic activity regulation. In neuronal development, the kinesin 
KIF4 inhibits PARP1 activity146 while activation of calcium dependent protein kinase 
(CaMKIIδ)124 leads to PARP1 phosphorylation and enzymatic activation, inducing 
neurogenic gene expression and nuclear export of KIF4. Mono-ADP-ribosylation by 
PARP3147 can also result in enhanced PARP1 activity hence auto-modification at 
centromeres.  
PARP1 enzymatic activity affects cellular pathways in a number of ways (Illustration 
9). With respect to chromatin remodeling, the activated PARP1 modifies and 
displaces histones H1 and H2B103, 126, 148, 149, enabling downstream reactions such as 
transcription or DNA repair to occur. With regards to transcription, poly ADP-
ribosylated transcription factors such as SP1 are repelled from DNA by the 
accumulation of negative charges117, resulting in altered transcript expression profiles. 
ADP-ribosylation of the transcription factors NFkB and p53 also results in their 
nuclear retention by preventing their association with nuclear export factors150, 151. 
Other substrates of PARP1 include Oct-1119 and hnRNP K (heterogeneous nuclear 
ribonucleoprotein K)106, 118, but the consequences of ADP-ribosylation are not yet 
characterized. The extensive PAR network on activated PARP1 is also an important 
cue for the assembly of chromatin remodeling complexes, DNA repair machinery and 
DNA damage check-point proteins such as ATM (Ataxia Telangiectasia Mutated)152. 
Importantly, PAR on auto-modified PARP1 need not be synthesized by activated 
PARP1, as PAR can be added onto PARP1 by other members of the PARP family 
such as the DNA repair enzyme PARP2. 
PARP1 can also exert its effects as an inactive enzyme. For example, acetylation of 





in transcription of its downstream targets125. This may in turn be inhibited by PARP1 
sumoylation, preventing PARP1 from playing its role as an NFkB co-activator153. 
Much less is known about active PARP1 inhibition or its effects. Nevertheless, it is 
known that nicotinamide is a mild inhibitor of enzymatic activity, making this property 
the basis of designing nicotinamide analogues for therapeutic purposes in the 
treatment of diseases with PARP1 enzymatic hyper-activation such as cancer, 
inflammation and stroke131-134, 136, 154. Nicotinamide or its analogues however do not 
act specifically on PARP1, as the PARP enzymatic domain is highly conserved 
across family members109, 112. Interestingly, treatment outcomes with PARP inhibition 
display gender specificity155. Whether this translates into gender-specific differences 
in efficiency of PARP1 dependent activity remains to be tested. 
 
The Role of PARP1 in DNA Repair 
PARP1 has been termed a guardian of the genome due to its importance in DNA 
repair156. Even though mice knockout models are viable and phenotypically normal157, 
they have increased sensitivity to DNA damaging agents such as irradiation and DNA 
alkylation, resulting in the accumulation of DNA strand breaks and high genomic 
instability158. PARP1 knockout mice haploinsufficient for other DNA repair enzymes 
such as Ku80 also develop spontaneous HCC159, providing further evidence to 
support its important role in DNA repair. PARP1 seems particularly important in 
maintaining genomic integrity in the liver, as PARP1 knockout mice develop 
spontaneous DNA mutations in the liver158, 160 and have increased liver tumour 
incidence with age compared with their wild-type counterparts160.  
PARP1 does not actively carry out DNA repair. Instead, it acts as a DNA nick sensor 
(Illustration 10), binding both DNA single and double-strand breaks using its zinc 
fingers I or II to enhance enzymatic activity for auto-modification. DNA strand breaks 





strand-break inducers such as etoposide and bleomycin161. Strand breaks may also 
be in the form of gaps produced from stalled replication forks127. During base excision 
repair, alkylated or modified bases are removed to result in the formation of DNA 
strand breaks, hence alkylating agents such as NMU (N-nitroso-N-methylurea) and 
DNA cross-linkers such as cisplatins can also result in the activation of PARP1. Thus, 
PARP1 is a key regulator of DNA repair as several types of DNA lesions to be 
rectified depend on its activity. DNA strand-breaks need not be formed as a result of 
DNA damage, but may be purposefully induced to enhance genetic diversity required 
in immune processes or meiotic events. In antibody class-switching, DNA 
recombination induces strand-breaks that require PARP1 activity for resolution162. 
PARP1 knock-out mice thus have unusual antibody profiles with characterized by 
decreased class switching to IgG2a but increased IgGA secretion.  
The proteins recruited depend on the nature of the DNA lesion and bind sequentially 
at the site of DNA damage. In DNA repair involving the generation of single-strand 
breaks, the extensive PAR acts as the cue to recruit and assemble the DNA repair 
machinery, while its high negative charges keeps the DNA structure open163 for DNA 
repair enzymes to carry out their functions. In order of recruitment, they include the 
scaffold protein XRCC1 (X-ray Repair Cross-Complementing Protein 1), the DNA 
end-processing kinase/ phosphatase PNK (Bifunctional polynucleotide phosphatase/ 
kinase), the gap-filling polymerase DNA polymerase β and DNA ligase III. Auto-
modified PARP1 also recruits nucleosome repositioning proteins such as ALC1 
(Amplified in Liver Cancer 1) to make damaged DNA accessible for repair128, 164. At 
stalled replication forks, the activated and auto-modified PARP1 recruits another set 
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Even though PARP1 is required for the assembly of DNA repair or replication restart 
machinery, it also poses steric hindrance by binding at the site of DNA damage. 
Therefore, when PAR gets too extensive, the accumulation of negative charges on 
PARP1 forces its repulsion from DNA to allow DNA repair or DNA replication re-start 
to proceed. The release of PARP1 from DNA and the extensive PAR prevent further 
PARP1 enzymatic activity, and PARG may then hydrolyze PAR to convert PARP1 to 
its original state. 
When DNA damage is minimal, the recruitment of PARP1 to sites of DNA strand 
breaks results in repaired DNA. However, when the damage is extensive and 
irreparable, the apoptotic pathway is triggered, resulting in the cleavage of PARP1 by 
effector caspases to shut down PAR synthesis and futile DNA repair, conserving 
energy required for apoptosis. PAR synthesized by PARP1 may then act as a signal 
necessary for AIF (Apoptosis-inducing factor) to translocate from the mitochondria to 
the nucleus, mediating apoptosis101, 165. How this nucleus-to-mitochondria signaling is 
achieved is however not well-understood. When the damage is extensive, PAR 
synthesis rapidly depletes cellular NAD+, resulting in cell death by necrosis instead105, 
107, 109, 132, 137, 141. 
It can be seen that regardless the type of DNA repair enzyme recruited, PARP1 
enzymatic activity is necessary for them to function. Indeed, all male rats on a diet 
that suppresses NAD+ synthesis hence PARP1 activity develop HCC 
spontaneously166. Interestingly, the reduction of tissue NAD+ in such rats was most 
evident in the liver within two months of treatment, while in other tissues such as the 
muscles the reduction in NAD+ was only observable after a year, further emphasizing 
the susceptibility of the liver to DNA damage and HCC with reduced PARP1 activity.  
To prevent the high amounts of DNA lesions in cancer cells from acting against 
cancer cell proliferation and survival by inducing apoptotic cell death, PARP1 is often 





renders therapy involving the induction of DNA damage futile and potentially 
detrimental, as cancer cells with high levels of PARP1 enzymatic activity would be 
resistant to induced apoptosis and instead be selected for, leading to the 
development of drug-resistant cancers. Since PARP1 is involved in the repair of 
many forms of DNA lesions whose rectification processes converge at the point DNA 
strand break production, inhibition of its enzymatic activity with nicotinamide 
analogues should reduce DNA repair, resulting in the accumulation of toxic lesions 
when coupled with the use of DNA damaging agents108, 131-133, 135, 136, 154, 169. This 
strategy has produced promising results in various clinical trials of several cancers, 
spurring immense interest in the development of more PARP1 inhibitors. 
 
PARP1 Function in Transcription 
PARP1 is an important regulator of transcription, as was first demonstrated in PAR-
rich chromosomal “puffs” at actively transcribed loci in Drosophilla170. This is further 
supported by the altered expression of many genes including cyclins, p21, MDM2 
and β-2-microglobulin in cells derived from PARP1 knockout mice models171, 172. 
PARP1 exerts its effects on gene transcript expression in many ways (Illustration 
11). Importantly, as opposed to DNA damage repair where PARP1 enzymatic activity 
is required, transcriptional regulation can occur without PARP1 being enzymatically 
active. The effects of PARP1 on transcription may be DNA sequence independent as 
in chromatin remodeling103, 110 or sequence dependent as in the transcriptional 
regulation gene expression173-186. 
PARP1 is involved in multiple mechanisms that contribute to the relaxation of 
chromatin. These require PARP1 enzymatic activity. When activated nuclear 
receptors such as estrogen-bound estrogen receptor-α binds to its response element, 
a complex containing topoisomerase II-β and PARP1 is recruited126. Topoisomerase 





DNA structures and at the same time, activating PARP1 enzymatic activity for the 
ADP-ribosylation of histones H1 and H2B, allowing the resultant negative charges to 
repel DNA. This allows the formation of the “beads on a string” structure that renders 
DNA accessible to the transcriptional machinery103, 187. Not surprisingly, PARP1 is 
found in place of histone H1 in most transcriptionally active genes112, 130, 148, 172. 
Modified histone H1 may also then be exchanged for histone H1-HMGB (histone H1 
high mobility group B) favourable for transcription126. Enzymatically active PARP1 
further contributes to active transcription by maintaining the tri-methylated state of 
histone H3K4 through the ADP-ribosylation of histone demethylase, repelling it from 
“open” DNA130. Together, these mechanisms enable RNA polymerase II to easily 
load onto transcriptionally active promoter regions130.  
PARP1 can also modulate gene expression by directly modulating the activity of 
transcription factors. When enzymatically inactive, the ubiquitously-expressed 
transcription factor Oct-1 binds PARP1 via the BRCT domain119, stabilizing the 
interaction of Oct-1 and its DNA recognition motif. Stable DNA-transcription factor 
interaction was also observed in TGFβ signaling, where the duration of transcription 
factor occupancy of the Smad3/Smad4-PARP1 complex at target sites is increased 
with PARP1 inhibition188, enabling functional interaction between transcription factors 
and DNA to initiate transcription complex assembly. However, PARP1 does not allow 
the transcription factor to bind DNA indefinitely. By activation of its enzymatic activity, 
the ADP-ribosylation of the Smad3/Smad4-PARP1 complex188 results in repulsion 
from DNA hence release from their consensus recognition sequences. In embryonic 
stem cell differentiation, ADP-ribosylation of the transcriptional repressor SOX2 
results in its dissociation from the FGF4 enhancer189, enabling transcription. Other 
transcription factors such as SP1190, HES1124 and Oct-1119 are also known to be 
regulated by PARP1 dependent ADP-ribosylation, contributing to the large number of 





transcription factor required for PARP1 gene expression191, this relationship creates a 
negative regulatory loop where the over-expression of PARP1 hence high cellular 
PARP1 activity modifies and sequesters SP1 away from the PARP1 promoter, 




Illustration 11 PARP1 regulates gene expression in many ways. Grey arrows 
indicate low affinity of PARP1 species for DNA. R—ADP-ribosylation; TF—
transcription factor.  
 
PARP1 is increasingly recognized for its role as a transcription factor, where 
recognition of DNA in a sequence-dependent manner (Illustration 9) activates or 
represses gene expression. Genes under such PARP1 dependent control include the 
DNA repair enzyme BRCA2181, components of the SWI/SNF chromatin remodeling 
complex such as SMARCB1180, as well as viral products produced from 
transcriptional activity at the human T-cell leukemia virus Tax responsive element 
(HTLV Tax RE)175. Besides modulating the activity of NFkB125, 129, 153, 192, 193, PARP1 is 
itself a powerful regulator of the inflammatory response, as it transcriptionally 
regulates in a sequence dependent manner the expression of several inflammation-
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related products such as interferon-γ179 and IL-10185.  Although the deletion of PARP1 
zinc finger I abrogates its transcriptional repression activity194, it remains unclear how 
PARP1 can differentiate between damaged and undamaged DNA to bring about the 
different outcomes of DNA repair and transcription respectively. Curiously, in the 
mouse model, PARP1 is itself a sequence dependent transcriptional repressor at its 
own gene promoter191, enhancing the auto-regulatory feedback loop established by 
SP1 ADP-ribosylation190. Together, these mechanisms keep the relative amount of 
PARP1 and its activity in check.  
As with other transcription factors, it is believed that PARP1 has an optimal 
recognition motif for its function. Evidence for the existence of a motif comes from the 
association of gene promoter single nucleotide polymorphisms (SNP) that alter the 
affinity of PARP1 for DNA and consequently transcript expression. For example, a 
CÆT SNP within the IFNAR1 (Interferon-α/β receptor 1) promoter was found to 
reduce PARP1 dependent transcription hence increase susceptibility for chronic HBV 
infection184. It was further noted that HBV reduced the amount of PARP1 transcripts, 
presumably to reduce the sensitivity of infected host cells to IFNα/β to enable 
persistent HBV replication and infection184. A GÆT SNP within the SMARCB1 
promoter increased the affinity of PARP1 for DNA and this was associated with 
increased SMARCB1 transcript and protein expression180. However, due to the 
apparent lack of similarity in aligned PARP1 binding sites, its motif remains elusive.  
 
PARP1 in Disease States and Effect of PARP1 Inhibition 
With PARP1 playing multiple important roles such as DNA repair and transcriptional 
regulation, it is not surprising that altered PARP1 activity and expression has been 
associated with several disease states (Table 3). Because the effects of PARP1 as 
an active enzyme are better established, most diseases dependent on PARP1 to 





such as sepsis, diabetes, myocardial infarction (MI) and stroke108, 109, 131-133, 136, 137, 141, 
154.  In cancers, PARP1 hyper-activity reduces the chance of a cancerous cell dying 
from apoptosis as a result of the large amounts of accumulated chromosomal 
aberrations. In inflammation, the production of reactive oxygen species results in the 
generation of DNA strand-breaks, activating PARP1 hence consumption of large 
amounts of NAD+ to result in the necrotic death of tissues.  
 
Table 3 PARP1 associated diseases and outcomes of enzymatic inhibition 
PARP1 
function Disease Contribution to disease 
Effect of 
inhibition Ref 









Stroke Necrosis [☺] (Males) 131 
MI Necrosis and inflammation  [☺] 131 








Necrosis and inflammation 
Transcription of Reg  [☺] 
131 
197 
SLE Transcription of IL-10 ? 185 
Atherosclerosis Transcription of CCL2 ? 186 






HBV infection Transcription of IFNAR1 ? 184 
HTLV infection Transcriptional activator [/] 175 
 
HIV infection Integration into host genome [/] 198 
KSHV infection Viral genome replication [/] 199 
 
Square brackets indicate the effect of PARP1 inhibition in experimental studies or 
animal models, “☺” indicates improved health condition while “/” indicates increased 
severity in disease outcome with PARP1 inhibition. MI—Myocardial Infarction; SLE—
Systemic Lupus Erythematosus; ALL—Acute Lymphoblastic Lymphoma; HTLV—
Human T-cell leukemia virus; HIV—Human Immunodeficiency virus; KSHV—






Since PARP1 enzymatic activity contributes to the development of the disease state, 
its inhibition should prove useful in alleviating symptoms during therapeutic 
intervention131-134, 136, 141, 154 (Illustration 12). This indeed is the case in several 
animal models, where in the instance of stroke treatment with PARP inhibitors 
reduced ishaemia-reperfusion injury, reducing necrosis and inflammation. In cancer 
models, PARP inhibition coupled with the induction of DNA damage impaired DNA 
repair hence enables toxic DNA lesions to accumulate in actively dividing cancerous 
cells, triggering apoptosis hence enhancing the cytotoxicity of DNA damaging agents 
conventionally used for cancer therapy. Nevertheless, the strategy of combating 
illness with PARP1 inhibition is currently only used in the clinical setting in phase I or 
II trials for the treatment of cancers. Whether the efficacy of PARP inhibition 
observed in the animal models may be observed waits to be seen. 
Most PARP inhibitors achieve therapeutic efficacy by mimicking the weak but natural 
inhibitor nicotinamide, competing with NAD+ for the PARP catalytic site (Illustration 
12) to prevent ADP-ribosylation. However, even though it is known that the PARP 
catalytic domain is highly conserved amongst PARP family members112, 117, little 
effort has been made to study the effects of PARP inhibition on them. In fact, none of 
these inhibitors may be described as “specific” to PARP1, as most have better affinity 
for the less abundant PARP2 and tankyrase133 which are also involved in the 
maintenance of genomic integrity109, 195, 196. This relative abundance of PARP1 and 
the lower affinity of these inhibitors for its catalytic site suggests that large doses are 
necessary to achieve therapeutic efficacy. This further suggests that much of the 
toxicity associated with PARP inhibition may be related to the inhibition of other 
PARP family members. The development of an inhibitor specific for PARP1 would 












































































































inhibitors would enhance the effects of sequence dependent transcriptional 
regulation hence either ameliorate or aggravate the disease state. In diabetes for 
instance, besides reducing necrosis and inflammation associated with PARP1 hyper-
activity, PARP1 inhibition would increase the transcription of Reg required for β-cell 
regeneration197, thus result in the production of more insulin. In SLE however, PARP 
inhibition would enhance IL-10 expression, aggravating the hyper-active of B-cells 
state that contributes to the disease.  
The multi-functionality of PARP1 makes it a susceptible target for viruses to act on. 
Viruses that depend on PARP1 include HIV (Human immunodeficiency virus) that 
uses PARP1 to integrate into centromeric regions of the host genome198 as well as 
the oncogenic HTLV that relies on the Tax-PARP1 complex for efficient viral 
replication175. Furthermore, in KSHV (Kaposi’s sarcoma-associated virus) infection, 
PARP1 binds to viral DNA and regulates the amount of viral genome copies by ADP-
ribosylation of its latency-associated nuclear antigen199, 200. As opposed to improving 
the health status in diseases involving DNA repair and inflammation, the inhibition of 
PARP1 generally leads to enhanced viral replication (Table 3). This is reflected by 
increased centromeric DNA integration by HIV198, increased KSHV genome copies in 
latency199 as well as increased transcription at Tax-responsive promoters of HTLV175. 
Thus, while it is beneficial to use PARP inhibition for the treatment of diseases such 
as stroke and myocardial infarction in the clinical setting, this is not practical as the 
modulation of PARP1 activity by enzymatic inhibition may be contraindicated in many 
patients with multiple PARP1 dependent diseases such as viral infection and SLE.  It 
is nevertheless evident that PARP1 is a good therapeutic target for the treatment of 
many diseases, and therefore worthwhile the effort to find novel strategies besides 
catalytic domain inhibition to overcome the current pitfalls of nicotinamide analogue 






1.3 OUTLINE AND AIMS 
  
Rationale for Study 
With 350 million worldwide still chronically infected and its association with deadly 
diseases such as HCC, HBV remains a major health threat today. While therapeutic 
means are in place to control HBV replication in chronic carriers, none are capable of 
eliminating the virus. Furthermore, the efficacy of IFNα treatment is dependent on 
tolerance of its side effects and HBV genotype, and the use of nucleoside or 
nucleotide analogues generates drug-resistant strains. Therefore, there is a need to 
develop novel strategies aimed at preventing HBV replication for the treatment of the 
large population of chronic carriers.  
 
Aims of Study 
HBV replication depends on the synthesis of pgRNA, without which infectious 
particles cannot be made. Transcription of pgRNA is controlled at the HBV core 
promoter, which is in turn dependent on the variable properties of the factors carried 
by the infected host cell. Thus, targeting the host factors critical for efficient pgRNA 
synthesis should prove useful in controlling and preventing HBV replication. This 
study thus aims to identify susceptible host factors vital for efficient HBV replication, 
and characterize their properties that contribute to differential capabilities in enabling 
efficient HBV replication in amongst individuals. This would enable the better 
understanding of how the novel therapeutic should be designed to serve its purpose 








Outline of Study 
To study HBV host-pathogen interactions, a suitable and easily manipulated HBV 
replication model is required. Chapter 2 describes a replicative HBV model that was 
established and tested in liver-derived cell lines reported to enable efficient HBV 
replication. Four liver-derived cell-lines were then tested for their ability to effectively 
enable HBV replication with this model, hence the categorization of the cell lines 
based on their differential abilities in supporting HBV replication. This served as the 
basis useful for subsequent work to pinpoint the differences of a favourable target 
host factor that contributes to its ability to effectively support HBV replication.  
A thorough screen for host binding factors at the HBV core promoter was performed. 
Guided by the differences in contribution of transcriptional activity by specific sites 
within the HBV core promoter, the multifunctional enzyme poly (ADP-ribose) 
polymerase 1 (PARP1) was identified as the most important specific binder critical for 
efficient HBV replication. By studying the differences in PARP1 between the 
categorized cell lines, it was revealed that a reduction in PARP1 enzymatic activity 
conferred by the V762A polymorphic allele commonly found in parts of the world 
where HBV infection is endemic contributes to these cell lines’ ability in supporting 
efficient HBV replication. Thus, Chapter 3 describes the identification of PARP1 as a 
novel transcriptional activator at the HBV core promoter capable of accounting for 
variable infection outcomes in HBV infections. This is the basis for in-depth analysis 
of the regulation of PARP1 activities in the cell. 
During the course of determining the identity of the novel transcriptional activator at 
the HBV core promoter, the inability of established transcription factor databases to 
immediately recognize the site of interest to be a motif belonging to the PARP1 
transcription factor prompted the characterization of the PARP1 binding motif. Using 
the PARP1 binding site at the HBV core promoter as a model, the PARP1 binding 





phenomenon of the well-known characteristic of PARP1 binding DNA strand breaks 
to induce enzymatic activity, yet having shown that this in turn would reduce 
transcriptional activation at the HBV core promoter, the effect of PARP1 binding on 
its PARP1 binding motif was investigated. Surprisingly, PARP1 binding to its motif 
resulted in the reduction of its enzymatic activity, enabling exogenous expression of 
the PARP1 binding motif to impair PARP1 dependent DNA repair for the 
enhancement of cytotoxicity in cells treated with DNA damage inducers. The work 
presented in Chapter 4 thus proposes that DNA bearing the newly-defined PARP 
binding motif can act as novel PARP1 specific inhibitors, modulating the effect of 
PARP1 dependent functions in a cell. Importantly, as opposed to conventional 
PARP1 inhibitors currently used in cancer therapy, the novel PARP1 inhibitor does 
not result in enhanced HBV replication. Given the importance of PARP1 in multiple 
disease models, the novel PARP1 inhibitor thus has potential for the development 
into a broad-range therapeutic for multiple diseases including chronic HBV infection 
and cancer.  
In Chapter 5, a model explaining how the modulation of PARP1 activity accounts for 
the variability in disease outcomes in HBV infection, and its relation to the 






















HBV infects higher order primates, making it difficult to study the mechanisms of its 
replication. To understand how differences in host factors can affect the efficiency of 
HBV replication, a convenient replicative model has to be made and tested. 
Furthermore, the characteristics of host cells’ response to the test model have to be 
determined, so that these cells may be categorized according to their abilities in 
sustaining effective HBV replication. By cloning 1.1-fold of the entire HBV genome 
into an expression vector, a replicative model was achieved such that the expression 
of HBV products depended only on the ability of host factors binding to the HBV 
promoters. This enabled the segregation of four liver-derived cell lines, HepG2, Huh-
6, Huh-7 and Sk-hep-1 into 3 classes based on their ability to efficiently produce 
replicative HBV markers such as HBV transcripts, cccDNA and envelope proteins. 
On one end of the spectrum, HepG2 was found to efficiently enable HBV replication 
as indicated by high cccDNA generation, while on the other, Sk-hep-1 was found to 
be unsupportive of HBV replication as synthesis of HBV transcripts could not be 
sustained. This finding would prove useful in pinpointing the subtle differences in host 




HBV has infected a third of the world’s population. While most primary infections may 
be resolved and lead to recovery, approximately 5% of infections are persistent and 
another 0.5% lead to fulminant hepatitis hence death1 (Illustration 1). Chronic 
infection with HBV is associated with increased risk of developing liver diseases such 
as HCC1, 2, 10, 20, 82, 85. Notably, the longer it takes to resolve the infection, the greater 
the risk for developing HCC. Presumably, chronic inflammation of the liver by the 




immune system’s attempt to eliminate the virus leads to continual regeneration of 
damaged liver cells hence tissue scarring, which when uncontrolled leads to aberrant 
cell growth hence HCC, accounting for the length of duration needed for disease to 
develop20, 81-85. Besides the duration of unresolved infection, high viral load and HBV 
DNA reflective of efficient viral replication are associated with increased risks of 
developing HCC80 although the cause for this is unknown.   
Like all viruses, HBV replication depends on the properties of its host’s factors. The 
interaction between viral components and host factor variability would determine 
whether HBV replicates efficiently. This can be seen in the association of infection 
outcomes with the geographical distribution of HBV genotypes and ethnicity of its 
host population14 (Illustration 2), such that infections with HBV genotype C and 
being of Asian descent14 tend be prognostic markers for severe disease and poorer 
therapeutic intervention outcomes. In Central and Southern Americas, HBV genotype 
F has been reported to be associated with fulminant hepatitis and the development of 
HCC in young males11, 12, 90, 201. Furthermore, gender-specific differences can also 
affect the outcome of chronic infection as chronically infected males are known to 
have higher risk of developing HCC2, 3. Thus, several factors contribute to the 
efficient replication of HBV including host factor variability as well as HBV genotype. 
Current therapeutic strategies (Illustration 6 and Table 2) include enhancing the 
anti-viral function of the immune system by IFNα treatment14, 98, 202 and preventing the 
synthesis of rcDNA with nucleotide or nucleoside analogues but none are capable of 
eliminating the virus. The use of nucleoside or nucleotide analogues has also been 
associated with the generation of drug-resistant strains14, 20, 85, 94, 96. The limitations of 
these approaches prompt the search for novel strategies for the treatment of chronic 
HBV infection.  
To achieve this, a better understanding of the host factors required for HBV 
replication and how the variability in individual factors contribute to effective HBV 




replication are required. A replicative HBV construct of genotype A was generated 
and transfected into different cell lines from genetically different backgrounds, 
followed by the analysis of various HBV replication markers including cccDNA, HBV 
transcripts and HBV protein expression, with the aim to establish the capability of 
tested cell lines in supporting effective HBV replication. This would enable the 
identification of subtle differences of defined critical host factors required for effective 
pgRNA synthesis between the “supportive” and “non-supportive” cell lines, revealing 
how host cell factor variability accounts for effective HBV replication. 
 
2.2 The Replicative HBV Construct 
 
HBV replication depends on pgRNA synthesis (Illustration 3), without which 
infectious particles cannot be made16, 20, 25. To generate HBV in cell lines of interest, a 
replicative construct bearing 1.1-fold of the 3221bp genome from HBV genotype A 
was cloned203, 204 and inserted into the pcDNA3.1+ plasmid vector upstream of the 
CMV promoter (Illustration 13). The construct (HBV-RFP) was designed such that 
pgRNA synthesis depended on host factors binding on the HBVCP alone and is not 
driven by the CMV promoter, serving the purpose of categorizing the cell lines to be 
tested into whether they contain host factors that allow efficient HBV replication or 
not. As pgRNA is formed by the initial read-through transcription of the poly-A 
signal15-17, 19, 25, 27, the region starting from the core promoter to the HBV poly-A signal 
cleavage site were duplicated, enabling elements within the pgRNA synthesized to 
fold into its characteristic secondary and tertiary structures that are recognized by 
HBV polymerase to initiate rcDNA synthesis (Illustration 3). Since it is possible that 
the cell lines to be tested do not contain host factors favourable for efficient HBV 
replication, the coding sequence of the red fluorescent protein (RFP) was inserted 
downstream of the CMV promoter, serving both to prevent the CMV promoter from 




driving HBV pgRNA transcription, as well as a transfection efficiency marker to 
ascertain that undetectable HBV replication was not due to poor uptake of the 




Illustration 13 The replicative HBV construct. CP—HBV Core promoter. 
 
HBV is a virus thought to replicate efficiently in the liver15. It therefore seems logical 
to assume that cell lines derived from the liver support efficient HBV replication. This 
is however not the case. As is observed with the dramatically variable outcomes of 
HBV infection from recovery to death, only the cell lines HepG2 and Huh-7 have 
been reported to enable HBV replication205. Thus, these cell lines were tested for the 
construct’s ability to enable HBV replication. 
As large amounts of HBs is required to envelope a single virion, if HBV replication 
were enabled in the cell lines tested, it would be one of the easiest proteins to detect. 
Figure 1A shows red fluorescent HepG2 cells due to constitutive RFP expression 
driven by the CMV promoter expressing large amounts of HBs 60 hours after 
transfection with HBV-RFP. In contrast, cells transfected with RFP alone do not 
express HBs, indicating that the HBs expression in HBV-RFP transfected cells was 
due to the successful transcription of the 2.1kb HBV mRNA encoded by the construct. 
Furthermore, it shows that HepG2 does not itself produce HBV products, thus any 















































































































Virions cannot be made if HBs synthesis is not sustained. Furthermore, all surface 
antigens need to be synthesized for virions to be produced. To ascertain that all HBV 
envelope proteins may be produced and that production is sustained, cytoplasmic 
lysates from HepG2 transfected with HBV-RFP were analyzed at various time-points 
for as long as 192 hours post-transfection. Figure 1B shows that shortly after 
transfection (14 hours post-transfection), no surface proteins were synthesized. This 
supports the observation in Figure 1A that HBs is not endogenously expressed by 
HepG2. All three envelope proteins, pre-S1 (Large S), pre-S2 (Medium S) and HBs 
(Small S) were abundantly expressed by 48 hours post-transfection and their 
expression was sustained till 192 hours post-transfection (Figure 1B). The continual 
production of HBV envelope proteins allows the envelopment of core particles that 
might be generated from the transfection of HBV-RFP.  Interestingly, the expression 
of all envelope proteins, most evidently that of pre-S1, was increased with time 
especially after 120 hours post-transfection. Since high amount of pre-S1 is 
associated with efficient HBV replication207, this suggests that the HBV-RFP 
construct is indeed able to enable efficient HBV replication to occur in HepG2.  
To test if HBs hence virions may be secreted, the culture medium used to grow 
HepG2 cells transfected with HBV-RFP was collected at various time-points. It is 
known that HBs secretion need not be the best marker indicating the secretion of 
infectious virions, as non-infectious particles harbouring HBs may outnumber 
infectious particles by more than a thousand-fold20. However, as Figure 1B has 
already shown that the large envelope protein (Pre-S1) is synthesized in abundance, 
and that it is known that the large envelope protein is made in large quantities only 
when HBV replication is efficient and high207, the HBs secretion assay was performed 
to show that there is no deficiency in the host cell secretory pathway, that virions if 
synthesized, could be secreted. Indeed, since transfected cells remain viable, the 
detection of increasing amounts of HBs in culture medium with time (Figure 1C) 




indicates active secretion of HBs. In contrast, HepG2 cells transfected with RFP did 
not secrete HBs, further confirming that the HBs secreted was produced as a result 
of transfecting the HBV-RFP construct into the cells. 
HBV produces several transcripts (Illustration 4). The expression of all the envelope 
proteins implies that the 2.4kb mRNA and the 2.1kb mRNA were synthesized. 
However, the transcription of the 3.5kb pgRNA and pcRNA as well as the 0.7kb 
mRNA species has yet been proven. As the 3.5kb pcRNA is responsible for the 
synthesis of HBe antigen that is secreted and not essential for HBV replication16, 17, 19, 
36, 54, it is thought to have little direct effect on intracellular proteins required for HBV 
replication. HBx is also not essential for viral replication, but its intracellular nature 
and modulation of intracellular host cell proteins functions may have more direct 
consequences to host factors, hence the synthesis of the 0.7kb mRNA species and 
its protein expression are more relevant to this study. pgRNA is also important, as it 
does not only code for the viral polymerase and capsid protein HBc16, 18, 19, 25, it is also 
encapsidated and used as a template for rcDNA synthesis (Illustration 3). To 
overcome the difficulty in differentiating individual transcripts due to the extensive 
overlap of nucleotide sequences (Illustration 4), the expression of the proteins 
translated from them were detected instead. Huh-7 cells were chosen in this case 
due to the ease in transfection, hence potentially enabling the detection of HBx 
known to be produced in trace amounts. Western blot analysis of the cytoplasmic 
lysates of Huh-7 cells transfected with HBV-RFP revealed that HBc synthesized from 
pgRNA and HBx synthesized from the 0.7kb mRNA species were produced by 30 
hours post-transfection (Figure 2A).  As was observed in HepG2 cells, HBx and HBc 
were only produced by cells transfected with HBV-RFP and not RFP alone, 
confirming that Huh-7, like HepG2, has no intrinsic capability to synthesize HBV 
products, and that HBV replication if any, is conferred by the transfection of the HBV-
RFP construct. Taken together with Figure 1, the HBV-RFP construct was shown to 




be capable of producing all the HBV transcripts hence enabling the detection of 
proteins necessary for the generation of infectious HBV virions. 
In HBV infection models, cccDNA synthesis is required for pgRNA synthesis to ensue 
(Illustration 3). In the HBV-RFP transfection system, pgRNA may be synthesized by 
transcriptional activity at the HBVCP without having to synthesize cccDNA, as the 
entire pgRNA transcript is encoded by the double-stranded 1.1-fold HBV genome 
(Illustration 12). However, the transcription of pgRNA need not mean that HBV 
replication has occurred, as the pgRNA could just be a transcript coding for viral 
polymerase and HBc. Thus, to prove that the pgRNA can be encapsidated for rcDNA 
synthesis, cccDNA was detected to indicate that recycling of core particles containing 
rcDNA has occurred hence HBV replication. HepG2 cells transfected with HBV-RFP 
were washed and culture media replaced 6 hours post-transfection, such that the 
amount of plasmids taken up by transfected cells at this time-point was the “basal” 
level of double-stranded HBV genome obtainable by transfection. If cccDNA were 
produced, the amount of HBV double-stranded genome detectable would surpass 
the copy number carried by the HBV-RFP construct, hence the relative amount of 
“cccDNA” would be seen to increase when normalized to the amount of CMV 
promoters carried by the HBV-RFP plasmid. By quantitative real-time PCR (qRT-
PCR), the fold-change of cccDNA at various time-points relative to 6 hours post-
transfection was increased with time in HepG2 cells transfected with HBV-RFP 
(Figure 2B), indicating that HBV replication could indeed be achieved with the HBV-
RFP transfection model in HepG2 cells. In contrast, no cccDNA could be detected in 
HepG2 cells transfected with RFP, confirming the specificity of the primers used to 
detect cccDNA, and providing evidence that HepG2 cannot itself produce HBV 
transcripts. 
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Table 4 Properties of liver-derived cell lines used 
Cell line Extracted from Ethnicity Age Gender HBV integration
HepG2 HCC Argentine 15 M - 
Huh-6 Hepatoblastoma Japanese <1 M - 
Huh-7 HCC Japanese 57 M - 
Sk-hep-1 Liver adenoma Caucasian 52 M - 
M—Male; WT—wild-type 
 
The different cell lines were transfected with the same conditions, and their relative 
amounts of HBV transcripts produced was determined (Figure 3A). As all HBV 
transcripts have extensively overlapping sequences (Illustration 4), the expression 
of all HBV transcripts was determined by quantitative real-time PCR using a single 
primer set specific for the region between the core promoter and the poly-A signal. 
This approach cannot distinguish between all HBV transcripts, but is useful as a 
gauge to determine the efficiency of transcription if cellular host factors could bind to 
the different HBV promoters. The expression of HBV transcripts was normalized to 
the relative expression of the house-keeper gene GAPDH (Glyceraldehyde-3-
phosphate dehydrogenase).  
Consistent with the ability of the HBV-RFP construct enabling the production of viral 
proteins to enable HBV replication, the amount of HBV transcripts in HepG2 and 
Huh-7 was sustained with time (Figure 3A). Interestingly, the relative amounts of 
HBV transcripts expressed in Huh-7 compared to HepG2 is much lower than 
expected (approximately 2-fold) even though the transfection efficiency in Huh-7 was 
more than double that of HepG2 (Figure 3B). This suggests that HepG2 has a much 
higher efficiency in supporting HBV replication than Huh-7. The cell line Huh-6 was 
also able to support the production of HBV transcripts as large amounts of HBV 
transcripts were produced 48 hours after transfection with HBV-RFP and sustained at 










































































































actively suppress HBV replication. Thus Sk-hep-1 is a cell line that cannot support 
HBV replication. The inability of Sk-hep-1 to synthesize large amounts of HBV 
transcripts despite expressing RFP also proves that HBV replication associated with 
the transfection of the HBV-RFP construct is dependent on the host factors binding to 
the HBV promoters and not a consequence of CMV promoter driven transcription. 
To better understand the differences in HBV replication in the cell lines HepG2, Huh-
6 and Huh-7, the relative amounts of cccDNA synthesized and HBs secretion were 
investigated. Using exactly the same transfection conditions in all three cell lines, it 
was revealed that only HepG2 could generate large amounts of cccDNA (Figure 4A), 
such that the fold-change of cccDNA synthesized relative to 6 hour controls in 
HepG2 was nearly thrice that of Huh-6 and 6-fold that of Huh-7. As the increase in 
cccDNA is dependent on the amount of HBV core particles recycled to the nucleus, 
the much higher increase in cccDNA synthesis in HepG2 reflects the high efficiency 
of transcription of pgRNA, which is sufficient to make all the necessary components 
of the core particle. This is consistent with the high efficiency of HBV transcript 
synthesis in HepG2 observed in figure 3A despite its low transfection efficiency.  
Therefore, HepG2 contains cellular factors particularly favourable for the transcription 
of pgRNA synthesis and efficient HBV replication, while Huh-7 contains similar host 
factors but with impaired function to result in the low efficiency of pgRNA synthesis. 
Curiously, the relative amounts of HBs secreted 48 hours after HBV-RFP transfection 
observed a trend opposite to cccDNA synthesis, such that Huh-7 secreted more than 
6-fold the amount of HBs secreted by HepG2, which secreted the least HBs when 
compared amongst the three cell lines tested (Figure 4B). The finding of relative 
amounts of HBs secretion in the different cell lines correlating with the relative 
amounts of HBV transcripts (Figure 3A) suggests that the bulk of HBV transcripts 
code for HBs instead of pgRNA. Indeed, HBs is known to be secreted in large excess 
relative to infectious particles20, hence the detection of cccDNA is a better predictor 




for HBV replication. The excess HBs which may be secreted in more than 1000-fold 
excess as empty particles are thought to be used as decoys to evade immune 
clearance of the virus20. It is therefore conceivable that the HBs produced in HepG2 
could not be readily secreted at the relatively “early” time-point of 48 hours, as time is 
required to assemble the infectious HBV, which could take up to 3 days for 
synthesis205, 212. Interpreting this in the physiological context, there is no need to 
secrete large amounts of antigenic HBs to signal to the immune system that the host 
is infected with HBV, as stealth is the key to evade immune surveillance during early 
HBV replication. In this model, infectious particles are synthesized rapidly and likely 




Figure 4 Differential capabilities in expressing different HBV products. (A) Relative 
cccDNA fold-change of cells transfected with HBV-RFP. (B) Relative amount of HBs 
detected in culture medium 48 hours after HBV-RFP transfection. Results show 
mean ± SE of triplicates from representative experiments. 
 
Huh-7 however produces large amounts of HBV transcripts (Figure 3A) hence viral 





























































efficient in HBV replication in terms of pgRNA hence cccDNA synthesis. Since 
infectious virions cannot be efficiently assembled, virion secretion is likely delayed, 
by which time when ready for export, circulating anti-HBs is present in large amounts. 
Since pgRNA synthesis is rate-limiting, the HBs produced need not be retained for 
the envelopment of core particles that have yet to be assembled. Instead, the large 
amounts of HBs produced now serve as a “decoy” useful to sequester circulating 
anti-HBs produced by the time enough infectious particles may be secreted, 
increasing the chance of a virion to successfully infect another susceptible host cell. 
Indeed, similar relative expression of much larger amounts of HBs secretion was 
observed at 96 hours post-transfection in Huh-7 compared to HepG2 cells. This 




Using the HBV-RFP transfection model, a replicative HBV model is established. 
Amongst the four cell lines tested, HepG2 is the most supportive of HBV replication 
and pgRNA synthesis, while Sk-hep-1 cannot support HBV replication as HBV 
transcripts cannot be produced despite successful transfection. The efficiency of 
pgRNA transcription hence cccDNA synthesis in Huh-6 and Huh-7 lie between that of 
HepG2 and Sk-hep-1. With this new information, comparing the differences in the 
host factors carried by these cell lines critical for the transcription of pgRNA synthesis 
will lead to the better understanding of how functional host-pathogen interactions are 










PARP1 is a Novel Transcriptional Activator 











It is hypothesized that efficient HBV replication depends on the ability to establish 
functional host-pathogen interactions at the HBV core promoter (HBVCP). The 
functionality of these interactions is in turn dependent on subtle differences of host 
transcription factors that bind to the HBVCP. To determine which host factor 
contributes significantly to efficient HBV replication, the HBVCP was screened for 
binding factors, and their relative ability to initiate effective transcription at HBVCP 
compared.  The screen revealed a handful of transcription factors, SP1, HNF1 and 
hnRNP K were sufficient to establish “basal” transcriptional activity at the HBVCP. To 
achieve higher transcriptional activity associated with the cell lines HepG2 and Huh-6, 
a novel binding factor, poly (ADP-ribose) polymerase 1 (PARP1) is required. The 
significance of PARP1 to HBV replication was affirmed by reduced HBV replication 
with specific knockdown. To account for the differential abilities of the cell lines to 
support HBV replication, the differences in the form of PARP1 expressed was looked 
into. Consistent with enzymatic inhibition increasing HBV replication, HepG2 and 
Huh-6 were found to express the V762A polymorphic mutant with reduced enzymatic 
activity. The relative abundance of this polymorphic allele was further found to 
correlate well with the geographical prevalence of severe disease. The results 
suggest that PARP1 is a novel factor important for transcriptional activation at the 
HBVCP, and that its enzymatic inhibition would enhance HBV replication. 
Furthermore, the PARP1 V762A is a polymorphic marker that might be useful in 











The hepatitis B virus has infected a third of the world’s population, leaving 350 million 
worldwide chronically infected1. Chronic carriers of the virus have increased risk of 
developing liver associated diseases such as HCC2, 10, 20, 44, 82, 201 which is not only 
financial debilitating but also has very poor survival rates. While chronic infection with 
HBV may be treated with IFNα to boost the immune system’s capability in clearing 
the virus, or treated with nucleoside or nucleotide analogues to inhibit viral replication, 
these treatments have their limitations (Table 2). The efficacy of IFNα is variable and 
dependent on host factors as well as HBV genotype14. IFNα treatment is also 
associated with severe side effects hence low patient compliance. Nucleoside and 
nucleotide analogues show better efficacy but have lead to the generation of drug-
resistant strains14, 85, 94, 96, 213. Therefore, there is a need to develop new means of 
combating HBV replication for the treatment of chronic carriers of the virus. 
The efficiency of HBV replication is a major determinant of the outcome of HBV 
infection. High efficiency of HBV replication associated with high viral loads and viral 
DNA positively correlate with high risks of developing liver diseases such as HCC80. 
Thus, to develop novel therapeutics for the treatment of chronic HBV infection, it is 
crucial to understand how efficient HBV replication can be brought about. HBV 
replication depends on the transcription of pgRNA controlled at the HBV core 
promoter (HBVCP)16, 27, 50, 54 (Illustration 5), without which infectious particles cannot 
be produced (Illustration 3). Besides acting as the mRNA template for viral 
polymerase and capsid protein (HBc) synthesis15-17, 19, 25, 27, pgRNA is also the RNA 
template encapsidated in core particles required for the synthesis of HBV rcDNA. 
Therefore, to prevent HBV replication for the treatment of chronic hepatitis B, 
synthesis of pgRNA has to be inhibited. This may be achieved by targeting the 
activity of host factors that are critical for the establishment of functional host-




pathogen interaction at the HBVCP. To do so, a better understanding of the binding 
factors at the HBVCP is required. 
 
3.2 SCREEN FOR CRITICAL TRANSCRIPTIONAL REGULATORS 
 
The HBVCP54, 55 contains an upstream URR (Upstream Regulatory Region) which 
regulates the activity of the downstream BCP (Basal Core Promoter) (Illustration 5). 
The BCP contains four TATA-like boxes51, 52, 55, 56, of which the 3’ one is associated 
with the initiation of pgRNA synthesis54. The three 5’ end TATA-like boxes in turn 
initiate the synthesis of pcRNA, the 3.5kb RNA species from which the non-essential 
HBe antigen is synthesized. The mechanism for discriminating between pcRNA and 
pgRNA synthesis is not well-understood. As the BCP is the site for loading the basal 
transcriptional complex54, 55, transcription factors that bind the BCP tend to be 
functionally important for the cell’s survival and are ubiquitously expressed. These 
transcription factors are not particularly suited as targets for therapeutic intervention.  
 The URR on the other hand is a regulatory element that binds to most of the 
transcription factors reported to interact with the HBVCP. It is believed to confer the 
“liver-tropism” of HBV as many specific binders such as HNF360, 63, 64, HNF4α58, 60, 61, 
77, 205 and c/EBPα/β60, 65, 214 are enriched in the liver (Illustration 14). The relative 
tissue specificity hence general “redundancy” towards a cell’s survival renders the 
URR a more attractive region for initiating a screen to identify potential therapeutic 
targets. Furthermore, host factors that bind the URR specifically modulate the 
initiation events occurring at the BCP hence are no less important than those binding 
the BCP required for pgRNA synthesis.  Therefore, emphasis was placed on 
performing a thorough screen at the URR for host binding factors that are critical for 
the regulation of transcription at the HBVCP. 
 






Illustration 14 Described binders63, 64, 67, 215-219 of the HBVCP upper regulatory region. 
Transcriptional repressors binding to the NRE are indicated in dark grey, while 
transcriptional activators known to bind enhancer II are indicated in light grey. Each 
numbered line corresponds to a 15bp URR deletion. Nucleotide positions of the URR 
are as indicated with respect to HBV genotype A. 
 
The URR has been functionally divided into the upstream negative regulatory 
element (NRE), as well as a positive regulatory element enhancer II, which partially 
overlaps with the BCP (Illustration 5 and 14). This suggests that transcriptional 
repressors preferentially bind the NRE to exert inhibitory effects while transcriptional 
activators bind enhancer II to result in enhanced pgRNA synthesis. Both types of 
host factors have potential as candidates of therapeutic intervention.  
To determine which host factors that bind the URR are important for the efficient 
synthesis of pgRNA, the precise sites to which these factors bind had to be 
determined. Thus, 21 overlapping deletions within the URR spanning 15bp each 
were designed (Illustration 14), and the entire mutant HBVCP of HBV genotype A 
background was inserted into the PGL3 Basic luciferase expression vector. The 
mutant HBV core promoter constructs were tested in the four different liver-derived 
cell lines—HepG2 which supports efficient HBV replication, Huh-6, Huh-7 and Sk-













































individual URR deletions across the cell lines would provide evidence on whether the 
host factor binding site removed displays functional variability in different host cells to 
affect host-pathogen interactions. Several guidelines outlined in Table 5 were drawn 
for the characterization of the nature of the binder and host-pathogen interaction that 
may be deduced by the 4 possible scenarios with analysis of the results. These 
guidelines would help determine if the HBVCP specific binder were suited for 
therapeutic manipulation designed for the treatment of chronic HBV infection. 
Significant changes in luciferase expression of deletion mutants relative to that of 
wild-type HBVCP would indicate that the site specific for a critical host factor to bind 
has been removed. The nucleotide sequence of this site would then be used for the 
identification of the specific binder. The deletions were designed with extensive 
overlaps, such that the binding site of a candidate host factor would be expected in 
most cases to span at least 2 designed deletions. This allows the identification of true 
positive binding sites which will be characterized by having adjacent deletions 
presenting similar significant trend of altered luciferase expression, enabling the 
elimination of false positive sites when the trend is not observed (Scenario 1). 
However, not all true positive binding factors are necessarily good targets for 
therapeutic manipulation. Host factors that exert effects only in a specific cell line 
reflect a host-pathogen relationship unique to the cell line (Scenario 2) hence there is 
no means of characterizing whether the host factor exhibits properties that enables 
efficient HBV replication applicable to a large and variable population. Such true 








































1 No No No No No N.A. N.A. N.A. 
2 Yes Yes/No No No Yes Cell line specific Atypical No 






activity at HBVCP 
No 
4 Yes Yes Yes No Yes Displays variability  
Variants dictate 




* Applicable only to host factors whose binding site centers over more than one sequence to be deleted. 
# “Graduated” luciferase expression refers to the deletion of critical host binding factor site displaying a trend of increasing altered luciferase 
expression as the core of the binding site is approached. 




Total ablation or dramatic changes of luciferase expression in Sk-hep-1 incapable of 
enabling efficient HBV replication would correspond to the ubiquitous nature of the 
host factor in question and suggest its absolute role in regulating basal pgRNA 
synthesis (Scenario 3). The role of such factors is likely to be highly important 
towards a cell’s well-being hence modulation of its activity would most probably be 
cytotoxic, rendering such factors to be unfavourable therapeutic targets. In contrast, 
deletions that result in a trend that positively or negatively correlates with the ability of 
a cell line to synthesize cccDNA would suggest that the host factor associated with 
the deleted site is a favourable target for therapeutic intervention (Scenario 4). This is 
because the identified factor is critical for effective transcription at the HBVCP hence 
pgRNA synthesis yet its activity can be manipulated without adversely affecting the 
cell’s survival. Studying how the properties of this host factor differs in cells that 
enable efficient HBV replication and those that do not will shed light on how the 
therapeutic agent in question is to be designed. By disrupting host-pathogen 
interaction functional for effective HBV replication, switching the identified candidate 
therapeutic target from a form that enables transcriptional activation at the HBVCP to 
another that disfavours transcription would be a gentle yet effective means of 
preventing pgRNA synthesis in chronic HBV carriers. 
The results of the URR deletions in the four cell lines are shown in Figure 5. 
Congruent with the prediction that the amount of cccDNA produced is reflective of the 
capability of the host factors found within each cell line in enabling efficient 
transcription of pgRNA at the HBVCP (Figure 4A), comparison of the relative 
luciferase expression driven by the wild-type HBVCP reveals that HepG2 is most 
transcriptionally active at the HBVCP, followed by Huh-6, Huh-7 and Sk-hep-1 which 
was could only drive trace amounts of luciferase expression.  This is consistent with 
the hypothesis that the cell lines tested differ in their ability to enable efficient HBV 
replication due to the variability of critical host factors that are needed for pgRNA  






Figure 5 Effect of URR deletions on the HBV core promoter. Bars represent the 
mean normalized luciferase expression relative to the wild-type luciferase expression 
of each cell line. Deletions of the NRE are indicated in dark grey, while deletions of 
enhancer II are indicated in light grey bars. Binding factors that contribute to altered 
luciferase expression are indicated as circles. A—NREBP; B—FTF; C—C/EBP or 
E4BP4 or HLF; D—HNF3; E—HNF1; F—SP1.  Results show mean ± SE of 



































































































transcription. Therefore, the deletion of binding sites to which host factors critical for 
pgRNA transcription would produce the greatest response in HepG2 followed by 
modest responses in Huh-6 and Huh-7, whereas in Sk-hep-1, the deletion of such 
sites should have little or no effect. This was indeed the case, as all deletions in the 
NRE resulted in an increase in luciferase expression and all deletions in the 
enhancer II (except deletion 6) drastically reduced luciferase expression by more 50% 
wild-type expression in HepG2, in stark contrast to the relative milder changes in 
luciferase expression in Huh-6 and Huh-7, and no change in luciferase expression 
with most deletions in Sk-hep-1. Huh-6 is more efficient that Huh-7 in synthesizing 
cccDNA (Figure 4A) hence expectedly more efficient in pgRNA synthesis. This is 
supported by the greater reduction in luciferase expression in URR enhancer II 
deletions in Huh-6 than Huh-7 (Figure 5), such that the effect of all the URR 
deletions observed in Huh-6 almost parallel that of HepG2. 
In the cell lines capable of HBV transcript synthesis, all NRE deletions resulted either 
in enhanced luciferase expression or had little effect. In comparison, all enhancer II 
deletions resulted in reduced luciferase expression (Figure 5). These observations 
are consistent with the description that the NRE binds transcriptional repressors 
while the enhancer II binding transcriptional activators54, 55. However, even though 
many transcription factors have been reported to regulate transcriptional activity at 
the HBVCP63, 64, 67, 215, 216, 218, 219 (Illustration 14), the results show that only a handful 
are important.  
The liver-enriched transcriptional activator HNF4α described as being positively 
correlated with HBV titres in patients60 had milder effect with the removal of its 
binding site by deletion 9 (Illustration 14 and Figure 5) when compared to all other 
URR deletions in HepG2. Similar results were obtained in Huh-6 and Huh-7, where 
more than 50% of wild-type luciferase expression remained. Thus, interaction of 
HNF4α with the HBVCP is not as crucial to pgRNA synthesis as reported. In contrast, 




absence of the described binding site for another liver-enriched factor HNF161, 219 
centered about the nucleotides removed by deletion 19 (Illustration 14) consistently 
decreased wild-type luciferase expression by more than 75% in all cell lines (Figure 
5). However, as HNF1 is functionally important as its mutations are associated with 
multiple diseases62, 70, 73, 220, the manipulation of HNF1 activity could have severe 
consequences rendering it an unsuitable target for therapeutic modulation. The 
HNF1 binding site removed by deletion 19 also resulted in total ablation of the basal 
luciferase expression in Sk-hep-1 (Figure 5), corresponding to scenario 3 (Table 5) 
under which describes HNF1 to be an unsuitable therapeutic target.  
The removal of the SP1 binding site54, 55, 67, 68 by deletion 21 (Illustration 14) also 
resulted in the complete loss of luciferase expression in Sk-hep-1 and Huh-7 (Figure 
5), fulfilling the requirements depicted in scenario 3 (Table 5), rendering SP1 a poor 
candidate of therapeutic manipulation. Interestingly, the effects of SP1 mediated 
transcription at the HBVCP are less important in cell lines that are more capable in 
enabling efficient HBV replication such as HepG2 and Huh-6, as deletion 21 did not 
the maximal loss of HBVCP transcriptional activity (Figure 5). Therefore, in cells 
such as HepG2 capable of enabling efficient HBV replication, the transcription 
activation role of ubiquitous hence highly conserved factors such as SP1 is less 
substantial compared to the role played by host factors displaying variability. This 
further supports elimination of SP1 from the list of potential therapeutic candidates.  
Deletions of sites 1 and 5 are the only sites of the NRE that consistently produce an 
increase in wild-type HBVCP luciferase expression (Figure 5) in the cell lines 
capable of enabling HBV replication (HepG2, Huh-6 and Huh-7). There was however 
no correlation between the extent of increase in luciferase expression with the ability 
of the cell line to support efficient HBV replication as depicted by scenario 2 (Table 5), 
thus even though the host factors for these sites are true positives, they are not the 
most ideal therapeutic candidates because they may reflect atypical host-pathogen 




interactions. The site removed by deletion 1 most likely corresponds to that of the 
transcriptional repressor NREBP (NRE-binding protein)218 (Illustration 14). This was 
based on the negligible effect on luciferase expression by removal of the overlapping 
SP1 binding site by deletions 2 and 3 (Figure 5), as well as the fact that the bulk of 
NFACT1-C217 and RFX-MBP1215 complex recognition sequences lie 5’ external to the 
site removed in deletion 1 (Illustration 14), rendering them to be unlikely candidates 
for the effects observed by deletion 1. The identity of the binding factor for the site 
removed by deletion 5 was questionable as the best candidate is described to be a 
transcriptional activator FTF216 (Illustration 14). The increase in luciferase 
expression by the removal of nucleotides in deletion 5 thus contradicts the expected 
results of a reduction in luciferase expression. In Sk-hep-1 not suited for efficient 
HBV replication, deletions 1 and 5 both result in a reduction in relative wild-type 
luciferase expression (Figure 5). This is an interesting observation, as it suggests 
that NREBP and FTF shown to mediate transcriptional repressive effects in HepG2, 
Huh-6 and Huh-7 is now a transcriptional activator in the Sk-hep-1 cell line incapable 
of enabling HBV replication. This may be investigated in future. 
In enhancer II, other than deletion 6, the loss of more than 50% wild-type luciferase 
expression in all URR deletions in HepG2 (Figure 5) makes it difficult to distinguish 
the contribution of each binding site towards transcriptional activation activity at the 
HBVCP.  Nevertheless, it is very clear that deletions 7 and deletion 17 result in 
maximal attainable loss in luciferase expression, such that only 7% and 4% 
respectively of wild-type luciferase expression remained. Of note, both exhibited a 
“graduated” response, in that deletion of adjacent nucleotides resulting in a step-wise 
loss of luciferase expression which to reach a trough observed by the minimal 
luciferase expressions with deletions 7 and 17. This confirms that both sites bind to 
host factors critical for the transcriptional activation of HBVCP, as the extensive 




overlapping of the deletions was designed to capture such a trend for true positive 
binding sites.  
The site removed by deletion 7 has been well-described (Illustration 14), and 
reportedly bound by several factors, including the well-known transcriptional activator 
c/EBPα/β65, 214, HLF (Hepatic Leukemia Factor)216 known to accumulate in 
accordance with the circadian rhythm, as well as a component of the circadian clock 
E4BP4216. However, as deletion 7 showed mild effects in Huh-6 and Huh-7 such that 
50% or more of wild-type luciferase expression remained (Figure 5), this site 
behaved in the way described by scenario 2 (Table 5) and deemed to exert its 
effects more specifically in HepG2 (Table 5) thus not of primary interest.  
The site removed by deletion 17 generates greatest interest, as its effects correlate 
well with the cell line’s ability to support efficient HBV replication, a trend indicative of 
the binding factor’s suitability as a candidate therapeutic target. Removal of site 17 
shows maximal loss of wild-type luciferase expression in HepG2, followed closely by 
Huh-6 with approximately 10% wild-type luciferase expression remaining, Huh-7 with 
approximately 25% wild-type luciferase expression remaining, and Sk-hep-1 which 
remained unaffected by the deletion (Figure 5). This is the only site that fulfills the 
requirements depicted by scenario 4 (Table 5), making the binding factor to the site 
removed by deletion 17 the only promising candidate for the development of a novel 
therapeutic aimed at preventing pgRNA synthesis in the URR screen. 
The identity of the binding factor specific for the site removed by deletion 17 however 
is not known. Progressing from a 5’Æ3’ direction, deletion 15 to 17 resulted in 
increasing reduction of luciferase expression, indicating the binding factor to bind 
towards the 3’ end of deletion 16 or 17. However, deletion 18 breaks the trend of 
increasing reduction in luciferase expression, suggesting that the nucleotides 
recognized by the critical binding factor center the 3’ end of the sequence deleted by 
site 16. HNF3 cannot be the binding factor of interest, as its recognition site is 




centered about the sequence removed in deletion 18 (Illustration 14) which by 
comparison displayed more than 40% wild-type luciferase expression remaining in all 
cell clines capable of HBV transcript synthesis. Therefore, since the site removed by 
deletion 17 (henceforth known as URR17) is not known to bind any transcription 
factor (Illustration 14), a novel transcriptional activator binding site critical for 
transcription at the HBVCP has been discovered. This factor is the best candidate 
from the URR screen for the manipulation of its activity in the quest for a novel 
strategy to control HBV replication by preventing pgRNA synthesis. 
In summary, the thorough screen at the URR for host binding factor necessary for 
enabling functional host-pathogen interaction revealed that only a handful of 
described transcription factors are important for regulating transcription at the 
HBVCP. Of these, only NREBP and possibly FTF are negative regulators. 
Transcriptional activators such as HNF1 and SP1 act as regulators necessary for 
sustaining basal transcription in cell lines less capable of enabling efficient HBV 
replication, such as Huh-7 and Sk-hep-1. Other transcription factors such as HNF4α 
are not as important as described for transcription at the HBVCP, as the deletion of 
its binding site results in relatively mild reduction of wild-type luciferase expression 
when compared to the deletion of other host factor binding sites. c/EBPα/β, E4BP4 
and HLF exert their transcriptional effects only in HepG2. Only a single host factor of 
unknown identity that binds a site named URR17 fits the qualities that describe the 
putative therapeutic target. Determining the identity of this host factor is thus of 
utmost importance. 
  




3.3 NOVEL TRANSCRIPTIONAL ACTIVATOR HAS UNCHARACTERIZED MOTIF 
 
The “TTCAAA” motif and potential binding candidates 
Transcription factors have recognition motifs, preventing them from binding in a 
haphazard manner, achieving transcriptional regulation only at specific loci. A site 
within the URR of the HBVCP critical for determining the efficiency of HBV replication 
in cell lines was identified, but the host factor that recognizes this sequence (URR17) 
remains to be determined. Presumably, candidates for the identity of this binder 
should be readily attainable by performing a transcription factor database search 
using softwares such as MATCHTM, where high degree of similarity of the URR17 
sequence to described recognition motifs would indicate that the URR17 sequence 
potentially binds the factor to which the recognition motif was ascribed to. In order not 
to miss out any potential candidate, the entire HBV core promoter sequence was 
screened using the transcription factor database MATCH for potential URR17-
binders. 
The search output is depicted in Figure 6, and predicts that COMP1, Pax 4, Pax6 
HNF4α and Oct-1 were potential binders of URR17. To determine which of these 
transcription factors is the true therapeutic target binding to URR17, the core of the 
recognition motif of the URR17-binder must be obtained. This was achieved by in-
depth analysis of the relative luciferase expression with deletions 14 to 18 within the 
URR (Figure 5), where the extensive overlap of the nucleotide sequences deleted 
(Illustration 14) enables the precise nucleotides constituting the core of the 
recognition motif to be pinpointed (Figure 6).  






Figure 6 Prediction of transcription factors binding to URR17. The nucleotide 
sequence of part of the URR is as shown, and the deduced binding motif “TTCAAA” 
of the novel transcriptional activator is highlighted in bold typeface. URR deletions 
are indicated as grey lines, and the effect of each deletion relative to wild-type 
luciferase expression in HepG2 is also indicated. The relative binding sequences of 
transcription factors with core match scores greater than 0.75 predicted by MATCH 
to contain the deduced “TTCAAA” sequence are indicated in grey double-headed 
block arrows. The matrix match scores of these factors are also represented. 
 
Based on the altered luciferase expression with URR deletions obtained from HepG2, 
removal of nucleotides 1707-1721 by deletion 17 resulted in only 4% of wild-type 
luciferase expression remaining. This is in stark contrast with the 39% wild-type 
luciferase expression remaining by the removal of nucleotides 1713-1727 with 
deletion 18. Therefore, the core of the recognition motif of the URR17-binder must 
contain the 6 nucleotides covered by deletion 17 but not removed by deletion 18, 
which corresponds to the “TTCAAA” sequence (nt 1707-1712 of HBV genotype A). 
Notably, this core motif is in the center of the sequence removed by deletion 16, 
accounting for the low luciferase expression of only 8% wild-type expression. Further 
deletions extending 5’ of the “TTCAAA” core result in the amelioration of reduction in 
















































nucleotides 5’ of the “TTCAAA” sequence do not significantly contribute to the 
transcriptional activation of the HBVCP required for pgRNA synthesis. Therefore, the 
URR17-binder must have a recognition sequence with the “TTCAAA” sequence 
strategically located within the center of its motif predicted by the MATCHTM software. 
Only the “liver-enriched” HNF4α as well as the ubiquitous Oct-1 fit this criteria 
(Figure 6). 
To determine which of these candidates are better candidates befitting the 
description of the URR17-binder, the degree of similarity between the predicted 
binding sites of the putative transcription factor and that of described consensus was 
analyzed. Since both HNF4α and Oct-1 consensus recognition motifs have equal 
similarity to that of the predicted binding site on the URR as indicated by equal matrix 
match scores of 0.70 (Figure 6), they may not be distinguished based on the matrix 
match scores. Only the core match score sets the two transcription factors apart 
(Figure 6). HNF4α had a perfect core match score of 1.0, indicating that the 
predicted HNF4α binding site within the URR was identical to 5 consecutive 
nucleotides in the consensus recognition sequence of HNF4α. However, these 5 
consecutive nucleotides need not be the nucleotides central to the HNF4α 
consensus binding site. In comparison, the Oct-1 core match score was much lower 
at 0.82, indicating that any 5 consecutive nucleotides within the predicted Oct-1 
binding site has no sequence identity to 5 consecutive nucleotides of the consensus 
Oct-1 recognition motif. Even though the likelihood of HNF4α recognizing the URR 
sequence bearing the “TTCAAA” motif within is higher, the role of the nucleotides 
flanking the 5 “core” nucleotides cannot be neglected. Therefore, the relatively low 
matrix match score of 0.7 suggest that the probability that HNF4α is the URR17-
binder is also not very high. Furthermore, two HNF4α binding sites in the HBVCP 
have already been described52, 58, one of which has already been shown as playing a 
role less important to efficient HBV replication as claimed. On top of this, if the 




URR17-binder were HNF4α, the differential contribution of HNF4α to the 
transcriptional activity at different sites of the HBVCP found within a short distance of 
one another would be very peculiar. Therefore, detailed analysis was required before 
jumping to conclusion that HNF4α is the URR17-binder thought to be of therapeutic 
value. 
 
HNF4α consensus binding motif bears some resemblance to “TTCAAA” motif 
HNF4α (Hepatocyte Nuclear Factor 4α) is a member of the orphan nuclear receptor 
family of transcription factors221, where the ligand for activation of its transcriptional 
activities has not been defined . HNF4α is however known to be constitutively bound 
by a variety of fatty acids. Even though HNF4α is highly enriched in the liver, it may 
be found in other tissues and organs such as the kidneys and the β-cells of the 
pancreatic islets212, 221, 222. Mutations to HNF4α have been associated with human 
diseases such as maturity onset diabetes of the young type 1 (MODY1)71, 73, 221. 
Therefore, if the URR17-binder were HNF4α, therapeutic manipulation of its activity 
would not be wise as the consequences of which could be very severe. Nevertheless, 
to determine if HNF4α is the specific binder at the novel site of the HBVCP important 
efficient HBV replication, Electrophoretic mobility shift assays (EMSAs) were 
performed. If HNF4α could bind the nucleotide sequence of URR17 to result in a 
shifted complex identical to that formed between HNF4α and its consensus 
recognition motif, the URR17-binder would undoubtedly be HNF4α.  
URR17 is a unique site on the HBVCP as an unknown property of the host factor 
recognizing the “TTCAAA” sequence within URR17 varies between the cell lines 
tested. This variable property determines the ability of the cell line to enable efficient 
HBV replication. A means to obtain variability of protein properties across cell line 
and human populations may be the preferential expression of specific isoforms. If 




HNF4α is the host factor of interest, it must possess some variability in the different 
cell lines used. Before performing EMSA to prove the association of HNF4α with the 
URR17 DNA sequence, the variability of HNF4α in the cell lines was first investigated.  
It has been reported that as many as 9 isoforms of HNF4α may be possible221, 
although only 6 such isoforms have been proven to exist in humans (Figure 7A). 
These isoforms are produced by alternative splicing and the use of alternative 
promoter elements222, 223, although the mechanism for regulating the expression of 
each isoform is not well-understood. The best studied isoforms are HNF4α1 and 
HNF4α2, which differ in the C-terminal domains, reported to be abundantly 
expressed in normal hepatocytes221.  HNF4α7 and HNF4α8 are isoforms with N-
termini lacking the AF-1 domain thought to be important for the regulation of HNF4α 
transcription factor activity224. Whether this translates into their constitutive 
transcriptional activation properties is not known, but these isoforms are reportedly 
associated with stem cell status221. HNF4α3 and HNF4α9 are less understood, and 
the expression of HNF4α9 is thought to be restricted to pancreatic β-cells. It is 
possible that the preferential expression of HNF4α isoforms in the cell lines tested 
confer the cell lines ability to support efficient HBV replication. Furthermore, while the 
HNF4α transcription activator can only exert its effects as a homodimer221, it is not 
known if the homodimer can comprise of different isoforms to give even greater 
diversity of transcriptional activity. To investigate, the expression of HNF4α isoform 
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for efficient HBV replication. HNF4α3 was the only isoform whose protein expression 
positively correlates with the ability of the cell line to efficiently synthesize cccDNA 
(Figure 4 and 7C), such that the protein expression of HNF4α3 is highest in HepG2 
which produced most cccDNA and lowest in Huh-7 which produced least cccDNA 
amongst the 3 cell lines. Taking this into account with the negligible amount of 
HNF4α3 protein expression in Sk-hep-1 that cannot support efficient HBV replication, 
HNF4α3 has the greatest potential to be the URR17-binder. 
To prove whether HNF4α3 were the URR17-binder, EMSA was performed with 
HepG2 nuclear lysates shown in figure 7C to be enriched with HNF4α3. Using the 
HNF4α consensus recognition motif as a positive control, HNF4α was shown to bind 
the biotinylated probe in a dose-dependent manner with high affinity (Figure 8A), 
such that low amounts of biotinylated probe (0.5ng) was sufficient to show the 
HNF4α-probe shifted complex. Interestingly, a band for another protein-probe 
complex was observed with higher amounts (1.25ng) of biotinylated HNF4α 
consensus motif probe. The protein responsible for this complex bound DNA in a 
sequence-specific manner, as 0.75ng of the biotinylated URR17 sequence bearing 
the “TTCAAA” motif was not only sufficient to produce the same band (Figure 8A), it 
was able to bind the URR17 sequence in a dose-dependent manner. This protein 
therefore had a higher affinity for the URR17 probe sequence than the HNF4α 
consensus motif sequence. This protein-DNA interaction was unlikely to be non-
specific as a thousand-fold excess of poly-dIdC was present in the EMSA reaction to 
sequester DNA binders that bind in a sequence independent manner. Since HNF4α 
could not bind the URR17 probe even at high probe amounts (1.25ng), the protein 
that produced the novel band is instead the specific URR17-binder of interest. As the 
affinity of the URR17-binder for its “TTCAAA” motif is much lower than that of HNF4α 
since relative larger amounts of biotinylated URR17 probe (1ng) is required to 
produce a prominent band somewhat equivalent to the HNF4α-HNF4α consensus 




motif complex, it is very likely that the URR17-binder has to be found in the nucleus 
in abundance for it to effectively carry out its transcriptional activation function for 
effective pgRNA synthesis.  
To further prove that HNF4α is not the URR17-binder, another EMSA with HepG2 
nuclear lysates and large amounts of biotinylated probes (maximum 2ng) was 
performed, and the shifted DNA-protein complexes electroblotted onto PVDF 
membrane followed by detection for HNF4α (Figure 8B). Using 1ng of biotinylated 
HNF4α consensus sequence probe was sufficient to produce maximum signal for 
HNF4α in the western blot, indicating that maximal amount of HNF4α present in 2μg 
of HepG2 nuclear lysate was specifically sequestered by the HNF4α consensus motif 
probe. In contrast, 2ng of biotinylated URR17 probes did not produce any HNF4α 
specific band, indicating that HNF4α cannot recognize the URR17 probe sequence. 
HNF4α thus cannot be the URR17-binder of interest.  
To further prove that HNF4α cannot bind the URR17 sequence, a competitive assay 
was performed. As shown in figure 8C, 1ng of biotinylated HNF4α consensus 
binding sequence produced a band specific to HNF4α which could be super-shifted 
with the addition of HNF4α specific antibody. Large excess of 250-fold of unlabeled 
HNF4α completely removed the HNF4α-biotinylated probe complex, indicating the 
affinity of HNF4α for the HNF4α consensus sequence. However, addition of 250-fold 
of unlabeled URR17 sequence probes failed to remove the HNF4α specific band, 
indicating that HNF4α had little affinity for the URR17 sequence, hence cannot 
possibly be the URR17-binder. Taking all the results from EMSA together, it is clear 
that HNF4α hence HNF4α3, is not the protein of interest that binds the “TTCAAA” 
motif core within the URR17 sequence. Instead, the unknown protein producing the 
novel band observed in figure 8A is the URR17-binder of interest. However, the 
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consensus. Indeed, HNF4α binds DNA as a homodimer221, each monomer 
recognizing the sequence consensus half-site “AGGTCA” to form a direct repeat 
motif separated by a single nucleotide spacer “N” which can be any nucleotide 
(Direct Repeat 1 nucleotide spacer, DR1) (Figure 8D). Comparing this sequence 
with the URR17 sequence, it can be seen why the MATCHTM software produced a 
perfect core match score of 1.0 (Figure 6). Both the HNF4α consensus and the 
URR17 sequence share the 5 consecutive nucleotide sequence “TCAAA” located 
within the “TTCAAA” core which was deduced to be important for the URR17-binder 
to exert its transcriptional activation effects. The slight change of just one base at the 
5’ end of the “TTCAAA” core in the URR17 sequence to “GTCAAA” sequence in the 
HNF4α consensus binding motif thus may not be significant to abrogate the URR17-
binder from recognizing the sequence hence accounts for its binding to the HNF4α 
consensus with lowered affinity. In such case, within the “TTCAAA” motif, the 3’ end 
of the sequence is more important than the 5’ end for the URR17-binder to recognize 
its motif, accounting for the milder loss of 85% of wild-type luciferase expression with 
deletion 15 that removed only the 5’ end nucleotides of the motif core when 
compared to the 92% loss of wild-type luciferase expression with the complete 
removal of the “TTCAAA” sequence with deletion 16 in HBVCP deletion mutants 
expressed in HepG2 (Figure 5). The lower affinity of the URR17-binder for the 
HNF4α consensus recognition motif can also account for the increase in HNF4α 
specific band intensity observed with the addition of 250-fold unlabeled URR17 
probes (Figure 8C), as the large excess of the “TTCAAA” motif and the higher affinity 
of the URR17-binder for the “TTCAAA” sequence than the “GTCAAA” sequence of 
the biotinylated HNF4α consensus motif probe sequesters the bulk of the URR17-
binder, enabling more HNF4α-HNF4α recognition motif complex to form. This 
increase in band intensity is only possible if the URR17-binder were present in large 
amounts in the nuclear lysate as was already suggested, URR17-binder can only 




sequester the biotinylated HNF4α consensus sequence probe to produce the 
“diminished” HNF4α specific band by overcoming its low affinity for the HNF4α 
consensus sequence with its relative abundance.  More importantly, as the URR17 
sequence possesses only a “near” perfect HNF4α 5’ half-site, with the 3’ half-site 
sequence “AGACTG” bearing low resemblance to the “AGGTCA” HNF4α consensus 
half-site, accounting for the inability of HNF4α to bind the URR17 sequence. Thus, it 
is proven that HNF4α is not the URR17-binder, but the identity of the URR17-binder 
remains unknown. Nevertheless, the properties of the motif recognized by URR17-
binder and its relative abundance in the nucleus are now better understood. 
 
Elimination of Oct-1 as the URR17-binder 
Only Oct-1 remains as a candidate specific binder of the “TTCAAA” motif predicted 
by the MATCHTM software. It is also now clear the 3’ end of the “TTCAAA” motif is 
more important for the URR17-binder to recognize it, and that the URR17-binder 
probably exists in the HepG2 nucleus in high abundance. Therefore, should the Oct-
1 consensus binding motif deviate greatly from the 3’end of the “TTCAAA” motif, it 
would be obvious that Oct-1 cannot be the URR17-binder. Comparing the Oct-1 
consensus recognition motif with the URR17 sequence (Figure 9A), the disparity 
between the two sequences can be clearly seen. Oct-1 is therefore highly unlikely to 
be the URR17-binder of interest.  
To prove so, EMSA with the HepG2 nuclear lysate was performed (Figure 9B). As a 
positive control, Oct-1 was shown to bind the Oct-1 consensus recognition motif in a 
somewhat dose-dependent manner. The alternating pattern of band intensity with 
increasing probe concentration is an indicator of the low abundance of Oct-1 in the 
HepG2 nuclear lysate, as tiny fluctuations in the volume of lysates used would greatly 
alter the number of Oct-1 molecules present in the reaction. This property contradicts 
the probable abundance of the URR17-binder in the lysate.  Indeed, Oct-1 specific 
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However, it was shown that in fact the HNF4α and Oct-1 consensus binding motifs 
either do not contain the “TTCAAA” motif or bear resemblance to the URR17 
sequence. Both transcription factors were also shown to be unable to bind the 
URR17 sequence. Thus, no known transcription factor has been described to bind 
the “TTCAAA” motif required for binding a transcriptional activator to efficiently 
enable HBV replication. An alternative approach is required to ascribe the novel 
recognition motif to its binding transcription factor. 
 
3.4 PARP1 BINDS HBV CORE PROMOTER IN SEQUENCE-SPECIFIC MANNER 
 
PARP1 binds the HBVP in sequence dependent manner 
It was deduced earlier that the URR17-binder is likely to be present in abundance in 
the nucleus of HepG2 lysates. Thus, by performing affinity pull-down assays using 
the URR17 sequence as a probe, the specific binder should be enriched to 
concentrations that are readily detectable. Purifying the specific binding factor and 
sending the protein for MALDI-TOF/TOF analysis should yield the identity of the 
URR17-binder.  
Biotinylated URR17 sequence was used as bait in independent streptavidin pull-
down assays, and a strong band of approximately 120kDa was obtained with the 
eluate which could not be detected when biotinylated EBNA probes were used 
instead as negative controls (Figure 10A). The URR17-binder is thus a large, 
abundant nuclear protein of approximately 120kDa. When sent for MALDI-TOF/TOF 
analysis, the results from the independent assays produced only a single 
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generally healthy157, suggesting PARP1 to be a suitable candidate for therapeutic 
manipulation. PARP1 enzymatic inhibitors (Illustration 12) are already being tested 
in clinical trials for the treatment cancer108, 132-134, 154, 169. To test whether these drugs 
would also be efficacious in preventing HBV replication, the specificity of PARP1 
binding to the URR17 sequence must first be ascertained. 
The identity of the novel band observed in the EMSA from figure 8A was proven to 
belong to PARP1. Using nuclear lysates from HepG2 treated with non-specific siRNA, 
the novel protein-DNA complex was reproduced. The intensity of the specific band 
was greatly diminished when nuclear lysates from HepG2 treated with PARP1 
specific siRNA was used instead, confirming that the band observed was formed by 
the interaction between PARP1 and the URR17 sequence. The interaction of PARP1 
with the URR17 sequence was sequence-specific, as the EMSA was performed in 
the presence of a thousand-fold excess poly-dIdC that sequesters DNA binders with 
little sequence specificity. The specific interaction between PARP1 and the URR17 
sequence was further demonstrated when a thousand-fold excess of poly-dIdC was 
incapable of diminishing the PARP1-URR17 band (Figure 11B) when a 100-fold 
excess of unlabeled URR17 probe was sufficient to do so (Figure 11A and 11B). 
Therefore, PARP1 is a transcription activator that recognizes the URR17 sequence in 
a sequence dependent manner. 
The identity of the URR17-binder was further ascertained by the use of PARP1 
specific antibodies that recognized its N-terminal domain, posing steric hindrance to 
prevent the association of PARP1 with the URR17 DNA sequence to result in a 
diminished PARP1-URR17 band (Figure 11A and 11C). The reduction in band 
intensity cannot be achieved with the use of other antibodies specific towards the 
transcription factors HNF1 or HNF3 thought to bind within the vicinity of URR17 
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specific siRNA 24 hours before transfection with the wild-type HBVCP construct, and 
the results revealed that luciferase expression was indeed reduced when compared 
to cells treated with non-specific siRNA (Figure 12A). This provides confirmation that 




Figure 12 PARP1 regulates transcription at HBVCP in motif dependent manner. (A) 
The effect of PARP1 specific knockdown on transcription at the HBVCP in HepG2 is 
represented by bars as the mean normalized luciferase expression ± SE relative to 
the wild-type (WT) HBVCP luciferase expression. (B) The effect of single base 
substitutions in HepG2 within the “TTCAAA” motif by A1712C substitution or flanking 
the motif by the G1713C substitution on PARP1 motif dependent transcription. 
Normalized luciferase expression with deletion 17 (URR17) is also shown for 
reference. ***P-value <0.001 with one-tailed student’s t-test.  
 
To further prove that the PARP1-HBVCP interaction is motif dependent, mutations of 
any nucleotide within the core “TTCAAA” motif should yield significant changes to 
wild-type luciferase expression. Since it had been deduced that the 3’ end of the 
“TTCAAA” motif is more important for the URR17-binder to exert its effects, a single 
base substitution at the 3’ end nucleotide would suffice to prove this. As expected, 
mutating the 3’ end nucleotide from “A” to “C” with the A1712C mutation that changes 
the core motif sequence to “TTCAAC” resulted in the loss of more than 80% wild-type 
luciferase expression (Figure 12B), confirming that PARP1 is a sequence dependent 
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a single base mutation of the 3’ nucleotide flanking the “TTCAAA” motif (G1713C) 
had little effect on wild-type luciferase expression, indicating that the loss of PARP1 
mediated transcription with the A1712C mutation was the specific outcome of a 
mutation to the “TTCAAA” motif, and that the 3’ boundary of the uncharacterized 
PARP1 binding motif was accurately defined. The results thus far have shown that 
PARP1 is a novel transcriptional activator at the HBVCP that acts through the 
recognition of the core binding motif “TTCAAA”. To prove the association of PARP1 
with the efficiency of a cell’s ability to enable efficient HBV replication, it has to be 
shown that pgRNA synthesis depends on PARP1. Only when this host-pathogen 
relationship has been confirmed can it be implied that modulation of PARP1 function 
and activity with therapeutics would alter the outcomes of HBV infection. 
 
Variable PARP1 transcriptional activation of pgRNA and pcRNA synthesis 
To prove that PARP1 regulates pgRNA synthesis, a better understanding of how the 
synthesis of pgRNA is transcriptionally controlled needs to be established. Thus, the 
cis-elements at the basal core promoter (BCP)54, 55 regulating pgRNA transcription 
was re-examined (Illustration 15). The BCP has been described to contain the cis-
elements required for the transcription of pgRNA and pcRNA, including four TATA-
like boxes and the pgRNA and pcRNA initiators56. The three 5’ TATA-like boxes are 
associated with the initiation of pcRNA transcription, while the fourth 3’ TATA-like box 
is associated with transcription initiation of pgRNA54. The pgRNA initiator is located a 
few nucleotides downstream of the pcRNA initiator, hence the 3.5kb pgRNA is 
slightly shorter than pcRNA50-52, 54, 56. It is not known how transcription initiation of the 
two RNA species is regulated to specifically allow the transcription of a particular 
transcript.  A DR1 element (not to be confused with the HNF4α consensus binding 
motif) located just downstream of the pgRNA initiator is required in pgRNA for the 
synthesis of rcDNA15-17, 19, 25, 27.Enhancer II that stretches over the URR and overlaps 




into the BCP, such that transcriptional activator binding sites overlap the TATA-like 
boxes required for pcRNA initiation. As was observed in the URR, these transcription 
factors may be ubiquitous in nature such as SP167 and hnRNP K204 or enriched in the 
liver such as HNF4α and HNF1. Of note, the SP1 site in the BCP is just adjacent to 
the SP1 site in the URR (Illustration 14). Consistent with the site of loading of the 
large RNA polymerase II complex, no transcription activator has been described to 




Illustration 15 The functional elements of the basal core promoter. Enhancer II (En II) 
overlaps with the BCP. Factors described to bind enhancer II67, 204, 225-227 are depicted 
in light grey boxes. TATA-like boxes 1-3 (TA1/2/3) indicated as grey circles are 
functionally redundant and required for pcRNA initiation, while TATA-like box 4 
indicated as a black circle is required for pgRNA initiation. The stars represent the 
common 1762 and 1764 mutations associated with increased viral load228. Numbered 
lines indicate the relative positions of 15bp deletions. The pcRNA initiator (pc Inr) is 
indicated in light grey while the pgRNA initiator (pg Inr) is indicated in black. 
Nucleotide positions with respect to HBV genotype A are also provided. DR1—Direct 
repeat 1.  
 
To investigate how pgRNA was transcriptionally regulated at the HBVCP, 9 
































designed were less extensive than that used in the identifying critical factors at the 
URR that enable efficient HBV replication, as the precise nucleotide sequences of 
transcription factors were not of interest. Instead, the deletions were aimed at 
understanding how each cis-element contributed to transcriptional regulation at the 
HBVCP, so that the effect of PARP1 on transcription activation at the HBVCP may be 
better understood. 
The effects of each BCP mutant on transcription at the HBVCP were tested in HepG2, 
Huh-6, Huh-7 and Sk-hep-1 (Figure 13). Interestingly, in HepG2 capable of efficient 
HBV replication, all BCP deletions except at site 1 resulted in an increase in 
luciferase expression. The two deletions that produced the maximum increase in 
luciferase expression were deletion of sites 4 and 8, such that luciferase expression 
was 3-fold or more of than the wild-type HBVCP (Figure 13). Deletion 4 removes the 
third TATA-like box and parts of the pcRNA initiator, while deletion 8 removes the 
entire pgRNA initiator (Illustration 15). The removal of either initiator suggests that 
the transcription of pcRNA would inhibit the transcription of pgRNA and vice versa. 
Perhaps, the RNA polymerase II complex that has initiated pcRNA synthesis cannot 
progress when pgRNA transcription is initiated at the same time, accounting for the 
relief of pcRNA synthesis inhibition when the pgRNA initiator is removed by the 
deletion of site 8 hence increased luciferase expression by the generation of longer 
transcripts initiated at the pcRNA initiator. Likewise, binding of the RNA polymerase II 
complex at the pcRNA initiator would prevent the utilization of the 3’ TATA-like box 
required for pgRNA initiation, thus its removal with deletion 4 would result in increase 
luciferase by producing transcripts initiated at the pgRNA initiator. As such, the 
relative luciferase expression in each cell line can be interpreted where deletion of 
site 4 would reflect the ability of the cell to efficiently transcribe pgRNA, while the 
deletion of site 8 would reflect the ability of the cell to efficiently transcribe pcRNA.  
 






Figure 13 PARP1 regulates pgRNA and pcRNA synthesis. 15bp deletions of the 
enhancer II region within the BCP are indicated in light grey, while other BCP 
deletions are indicated in dark grey bars. The means of normalized luciferase 
expression ± SE relative to the wild-type of representative experiments are shown. 
Relative positions of SP1 (A) and hnRNP K (B) that contribute to altered luciferase 
expression by deletion 1 are indicated as circles. The relative positions of elements 
making up the BCP are also indicated as boxes. TA—TATA-like box; pc—pcRNA 
initiator; pg—pgRNA initiator; DR1—Direct repeat 1.  
 
Therefore, the results from figure 13 suggest that only HepG2 can efficiently produce 
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not, as deletion of site 4 had little effect on the relative wild-type luciferase expression. 
This is consistent with the ability of HepG2 to synthesize large amounts of cccDNA. 
Hence, the ability of PARP1 to modulate luciferase expression with the deletion of 
site 4 in the BCP of the HBVCP would prove that PARP1 is the transcriptional 
activator whose properties would determine a host cell’s ability to enable efficient 
HBV replication. In comparison, if PARP1 could only exert its effects to modulate the 
expression of luciferase in the mutant HBVCP with the deletion of site 8, then PARP1 
can only exert its effects specific to the initiation of pcRNA which has little direct 
effect on HBV replication, thus the therapeutic potential of modulating PARP1 activity 
for the reduction of pgRNA synthesis in such case would not be justified. 
The A1712C single base substitution at the “TTCAAA” core motif of the PARP1 
binding site has been demonstrated to specifically reduce PARP1 dependent 
transcription at the HBVCP (Figure 12). To determine if PARP1 were required for the 
initiation of pgRNA and pcRNA, the ablation of PARP1 dependent transcription by 
the A1712C single base substitution was investigated in all four cell lines (Figure 13). 
Intriguingly, the A1712C mutation coupled with the deletion of site 4 resulted in 80% 
reduction of luciferase expression when compared to the luciferase expression of site 
4 alone in both HepG2 and Huh-6, but in Huh-7 and Sk-hep-1 a slight increase in 
luciferase expression was instead observed. As the deletion of site 4 suggests that 
the initiation of luciferase transcripts can only occur at the pgRNA initiator, this results 
indicates that PARP1 indeed exerts variable activity in the cell lines to confer HepG2 
and Huh-6 the increased ability to generate cccDNA by transcriptional activating 
pgRNA synthesis, but in the cell lines Huh-7 and Sk-hep-1 less able to support 
efficient HBV replication, PARP1 was unable to do so. PARP1 is therefore the host 
factor involved in enhancing functional host-pathogen interaction to enable efficient 
HBV replication. PARP1 also exerted its effects on pcRNA transcription (Figure 13). 
Comparing the luciferase expression of the A1712C mutation in HBVCP with deletion 




8 to that of the deletion of site 8 alone reveals that in HepG2 and Huh-6, a reduction 
of luciferase expression was also observed, while in Huh-7 and Sk-hep-1, the 
A1712C mutation had little effect on luciferase expression. Thus, PARP1 exerts its 
transcriptional activation effects by binding the “TTCAAA” core to regulate the 
transcription of pgRNA and pcRNA. Preventing PARP1 from exerting its effects as a 
transcriptional activator at the HBVCP therefore would prevent pgRNA and pcRNA 
synthesis to result in the inability of a cell to sustain infectious virion synthesis, de 
novo cccDNA synthesis as well as HBe secretion, achieving the aim of shutting down 
HBV replication to clear HBV infection. 
Besides the deletion of the pgRNA initiator site, removal of the 3’ end TATA-like box 
required for the initiation of pgRNA transcription together with the pcRNA initiator by 
the deletion of site 5 in the BCP (Illustration 15) should also shed light on how well 
the cell line can support transcription at the pgRNA initiator. Surprisingly, removal of 
the 3’ end TATA-like box did not result in the abrogation of pgRNA synthesis in 
HepG2 most capable of enabling efficient HBV replication, indicating that luciferase 
transcripts could be initiated at the pgRNA initiator by the use of alternative TATA-like 
boxes as well. In such case, congruent with the ability of the cell line to efficiently 
generate cccDNA, the deletion of site 5 in the BCP resulted in an increase in wild-
type luciferase expression in the cell line best able to support HBV replication, while 
little change in wild-type luciferase expression was observed in Huh-6, 70% reduction 
in wild-type luciferase expression was observed in Huh-7, and the total ablation of 
luciferase expression in Sk-hep-1 deemed to be not supportive of HBV replication, 
indicating that the amount of cccDNA generated by the different cell lines positively 
correlate well with the ability of the cell  line to initiate transcription of pgRNA. This is 
important, as it implies that the amount of cccDNA detected in figure 4A is a true 
reflection of the amount of pgRNA synthesized, hence proves that the cccDNA 
produced is indicative of HBV replication with the HBV-RFP transfection model. 




Deletion of site 6 removes the bulk of the 3’ TATA-like box and part of the pcRNA 
initiator (Illustration 15), preventing the recognition of the 3’ TATA-like box and the 
initiation of pcRNA as well. Expectedly, the results obtained in every cell line 
paralleled that of the altered luciferase expression observed with the deletion of site 5. 
Since the 3’ TATA-like box may not be exclusively utilized for the initiation of pgRNA 
transcription, the utilization of any of the 5’ TATA-like boxes must have resulted in the 
sustained luciferase expression with the deletion of sites 5 and 6. Therefore, these 
TATA-like boxes may not be described to be exclusively utilized for the initiation of 
pcRNA transcription as well. Thus, the decrease in luciferase expression in all cell 
lines with the removal of the second and third TATA-like boxes by deletions 2 and 3 
when compared to deletion of sites 4 and 8 (Figure 13) can only suggest that these 
TATA-like boxes do contribute to transcription at the HBVCP, but nothing may be 
said about how much each cis-element contributes to the initiation of pcRNA or 
pgRNA transcription. Due to the extensive overlap of the enhancer II into the BCP, 
deletions 2 and 3 also result in the removal of binding sites of transcription activators 
such as HNF4α and HNF1 (Illustration 15). Assuming that alternative TATA-like 
boxes may be utilized in the initiation of pgRNA and pcRNA, it is clear that none of 
these transcription activators thought to bind to the sites removed by deletion 2 or 3 
are critical for transcription at the HBVCP, as both deletions in all cell lines were still 
able to sustain at least 50% wild-type luciferase expression. This implies that HNF1, 
HNF4α, COUP-TF1, TR4 and the FXR/RXR complex are not critical for 
transcriptional activity at the HBVCP.  
The removal of the first 5’ TATA-like box by deletion 1 is the only deletion that results 
in the reduction of luciferase expression in all cell lines (Figure 13). Due to the 
presumed redundancy of the TATA-like boxes, the reduction of luciferase expression 
can be said to reflect the importance of the transcription activators binding to this site 
in enabling transcription at the HBVCP. The transcription factors in question are the 




essential and ubiquitous SP1 and hnRNP K (Illustration 15).It has already been 
demonstrated that transcription activity at the HBVCP is highly dependent on SP1, as 
deletion of site 21 in the URR resulted in an 70% or more reduction in wild-type 
luciferase expression in all cell lines (Figure 5), although it was also shown that the 
effect of SP1 on transcription at the HBVCP is not as significant as that of PARP1 in 
cell lines with the ability to enable more efficient HBV replication, whose binding site 
when removed by deletion 17 in HepG2 and Huh-6 resulted in the loss of 90% or 
more of wild-type luciferase expression. Nevertheless, SP1 was absolutely required 
for transcription at the HBVCP in cells less capable of enabling efficient HBV 
replication as deletion of site 21 in the URR abrogated luciferase expression (Figure 
5). The removal of the SP1and hnRNP K binding sites by deletion 1 in the BCP 
echoes these findings obtained at the URR, as 30% or more wild-type luciferase 
expression remained in HepG2 and Huh-6 but transcription at the HBVCP was 
completely abolished in Huh-7 and Sk-hep-1. It may not at this point be determined 
which of the two, SP1 or hnRNP K, or both contribute to the “basal” transcriptional 
activity at the HBVCP in Huh-7 and Sk-hep-1. Nevertheless, the inability to abrogate 
luciferase transcription at the HBVCP by the removal of the SP1 and hnRNP K 
binding sites with deletion 1 at the BCP in HepG2 and Huh-6 once again 
demonstrates that PARP1 is more important than these essential transcription factors 
for the efficient transcription of pgRNA and pcRNA. Thus, targeting the transcriptional 
activity of PARP1 at the HBVCP should control and prevent pgRNA synthesis in 










3.5 PARP1 IS REQUIRED FOR EFFECIENT HBV REPLICATION 
 
PARP1 has been shown to be important for transcription of pgRNA and pcRNA at the 
HBVCP in cell lines that support efficient HBV replication. Therefore preventing 
PARP1 transcriptional activity would prevent pgRNA synthesis hence HBV replication. 
To prove the functional association of PARP1 and efficient HBV replication, the 
effects of PARP1 specific knockdown on HBV replication in HepG2 was investigated.  
PARP1 is an abundant protein residing mainly in the nucleus (Figure 14A). Even 
though it is a ubiquitously expressed protein that plays very important roles in several 
pathways including DNA repair, transcriptional regulation and cell death99-112 (Figure 
14A), the loss of the bulk of PARP1 protein expression in HepG2 60 hours after 
PARP1 specific knockdown did not display cytotoxicity. This is consistent with the 
fact that PARP1 knockout mice are viable and phenotypically healthy157, making 
PARP1 a suitable target for the therapeutic manipulation as minimal side effects 
would be expected. The specificity of PARP1 knockdown was demonstrated with the 
use of non-specific siRNA, which had little effect on PARP1 nuclear expression. 
Interestingly, despite its relative abundance, the half-life of the PARP1 protein is 
relatively short, as PARP1 expression was effectively reduced by more than 90% 
within 24 hours of siRNA treatment (Figure 14B). This property further emphasizes 
PARP1 to be a favourable therapeutic target, as the relatively short term 
manipulation of its properties and functions during the treatment of chronic HBV 
infection would not lead to long-term consequences. As soon as the HBV infection is 
cleared, therapy would cease and the PARP1 function may be quickly regained for 
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includes the 2.1kb mRNA required for the synthesis of HBs, which constitutes the 
bulk of the proteins found on the HBV envelope20. Indeed, co-transfection of the 
PARP1 specific siRNA with HBV-RFP resulted in a reduction of HBs secretion by 
HepG2 when compared to cells treated with non-specific siRNA (Figure 15B). The 
reduction in HBs secretion was a result of drastic reduction in HBs expression 
observed in HepG2 cells co-transfected with PARP1 specific siRNA and HBV-RFP 
(Figure 15C). As co-transfection of non-specific siRNA still enabled HBV-RFP 
transfected cells to express considerable amounts of HBs (Figure 15C), the loss of 
HBs expression was not a consequence of toxicity associated with transfection but a 
specific consequence of the loss of PARP1 expression. These results therefore 
strongly support the role of PARP1 in mediating its transcriptional activation effects at 
the enhancer II, positively regulating the transcription at other HBV promoters.  
As shown by the inverse relationship between the ability to generate cccDNA and the 
amount of HBs secreted in the cell lines HepG2, Huh-6 and Huh-7(Figure 4), it was 
proposed that the amount of HBs secreted and detected is not a true reflection of the 
relative efficiency of HBV replication. Instead, without the generation of core particles, 
it was not necessary to retain the envelope proteins such as HBs as there would be a 
lack of core particles ready to be enveloped. In such case, HBs would be secreted to 
serve as a “decoy”, sequestering available anti-HBs that might be produced when the 
infected cell is ready to secrete the infectious particles. Indeed, the observation that 
relatively large amounts of HBs is secreted with PARP1 specific knockdown (Figure 
15B) despite low HBs expression (Figure 15C), and the observation that cells 
treated with non-specific siRNA secrete relatively low amounts of HBs despite the 
large amount of HBs synthesized supports the proposition. This indicates that the 
inhibition of PARP1 transcriptional activation activity at the HBVCP would enhance 
relative HBs secretion. This would have implications in the use of HBs as a 
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Nevertheless, the inhibition of PARP1 transcriptional activity at the HBVCP is 
favourable and a feasible one, as this therapeutic would adversely affect host-
pathogen interactions at multiple levels. Not only would the inhibition of PARP1 
transcriptional activation function directly reduce pgRNA synthesis hence the 
generation of core particles, the synthesis of other HBV transcripts hence secretion 
of envelope proteins such as HBs would also be adversely affected. Together, 
prevention of core particle synthesis and reduction of envelope protein synthesis and 
secretion would shut down HBV replication, achieving the therapeutic goal of clearing 
HBV infection in chronic HBV carriers.  
 
3.6 PARP1 ENZYMATIC INHIBITION ENHANCES HBV REPLICATION 
 
PARP inhibitors enhance HBV replication 
PARP1 relies on its enzymatic activity to carry out several processes, such as DNA 
repair99, 104, 122, 127, 156, 164, 229-232 (Illustration 10) and chromatin remodeling100, 103, 126, 128, 
130, 149, 164 (Illustration 11). In particular, hyper-activity of the PARP1 enzyme 
associated with DNA repair is unwelcome in cancer therapy, where the application of 
DNA damage inducers is meant to increase cytotoxic DNA lesions for the apoptotic 
death of cancerous cells. To overcome this, general PARP inhibitors in the form of 
nicotinamide analogues (Illustration 12) are being tested in phase II clinical trials in 
combination with conventional DNA damage inducers for efficacy in enhancing the 
potential of DNA damage induction to produce cytotoxicity in the treatment of 
cancer108, 131-134, 136, 154, 169. PARP1 however need not mediate all its effects in an 
enzyme dependent manner. This is best illustrated in the case of transcriptional 
regulation, where PARP1 can itself act as a transcription factor173-186 (Illustration 11) 
to recognize DNA in a sequence dependent manner, as was also discovered at the 
HBVCP. Since the activation of enzymatic activity would result in auto-modification 




by PAR, hence result in the accumulation of large amounts of negative charges, 
forcing its repulsion from DNA and preventing PARP1 sequence dependent 
transcription117. This predicts that PARP1 enzymatic inhibition would enhance the 
association of PARP1 with the HBVCP, resulting in the synthesis of large amounts of 
pgRNA, pcDNA, as well as HBs. If this were true, the use of PARP1 inhibitors would 
result in an overall enhancement of HBV replication. To test this, the effect of PARP1 
enzymatic inhibition on HBV replication was determined. 
Using luciferase reporter constructs where luciferase expression is driven by the 
HBVCP, the addition of a mild PARP inhibitor 3-aminobenzamide (3-AB) resulted in a 
dose-dependent increase in wild-type luciferase expression in HepG2 (Figure 16A). 
A similar increase in luciferase expression could not be achieved in cells transfected 
with the HBVCP mutant where deletion 17 of the URR removed the “TTCAAA” core 
important for PARP1 dependent transcriptional activation (Figure 16A). Together, 
these results demonstrate that the effects of 3-AB are specific to PARP1, hence the 
application of PARP1 inhibitors an indeed enhance transcriptional activation at the 
HBVCP in HepG2 that can support efficient HBV replication.  As further confirmation 
that PARP1 enzymatic inhibition can indeed enhance transcriptional activation at the 
HBVCP, the effects of 3-AB were tested in Huh-7 previously shown to be less 
capable than HepG2 tin enabling efficient HBV replication. As anticipated, the 
application of 2mM 3-AB in cells transfected with the wild-type HBVCP construct 
resulted in the increase of luciferase expression by 75%, whereas PARP inhibition 
had no effect in the mutant HBVCP when the PARP binding site is removed (Figure 
16B). Thus, regardless of the capability of the cell line in enabling efficient HBV 
replication, the use of PARP inhibitors will increase PARP1 dependent transcription 
at the HBVCP, potentially increasing HBV replication. The ability of PARP inhibition 
to enhance PARP1 dependent transcription activation was therefore ascertained. 
 






Figure 16 PARP1 inhibition enhances PARP1 dependent transcription. Effect of 
PARP1 inhibition with 3-aminobenzamide (3-AB) on mean luciferase expression 
relative to wild-type HBV core promoter or buffer controls in HepG2 (A) and in Huh-7 
(B). **P-value < 0.01; ***P-value < 0.001. Results show mean ± SE of triplicates from 
representative experiments. 
 
PARP1 was first identified as a therapeutic candidate of great interest because the 
degree of reduction in PARP1 dependent transcription at the HBVCP by the removal 
of its binding site with deletion 17 in the URR correlated well with ability of a cell line 
to support efficient HBV replication (Figure 5). This demonstrates that PARP1 
exhibits variable forms in these cell lines, such that it is in a form favourable for 
transcription activation at the HBVCP in HepG2 efficient in HBV replication but in 
another form in SK-hep-1 incapable of enabling efficient HBV replication. The 
property that differs in these cell lines would provide the hint of developing a 
therapeutic strategy aimed at PARP1 for switching PARP1 from a form favourable for 
HBVCP transcriptional activation to another form that disfavours it. Assuming equal 
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enzymatic activity had a more pronounced effect in Huh-7 than in HepG2, such that 
2mM 3-AB was sufficient to result in 75% increase in wild-type luciferase expression 
in Huh-7 while a much milder increase of only 20% increase in wild-type luciferase 
expression in HepG2 (Figure 16). This suggests that PARP1 in Huh-7 is more 
“susceptible” to enzymatic inhibition. This could be achieved by two possibilities, a 
larger fraction of enzymatically active PARP1 or a form of PARP1 that is intrinsically 
more active than the form found in HepG2. This phenomenon was further 
investigated. 
To prove that PARP1 inhibition by the use of PARP inhibitors can increase HBV 
replication in host cells, a potent PARP inhibitor PJ-34 was used. HepG2 cells 
transfected with the replicative HBV construct HBV-RFP were treated with the PARP 
inhibitor PJ-34 24 hours later and the relative amount of HBV transcripts produced 
was determined (Figure 17A). At the point of PJ-34 administration, the amount of 
HBV transcripts obtained were equivalent, indicating that differences in transfection 
efficiency cannot account for any differences in the amount of HBV transcript 
produced with the treatment of PJ-34 or buffer controls. The effects of PJ-34 were 
not immediately noticeable, as 24 hour PARP1 inhibition with PJ-34 resulted in a 
significant but small increase in the amounts of HBV transcripts when compared to 
buffer controls. However, 48 hours after PJ-34 administration, the effects of PARP1 
inhibition was very clear, such that the amount of HBV transcripts produced was 
more than 3-fold that of buffer controls. Efficient HBV replication has been associated 
with cell cycle arrest233, 234. Indeed, by 96 hours after transfection with the HBV-RFP 
construct in the absence of cell death, the population of cells comprised mainly of 
HBV-RFP transfected cells (Figure 17B), implying that these cells supported high 
amounts of HBV replication and did not proliferate. In contrast, HBV-RFP transfected 
cells in buffer controls had less efficient HBV replication, and were therefore less 
susceptible to cell cycle arrest, hence proliferated, accounting for the large number of 
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the ability of adding PAR on histone H1 in the presence of activated DNA. The 
relative amounts of modified histone H1 would reflect the intrinsic enzymatic activity 
of PARP1 in the lysate. Interestingly, HepG2 and Huh-6 were shown to have lower 
ability to modify histone H1 (Figure 19), indicating that the endogenous PARP1 
enzymatic activity is low in these cells. In contrast, the ability to modify histone H1 in 
Huh-7 and Sk-hep-1 was approximately 2.5-fold that of HepG2, thus these cells have 
high endogenous PARP1 enzymatic activity. This finding indicates that in the cell 
lines more capable of supporting efficient HBV replication such as HepG2 and Huh-6, 
PARP1 was enzymatically less active, whereas in cell lines less capable in 
supporting efficient HBV replication, PARP1 is enzymatically more active, supporting 
the hypothesis that there are molecular differences in the form of PARP1 involved in 




Figure 19 HepG2 has low endogenous PARP1 activity. The endogenous PARP1 
activity of various cell lines in 5μg nuclear lysates measured using histone H1 
modification assay relative to HepG2. ***P-value < 0.001 with student’s two-tailed t-


































The factors that contribute to efficient HBV replication include the ability of HBV to 
evade host immunity, HBV genotype, as well as the variability in host factors critical 
for efficient HBV replication. PARP1 is such a susceptibility factor that has been 
identified in this study, as the endogenous enzymatic activity in the cell is correlated 
with how well the cells can initiative transcription at the HBVCP. It is therefore now 
clear, that the therapeutic agent to be designed for the treatment of chronic HBV 
infection should prevent PARP1 dependent transcriptional activation at the HBVCP, 
and should not result in PARP1 enzymatic inhibition. However, the reason for the 
disparate PARP1 enzymatic activities in the cell lines used is still unknown.  
Given the important finding that cell lines capable of supporting efficient HBV 
replication have lower endogenous PARP1 enzymatic activity, it suggests that low 
PARP1 enzymatic activity is a susceptibility marker for efficient HBV replication, 
resulting in greater difficulty in clearing HBV infection. It is possible that 
polymorphisms associated with reduced PARP1 enzymatic activity are preferentially 
inherited by susceptible groups. To investigate, the coding sequence of PARP1 in the 
cell lines HepG2, Huh-6, Huh-7 and Sk-hep-1 were analyzed, providing insight into 
the molecular differences in PARP1 that can account for the different enzymatic 
activity associated with them. 
Interestingly, wild-type PARP1 was found in Huh-7 and Sk-hep-1, while in Huh-6 and 
HepG2, similar mutations were found (Figure 20A). Two silent mutations were found, 
such that the amino acid sequence of PARP1 and its enzymatic function remained 
unaffected. These two mutations correspond to two single nucleotide polymorphic 
alleles, rs1805404 and rs1805414. Both cell lines also expressed mutant with a 
prominent nucleotide substitution, where “T” at nucleotide position 2456 was 
replaced by “C” (Figure 20B), resulting in the missense mutation for alanine in place 
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enzymatic activity in patients in a dose-dependent manner235-237. The reduction of 
PARP1 enzymatic activity with the V762A mutation is confirmed by the observation 
that nuclear lysates from HepG2 and Huh-6 expressing the V762A polymorphic 
PARP1 have reduced ability to modify histone H1 when compared to Huh-7 and Sk-
hep-1 that express wild-type PARP1 (Figure 19). Therefore, the molecular difference 
in PARP1 responsible for the difference in the ability of the cell lines in supporting 
efficient HBV replication has been identified. While structural differences between 
wild-type and V762A PARP1 contributing to altered affinities for the HBVCP may not 
be excluded, the polymorphic V762A PARP1 with reduced enzymatic activity should 
enable enhanced host-pathogen interaction, as the low PARP1 enzymatic activity 
allows PARP1 to associate readily with the HBVCP for transcriptional activation of 
pgRNA and pcRNA synthesis, and enhancing the expression of other HBV 
transcripts, resulting in efficient HBV replication in HepG2. In Huh-7, the 
enzymatically active PARP1 cannot make functional host-pathogen interaction by 
residing on the HBVCP for sustained periods, thus less transcriptional activation and 
less efficient HBV replication.  
The reason for the lower sensitivity of HepG2 to PARP inhibition and enzymatic 
activity when compared to Huh-7 is also now in light. Since amino acid 762 is in such 
proximity to the site of binding PARP inhibitors (Figure 21A), and that the wild-type 
amino acid valine is a much larger amino acid than alanine, the V762A mutation 
allows the molecules that bind the PARP1 enzyme active site to fit “loosely”. This 
prevents the sustained binding of NAD+ required for catalytic cleavage hence 
lowered PARP1 enzymatic activity. By the same principle, the “loose” fit of PARP 
inhibitors cannot sustain the blocking of the PARP1 catalytic site, hence the lowered 
sensitivity of V762A polymorphic PARP1 to PARP inhibition, resulting in poorer 
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a site within the proximity of another amino acid that may be post-translationally 
modified. By performing a search of potential sumoylation sites on the PARP1 protein, 
it was discovered that V762 is located within a potential sumoylation signal (Figure 
21B), and that amino acid 762 is just next to the lysine residue that may be 
sumoylated. Until it can be proven that this lysine residue may not be post-
translationally modified, the possibility that the V762A is also a mutation that alters 
the way PARP1 is post-translationally regulated cannot be dismissed. 
To show that the V762A mutant PARP1 is itself sufficient to enhance replication of 
HBV, the expression of HBs already shown to be dependent on PARP1 expression 
(Figure 15C) was investigated in HepG2 cells by co-transfection of HBV-RFP with 
PARP1 expression plasmids. In doing so, the dose of specific forms of PARP1 
proteins in HepG2 which expresses both the wild-type and the V762A mutant PARP1 
(Figure 20B) will be altered. As expected, the large excess of exogenous wild-type 
PARP1 (see Figure 38) increases the chance that wild-type PARP1 molecules 
associates with the HBVCP, resulting in the reduction of effective host-pathogen 
interaction, hence reduced HBs expression (Figure 22) as the enhancer II function 
dependent on PARP1 is lost. In contrast, over-expression of the mutant V762A 
PARP1 increases the amounts of V762A PARP1 produced, resulting in increased 
chance of a mutant PARP1 molecule associating with HBVCP hence enhancing 
functional host-pathogen interaction to result in the increased HBs expression. Since 
HBs expression is also dependent on the interaction of PARP1 to HBVCP 
recognizing and binding the “TTCAAA” motif, the increased HBs expression with 
over-expression of V762A mutant PARP1 can be taken to imply that the V762A 
mutant PARP1 can effectively initiate pgRNA synthesis as well. Therefore, the 
V762A mutant PARP1 can account for the efficiency of HBV replication in the cell 
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analogue 3-AB, it was shown that the V762A confers lowered sensitivity to the 
inhibitory effects of the drug when compared to the wild-type protein, demonstrating 
that a single drug can have very different effects between the V762A mutant and the 
wild-type PARP1. Since the V762A mutant PARP1 is the host factor responsible for 
enabling efficient HBV replication, this should be targeted instead of the wild-type. It 
is therefore be worthwhile the effort to design a therapeutic that specifically acts on 
the V762A mutant PARP1 protein.  Perhaps, the most obvious means to prevent 
PARP1 transcriptional activation at the HBVCP is to increase its enzymatic activity. 
However, it has already been shown that the V762A allele lowers PARP1 enzymatic 
activity in HepG2 and possibly in patients with chronic HBV, which might be a 
consequence of its inability to bind NAD+ effectively to increase PAR formation, it 
would not be sensible to “enhance” enzymatic activity of an enzyme whose activity is 




Several transcription factors have been reported to regulate transcriptional activity at 
the HBVCP, but few have compared the relative contribution of each transcription 
factor. To identify host factors critical for transcriptional activity at the HBVCP that 
may be modulated by therapeutic intervention for the treatment of chronic HBV 
infection, it was revealed that only a handful of transcription factors are necessary for 
“basal” transcription. These include the ubiquitous SP1, hnRNP K and the “liver-
enriched” HNF1, all of which are poor therapeutic targets because of their importance 
to cell survival or function. A fourth factor, PARP1, was also discovered and shown to 
be required for efficient transcription at the HBVCP. Its enzymatic activity negatively 
correlates with the ability of a cell line to support efficient HBV replication. Differential 
PARP1 enzymatic activity may be naturally achieved by the inheritance of the V762A 




polymorphic mutant, which is commonly associated with Asians. Thus, even though 
PARP1 is a safe alternative compared to the “basal” transcription factors for 
therapeutic manipulation of its activity, a novel strategy needs to be used other than 
















Aberrant PARP1 Binding Motif Expression 










PARP1 is a multi-functional enzyme involved in DNA repair and transcription. While it 
has been known to mediate transcription in a sequence dependent manner, its 
consensus recognition motif has not yet been defined. Using the PARP1 binding site 
within the HBVCP as a model, the contribution of each nucleotide of the PARP1 
binding site towards transcription was investigated. This revealed that the PARP 
binding motif is an octamer “RNNWCAAA”, and that the 3’ “CAAA” is essential for its 
function. Whereas the PARP1 enzyme may be activated by binding DNA strand 
breaks, PARP1 binding its recognition motif results in enzymatic inhibition. This has 
consequences to cellular functions, as exogenous expression of the PARP1 binding 
motif results in the impairment of PARP1 enzyme dependent DNA repair, hence 
increased cytotoxicity of cells treated with DNA damage inducers. This phenomenon 
may be useful in cancer therapy, where, like all other PARP inhibitors, the PARP1 
binding motif kills cancer cells by the accumulation of irreversible DNA damage when 
coupled with DNA damage inducers. The added value of developing the PARP1 
binding motif as a novel class of PARP1 specific inhibitor is that, as opposed to 
conventional PARP inhibitors, it is capable of suppressing HBV replication. The 
PARP1 binding motif thus has potential to be a PARP1 specific inhibitor useful in the 




PARP1 was identified to be a specific binder at the HBVCP by recognition of a core 
motif “TTCAAA”, resulting in transcriptional activation for the synthesis of pgRNA and 
pcRNA, as well as enhancing the synthesis of other HBV products such as HBs. Its 
enzymatic activity is a crucial determinant for the transcriptional activation function at 




the HBVCP, as the mutant V762A PARP1 with reduced intrinsic enzymatic activity 
expressed in HepG2 and Huh-6 is associated with increased transcriptional activity at 
the HBVCP for the enhanced efficiency in HBV replication when compared to the cell 
lines Huh-7 and Sk-hep-1 that express only the wild-type PARP1. Thus, low PARP1 
enzymatic activity confers PARP1 its ability to effectively act as a transcriptional 
activator at the HBVCP.  
Even though PARP1 is known to act as a sequence specific transcription factor, 
many properties of PARP1 that contribute to this function remain understudied. For 
example, it is not known how PARP1 can differentiate the type of DNA it binds to, 
such that on the one hand, it can recognize DNA strand-breaks in a sequence 
independent manner for DNA repair, and on the other, recognize intact DNA in a 
sequence dependent manner to serve its purpose as a transcription factor. This is 
interesting, as PARP1 is well-known to bind DNA strand-breaks for enzymatic 
activation122, 163, yet this study has also shown that enzymatic activity would prevent 
PARP1 from serving its purpose as a transcriptional activator which requires the 
binding and recognition of the “TTCAAA” sequence. Another unresolved issue is the 
consensus motif of PARP1 required for it to mediate its transcription factor function. 
While several PARP1 sequence dependent binding sites have been found in various 
promoters173-186, several attempts to define its recognition motif have yielded 
contradictory results. Indeed, there is no record of a PARP1 transcription factor 
consensus recognition sequence in transcription factor motif databases such as 
MATCHTM, resulting in the erroneous prediction of HNF4α and Oct-1 to be binders of 
the “TTCAAA” sequence instead (Figure 6). By analysis of the effects on 
transcription activity at the HBVCP with multiple overlapping deletions spanning the 
PARP1 binding site (Figure 6), it was deduced that the “TTCAAA” core motif is 
important for PARP1 to mediate its transcription activation effects at the HBVCP. 
Furthermore, it was shown that a single base substitution to change this motif to 




“TTCAAC” is sufficient to remove the 80% of PARP1 dependent transcription (Figure 
12). Therefore, by using a similar approach of performing a series of single base 
substitutions at the HBVCP PARP1 binding site, the precise contribution of each 
nucleotide within the “TTCAAA” motif towards PARP1 sequence dependent 
transcription would be attained, solving the mystery of the definition of the PARP1 
recognition motif. 
 
4.2 DEFINING THE PARP1 MOTIF 
 
A panel of 48 luciferase reporter constructs was generated whereby each nucleotide 
position of the “TTCAAA” sequence and the 3 flanking nucleotides at either ends 
were tested for all four base substitutions. The constructs were transfected into 
HepG2 cells whereby endogenous PARP1 interacts with the binding motif to 
transcriptionally drive luciferase gene expression. HepG2 was the cell line of choice 
for this study, since PARP1 dependent transcription at the HBVCP was 
demonstrated to be most sensitive in this cell line (Figure 5), the effects of single 
base substitution at each nucleotide position would be readily identifiable.  It was also 
assumed that there is no difference between the V762A PARP1 mutant and the wild-
type PARP1 in the ability to recognize its consensus binding motif, as the mutation 
and its effects on transcription is associated with altered enzymatic activity only. The 
results of each base substitution are shown in figure 24. 
The results indicate an absolute requirement for the 3’ “CAAA” sequence in which 
any change would result in 75% or more reduction in wild-type luciferase expression. 
This is consistent with the initial deductions that the 3’ end of the motif plays a 
greater role than the 5’ end in determining the transcription factor activity of PARP1. 
The most important of these nucleotides is the 5’ “A” within the “CAAA” sequence, as 
all mutations resulted on a loss of 90% or more wild-type luciferase expression, such 




that an “A” to “C” transversion is sufficient to achieve the effects of only 4% wild-type 
luciferase expression remaining by the removal of the entire “TTCAAA” motif with 





Figure 24 The PARP1 recognition motif. The effect of all possible single base 
substitutions on the predicted PARP1 core motif “TTCAAA”, together with 
substitutions on the 3 bases flanking either of its sides were determined by 
examining altered luciferase expression in HepG2. The results show mean ± SE 
normalized luciferase expression to that of the wild-type promoter of triplicates from a 
representative experiment. Relative positions of each nucleotide with respect to the 
defined PARP1 binding motif are as indicated. 
 
Even though the 3’ end of the “TTCAAA” motif can account for the bulk of PARP1 
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extend two positions 5’ of the putative “TTCAAA” motif such that an 8 nucleotide 
sequence “ACTTCAAA” was defined by the boundary where nucleotide substitutions 
did not result in any further change in luciferase expression. Interestingly, none of the 
substitutions except position 3 of the octamer motif resulted in increased luciferase 
expression, while all other substitutions were either neutral or deleterious. This 
suggests that the original motif in the HBVCP has a near-optimal PARP1 recognition 
consensus. Perhaps, this is necessary for the virus to sustain functional host-
pathogen interaction to ensure efficient transcription at the HBVCP amidst the 
background of other PARP1 binding sites in the host genome. Taking into account all 
the nucleotide substitution data, the PARP1 sequence dependent transcription motif 
can be described to be the octamer “RNNWCAAA”, where “R” is either “A” or “G”, “N” 
is any of the nucleotides, and “W” is either “A” or “T”, and that the optimal sequence 
for PARP1 sequence-dependent transcription is “ACATCAAA”. Of these, “A” at 
nucleotide position 6 is the most important for PARP1 dependent transcription. 
To confirm that the octamer motif “ACATCAAA” is indeed the PARP1 recognition 
consensus, the effects of single base transverse substitutions of the same region 
were tested in Huh-6 as well as Sk-hep-1. It was shown that even though Huh-6 is 
less capable of supporting HBV replication (Figure 4A), however, like HepG2 it 
expresses the V762A PARP1 mutant (Figure 20B) which is associated with 
enhanced transcriptional activation activity at the HBVCP. Therefore, the effects of 
each base substitution observed in Huh-6 should parallel that observed in HepG2. 
Conversely, Sk-hep-1 only expresses the wild-type PARP1 which is deemed to 
confer its poor capability in enabling transcription activation at the HBVCP. Therefore, 
little or no effect on luciferase expression is expected with each base substitution of 
the PARP1 consensus motif. Sk-hep-1 thus serves as a negative control to 
demonstrate that the alterations in the luciferase expression observed in HepG2 and 
Huh-6 are specific to PARP1 dependent transcription. 




Figure 25 shows the effects of the transverse substitutions in the PARP1 consensus 
HepG2, Huh-6 and Sk-hep-1. As expected, none of the substitutions within the 
PARP1 binding motif “ACATCAAA” resulted in deleterious effects of luciferase 
expression, hence changes in luciferase expression observed in Huh-6 would reflect 
that the ability of PARP1 sequence dependent transcription is affected, which was 
indeed the case. All adverse substitutions in Huh-6 within the PARP1 recognition 
motif resulted in the loss of luciferase expression. Moreover, the effects of 
substitutions of the 3’ “CAAA” sequence deemed to be important for PARP1 
transcriptional activity on luciferase expression was parallel to that observed in 
HepG2, such that maximal loss of luciferase expression was also obtained with the 
substitution of “A” at nucleotide position 6 of the motif. These results strongly support 
that the motif obtained with the study in HepG2 (Figure 24) is not cell-line specific, 
and that it may be applied to other PARP1 binding sites for transcription. The 5’ end 
of the PARP1 motif was deemed to be less important for PARP1 dependent 
transcription effects, which was also reflected in Huh-6 as substitutions in this part of 
the motif resulted in less reduction in luciferase expression. Except for the reduction 
in luciferase expression at position +9 relative to the start of the PARP1 motif which 
was also observed in HepG2 albeit to a smaller extent (Figure 24), substitutions 
flanking the motif octamer motif produced much milder effects on luciferase 
expression, the results in Huh-6 strongly support that obtained from HepG2 that the 
PARP1 binding motif is dependent on the defined octamer sequence.  In conclusion, 
by studying the effects of single base substitutions on PARP1 dependent 
transcription at the HBVCP, the elusive PARP1 binding motif can now be described 











Figure 25 Confirmation of the PARP1 motif in different cell lines. Results show mean 
normalized luciferase expression relative to that of the wild-type HBVCP (WT). The 
relative positions of each nucleotide with respect to the PARP1 binding motif are as 
indicated, and each transverse base mutation is numbered according to the 
respective nucleotide consensus position of HBV genotype A. Results show mean ± 
SE of triplicates from representative experiments. 
 
When compared to previously studied PARP1 binding sites, an alignment of the 
EMSA probe sequences employed in PARP1 binding revealed that a motif 
conforming to the currently defined “RNNWCAAA” sequence exists in them. An 
alignment of these probe sequences centered about their respective PARP1 binding 
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Figure 26 Describing validated PARP1 binding sites with novel PARP1 motif. PARP1 
binding motifs from PARP1 binding probes previously validated by EMSA are 
identified and aligned (highlighted in grey) with the newly-defined consensus 
“RNNWCAAA” motif. Underlined sequences denote PARP1 binding sites originally 
proposed by the corresponding authors. Pax-6, Paired box protein; MOR, μ opioid 
receptor; HTLV Tax RE, Human T cell Leukemia Virus Type I Tax Responsive 
Element; SMARCB1, SWI/SNF-related matrix-associated actin-dependent regulator 
of chromatin subfamily B member 1; Bcl-6; B-cell lymphoma. *The PARP1 binding 
motif was identified in the reverse strand of the SMARCB1 EMSA probe. 
 
Consistent with this proposition, probe sequences from the Pax-6174 and 
SMARCB1180 promoters fit perfectly with the “RNNWCAAA” motif. Furthermore, in 
agreement with the data presented in this study, substituting nucleotide position 1 of 
the SMARCB1 promoter EMSA probe from “A” to “C” had been reported to be 
associated with decreased PARP1 dependent transcriptional activity. Other reports 
on human T cell leukemia virus type I Tax responsive element (HTLV Tax RE)175, 177 , 
Bcl-6177 and the μ opioid receptor (MOR) gene182, describe the identification of 
PARP1 binding sequences that overlap but deviate from the “RNNWCAAA” motif by 
two nucleotides. A study of the PARP1 binding motif located within the HTLV Tax RE 
showed that mutations to the critical nucleotides 5 and 6 changing from “CA” to “AC” 
abolished PARP1 binding which is congruent with the finding that the “A” at 
nucleotide position 6 of the defined “RNNWCAAA” motif is especially important for 
PARP1 recognition (Figure 24). Furthermore, substitutions of nucleotides at 
positions 2 and 3 which we have shown to be less important for the functional 
Gene promoter EMSA probe sequence for PARP1 binding (5’Æ 3’) Ref
HBV CP -------------------------TTGAGGCCCTACTTCAAAGACTGTGT -
Pax-6 ---------------------GACGCGCGCGCCGCAGCTCAAACAAAAG 174
MOR ---------------------------AGAGGAGAATGTCAGATGCTCAGCTCGGTCCCCTCCGCCTGA 182








specificity of the motif were similarly not crucial for PARP1 binding in the HTLV Tax 
RE system. In line with the deleterious effects of nucleotide substitution at the critical 
consensus positions, a change at position 5 from “C” to “T” found at the Bcl-6 PARP1 
binding site was found to abrogate PARP1 dependent transcription. Hence it can be 
seen that the partial match of these sequences with the present PARP1 binding motif 
explains the early difficulties in confirming the PARP1 binding consensus.  
The fact that the HBVCP from HBV genotype A used in this study possesses a near-
perfect PARP1 binding motif supports the importance of the contribution of PARP1 to 
efficient HBV replication. If this were true, then the PARP1 binding site should be 
highly conserved across all HBV genotypes, and that the possibility of finding the 
optimal recognition motif “ACATCAAA” in HBV genotypes associated with efficient 
replication or more severe disease outcomes should be high. More than 900 
complete HBV genomes from patient isolates of the 8 different genotypes were 
aligned (Figure 27), and amazingly shown to have the PARP1 binding motif highly 
conserved in all genotypes. This emphasizes the importance of PARP1 for HBV 
replication. Like genotype A, the near-optimal “ACTTCAAA” PARP1 motif was found 
in most of the genotypes, including genotype C. Interestingly, the less-studied 
genotypes F and H predominantly possess the optimal PARP1 binding motif 
“ACATCAAA”, presumably conferring maximal transcription activation attainable by 
PARP1 binding at the HBVCP, suggesting that HBV replication should be the most 
efficient in these genotypes. While data for the outcome of infection with HBV 
genotype H is lacking, it has been reported that genotype F is associated with 
fulminant hepatitis and development of HCC in young males11, 12, 90, indicating that 
the efficiency of replication of HBV with genotype F is so high that the host succumbs 
to the effects of infection. Perhaps, this explains why few genotypes possess the 
“ACATCAAA” sequence, as the infection is self-limited, resulting in few progeny 
made. The “near-optimal” PARP1 motif “ACTTCAAA” is therefore the motif of choice 




utilized for efficient HBV replication without killing the host, ensuring continued 
survival of HBV. 
 
 
Figure 27 The PARP1 binding site is highly conserved across HBV genotypes. The 
HBV PARP1 binding sequence of all HBV genotypes is aligned to the consensus 
PARP1 binding motif “RNNWCAAA”. Gen A = HBV genotype A; n = number of 
aligned sequences. Most HBV genotypes possess the near-optimal PARP1 binding 
motif “ACTTCAAA” while HBV genotypes F and H possess the “ACATCAAA” optimal 
PARP1 binding motif. Only HBV genotype G possesses the “ACTTCAAG” motif 
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4.3 PARP1 INHIBITION AND IMPAIRED DNA REPAIR BY MOTIF BINDING 
 
Using the HBVCP as a model for PARP1 dependent transcription, the identity of the 
recognition motif of the PARP1 transcription factor is now resolved. The study of the 
PARP1 consensus motif has also undoubtedly produced useful insights into the 
importance of PARP1 dependent transcription in HBV replication, and the potential 
outcomes of HBV replication utilizing variations of the PARP1 binding motif. However, 
the effect of PARP1 motif binding on its enzymatic activity remains to be elucidated. 
To determine whether the same could be induced by the PARP1 binding motif, the 
functional effects of the “ACATCAAA” octamer motif binding to PARP1 protein was 
tested using histone H1 modification assays. 
Surprisingly, using short 20bp DNA duplexes bearing the “ACATAAA” PARP1 
recognition motif (wild-type), it was shown that the histone H1 modification was 
significantly reduced when compared to buffer controls (Figure 28). This suggests 
that in contrast to the binding of DNA strand breaks in DNA repair, sequence-specific 
binding of the PARP1 recognition motif inhibits PARP1 enzymatic activity, preventing 
the addition of PAR to histone H1. This important observation explains how effective 
transcription may be achieved. Recognition of the PARP1 binding motif inhibits 
PARP1 enzymatic activity, preventing auto-modification hence increasing promoter 
retention time to enable functional association of PARP1 with the basal 
transcriptional machinery, initiating transcription. If this were true, then mutation of 
the octamer motif to prevent PARP1 optimal PARP1 binding would reverse the 
inhibitory effects of the motif on the PARP1 enzymatic activity. In other words, the 
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same binding site that PARP1 utilizes to sense damaged DNA, but it appears that 
upon binding to an optimal motif sequence, the PARP1-DNA complex is stable and 
negates the activation of PARP1 to ADP-ribosylate targets. The complex formed 
between PARP1 and its binding motif is therefore distinct from that between PARP1 
and DNA strand breaks. 
Using nuclear lysates from HepG2 cells treated with PARP1 specific siRNA, the 
degree of histone H1 modification is reduced by about 40% when compared with 
lysates treated with non-specific siRNA (Figure 28). Considering that the PARP1 
knockdown is efficient, this suggests that very little PARP1 protein is sufficient to 
modify histone H1. Thus, large amounts of PARP1 need to be inhibited to produce a 
significant reduction in histone H1 modification, whereas a tiny amount of enzymatic 
activator will contribute to exaggerated histone H1 modification. The amount of 
histone modified is exponentially associated with the amount of available PARP1 
active enzyme. In such case, while the reduction of histone H1 in the assays by 
PARP1 motif binding seem moderate, it is likely that a considerable amount of 
PARP1 has been enzymatically inhibited. Due to the heterogeneous population of 
PARP1 molecules in the HepG2 nuclear lysates, it is not known at this point whether 
there is any difference in the wild-type and V762A mutant PARP1 in being effectively 
inhibited by the PARP1 motif. 
The ability of the PARP1 motif to inhibit PARP1 enzymatic activity raises the 
interesting possibility that when exogenously expressed, the PARP1 motif can inhibit 
enough PARP1 to impair PARP1 enzyme dependent functions such as DNA repair. 
Since HBV has a near-optimal PARP1 binding motif and HBV replication would 
undoubtedly increase the amount of PARP1 binding motifs in the cell. To find out if 
HBV replication can indeed impair PARP1 dependent DNA repair by means of motif 
recognition, the ability of the conserved “ACTTCAAA” HBV PARP1 binding sequence 
to inhibit PARP1 dependent histone H1 modification must first be ascertained. As 




shown in Figure 29A, 20bp DNA duplexes bearing the “ACTTCAAA” HBV PARP1 
binding motif can reduce histone H1 modification in HepG2 nuclear lysates, 
demonstrating that the viral PARP1 motif can also inhibit PARP1 enzymatic activity. 
This suggests that, by the introduction of exogenous PARP1 binding motifs, the 
replicating HBV can impair PARP1 enzyme dependent functions such as DNA repair, 
potentially resulting in the accumulation of DNA damage with prolonged infection to 
encourage the development of HCC.  
To test this, HepG2 cells ere transfected with HBV-RFP for 96 hours to enable the 
accumulation of cccDNA. Subsequently, they were treated with the DNA damage 
inducers etoposide (DNA single and double-strand break inducer) or bleomycin (DNA 
double strand break inducer) and the degree of DNA damage was followed by using 
alkaline comet assay. Consistent with the model proposed, little DNA damage 
accumulated in controls transfected with RFP when subjected to DNA damage 
whereas in cells with active replication of HBV (Figure 29B), the extent of DNA 
damage was high, indicating that DNA repair in these cells was impaired. Importantly, 
treatment of RFP or HBV-RFP transfected cells with DMSO (buffer control) did not 
result in DNA damage, indicating that, consistent with the non-cytolytic nature of HBV, 
viral replication cannot account for the increase in DNA damage when subjected to 
DNA strand-break induction. Therefore, the HBV PARP1 motif inhibited PARP1 
enzymatic activity in the cells with HBV replication, preventing the recruitment of the 
DNA repair machinery hence the accumulation of damaged DNA.  
Nevertheless, as the experiment involved using the full-length replicative HBV, such 
that all HBV components may be synthesized, the contribution of viral proteins such 
as HBx often described to be associated with enhancing HBV-infected cells to the 
cytotoxicity of DNA damage induction towards the impairment of PARP1 dependent 
DNA repair cannot be eliminated.  Further experiments are required to show that it is 
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etoposide or bleomycin treatment 24 hours after transfection and analyzed by 
alkaline comet assay 42 hours post-transfection. Consistent with the hypothesis that 
exogenous PARP1 motif can inhibit cellular PARP1 enzymatic activity to impair DNA 
repair, transfection of the motif clearly resulted in extensive DNA damage when 
compared to cells transfected with the empty vector (Figure 30B). This accumulation 
of damaged DNA was not due to the transfection procedure per se, as indicated by 
no DNA damage with DMSO treatment. Therefore, the PARP1 binding motif alone 
can when aberrantly expressed in a cell, result in sufficient PARP1 enzyme inhibition 
to result in the impairment of PARP1 enzyme dependent activities such as DNA 
repair. This mechanism may account for increased sensitivity of cells harbouring 
replicative HBV to cytotoxicity of DNA damage induction, as PARP1 dependent DNA 
damage repair is impaired.  
Several studies have suggested that the over-expression of HBx can impair DNA 
damage repair238-240. However, as these studies utilize the over-expression of HBx 
alone, the fact that the HBV PARP1 binding motif lies within the HBx coding 
sequence (Figure 31A) might also account for that these results. This is because, in 
HBV replication, HBx is produced in such tiny amounts that it may not be detectable 
in the nucleus. This is demonstrated by the lack of HBx nuclear expression with 
replicative HBV by the transfection of HBV-RFP into Huh-7 (Figure 31B) the large 
amounts of HBx produced by the over-expression system. 
To find out if the HBV PARP1 binding motif can account for reports that over-
expression of HBx is associated with impaired DNA damage repair, the effect of HBx 
over-expression was compared to that of the transfection with the plasmid bearing 
the HBV PARP1 motif in three tandem repeats. HBx can be said to impair DNA repair 
if the DNA damage observed with its over-expression is much higher than that 
obtained with the PARP1 binding motif. If comparable DNA damage were instead 
observed, then the role of HBx in the impairment of DNA damage repair is in 




question. Since Huh-7 cells express large amounts of HBx, these cells were used in 
the study. DNA damage was mildly induced by 0.01% NMU (N-nitroso-N-methylurea), 
resulting in DNA alkylation which can be repaired in a PARP1 dependent manner by 
the base-excision pathway which also generates DNA strand-breaks.  
Interestingly, despite the plasmid bearing the HBV PARP1 binding motif in three 
tandem repeats possessing more PARP1 binding sites, no difference in the extent of 
DNA damage was observed between the PARP1motif plasmid and the HBx 
genotype A over-expression plasmid that possesses only a single PARP1 binding 
site (Figure 31C). Perhaps the large PARP1 poses steric hindrance to other PARP1 
molecules bound to a PARP1 binding site, preventing more PARP1 molecules from 
binding. Thus, the effective PARP1 binding capacity of the PARP1 motif plasmid is 
similar to the HBx over-expression plasmids. The equivalent extent of the PARP1 
motif plasmid and the HBx genotype A over-expression plasmid, coupled with the 
large amounts of HBx produced in the nucleus with the HBx over-expression plasmid 
hence theoretical large extent of DNA damage if HBx served the function to impair 
DNA damage repair, demonstrate that HBx does not contribute to the impairment of 
DNA damage repair. Instead, it is the plasmid used to transfected HBx into the cells 
bearing the PARP1 binding motif that results in the accumulation of damaged DNA 
when treated with DNA damage inducers. When the effect of over-expression of HBx 
genotype A was compared with that of HBx genotype C on NMU induced DNA 
damage, it is clear that HBx genotype A is associated with more damaged DNA. The 
discordant results obtained with over-expression of HBx from two genotypes of HBV 
suggest that contrary to HBx impairing DNA damage repair, HBx might instead be a 
factor meant to suppress the accumulation of damaged DNA during HBV replication. 
Indeed, the extent of DNA damage was lower with the replicative HBV construct and 
bleomycin treatment (Figure 29B) when compared to cells transfected with the 



























































































































































































































While the suppression of DNA damage accumulation may seem to contradict the 
association of HBV genotype C with more severe disease outcome, it is possible that 
this may in fact be true. While HBV replication results in the accumulation of 
damaged DNA, the damaged DNA can trigger apoptosis to kill infected host cells. 
This limits the infection, and suggests that a “maximal” rate of HBV replication can 
occur without triggering the DNA damage check-point. In infections involving HBV 
genotype C however, the suppression of the accumulation of DNA damage increases 
the threshold that HBV can replicate efficiently without resulting in large amounts of 
DNA damage to trigger apoptotic cell death by the accumulation of damaged DNA, 
accounting for more severe disease by the larger amounts of virions produced.  
To demonstrate that the inhibitory effects on DNA repair observed thus far are 
specific to the inhibition of PARP1 enzymatic activity, the effect of the PARP1motif 
was investigated in Huh-7, which was shown to express the wild-type PARP1 only 
(Figure 20B). The plasmid bearing the HBV PARP1 motif in tandem repeats was 
transfected into Huh-7 DNA damage induced using 0.01% NMU (N-nitroso-N-
methylurea) to generate reactive nitric oxide to cause DNA alkylation, necessitating 
DNA repair to occur by the base-excision pathway which relies heavily on PARP1 
dependent enzymatic activity. The results show that RFP over-expression as a 
control for the toxic effects of protein over-expression had little effect on the ability of 
the PARP1 motif in enabling the accumulation of damaged DNA, hence increased 
the extent of DNA damage when compared to cells transfected with the empty vector 
(Figure 32) as had been anticipated. In contrast, over-expression of wild-type 
PARP1 reverses the accumulation of DNA damage with the PARP1 binding motif 
such that the extent of DNA damage in cells transfected with the empty vector or the 
PARP1 motif were comparably low (Figure 32). Therefore, aberrant expression of 
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therapeutic that would prevent the transcriptional activity of PARP1 at the HBVCP, 
the ability of  the PARP1 motif to impair PARP1 dependent functions such as DNA 
repair provides a hint that the motif itself can be the “drug” in question for the 
suppression of HBV replication. This can be achieved by the motif itself acting as the 
natural competitor to prevent PARP1 from binding the HBVCP, disallowing PARP1 
from exerting its transcriptional activator effects. The importance of this finding 
justifies the effort spent in subsequent studies on understanding the effects of the 
PARP1 binding motif in different scenarios. 
 
 
4.4 HBV GENOTYPE C POSSESSES EXTRA COPY OF PARP1 BINDING MOTIF 
 
Thus far, a highly conserved PARP1 binding site was found in all HBV genotypes 
within the HBVCP (Figure 27). It is required for PARP1 to bind and mediate 
transcriptional activation at the HBVCP for effective replication. By studying the 
contribution of each nucleotide within the PARP1 binding site to PARP1 dependent 
transcription activation, the elusive PARP1 motif is now defined as an octamer of 
“RNNWCAAA”, and that the “ACATCAAA” sequence confers maximum PARP1 
dependent transcriptional activity (Figure 24).  
As such, HBV genotype F possessing the “ACATCAAA” sequence is thought to be 
associated with highly efficient HBV replication, possibly accounting for its 
association with fulminant hepatitis11, 12, 90. By contrast, other HBV genotypes, 
including HBV genotype C possess the nearly-optimal PARP1 binding motif 
“ACTTCAAA”, possible sufficient to sustain efficient HBV replication hence chronic 
infection. By the unexpected finding that the PARP1 motif can inhibit PARP1 
enzymatic activity (Figure 28) to result in the impairment of PARP1 dependent DNA 
damage repair in cells with active HBV replication (Figure 29), it was proposed that 




chronic infection can allow the accumulation of sub-lethal DNA insults, possibly 
accounting for the development of HCC with prolonged infection and high viral load. 
However, since HBV genotype C possesses the “ACTTCAAA” near-optimal PARP1 
binding motif, none of these mechanisms can explain why infection with HBV 
genotype C is often associated with poorer disease outcome.  
To better understand the mechanism behind the association between HBV genotype 
C and the outcome of infection, the effect of the replicative HBV genotype A and HBV 
genotype C coupled with DNA damage induction were investigated. Huh-7 was the 
cell line of choice, as it produces little cccDNA (Figure 4) that might make data 
interpretation difficult. Furthermore, to minimize the confounding effects of the 
production of large amounts of HBV proteins that might differ between the genotypes, 
the effect of NMU-induced DNA damage 24 hours post-transfection was investigated 
in Huh-7 at the relatively early time-point of 48 hours after transfection. This 
expression thus assumes that the difference in effects observed between the 
genotypes is carried on the DNA sequence of the HBV genome, and not due to the 
variations of HBV proteins that would inevitably be expressed. Over-expression of 
RFP was used as a control to account for any toxicity associated with protein over-
expression. As expected, transfection of HBV-RFP resulted in the accumulation of 
DNA damage (Figure 33), due mainly to the presence of PARP1 binding motifs 
found on the plasmid. By comparison, induction of DNA damage resulted in more 
severe DNA damage when HBV genotype C was transfected. This demonstrates that 
a DNA element in the genome of HBV is different between the two genotypes.  As it 
was shown that the exogenous expression of the PARP1 binding motif can impair 
PARP1 dependent DNA repair to result in the accumulation of damaged DNA when 
treated with drugs such as etoposide, bleomycin (Figure 29 and 30) and NMU 
(Figure 31 and 32), the possibility that another PARP1 binding motif exists in the 
genome of HBV genotype C was investigated. 






Figure 33 Full-length genome of HBV genotype C induces greater DNA damage. 
The extent of DNA damage by 0.01% NMU in Huh-7 cells transfected with plasmids 
carrying different HBV genomes visualized by alkaline comet assays are plotted. The 
bar indicates the median extent of DNA damage from representative experiments. 
***P-value < 0.001. Gen A = HBV genotype A; n = number of aligned sequences. 
 
Curiously, another PARP1 binding motif, “ACTTCAAA” was found in the HBV 
genotype C pre-S1 promoter (Figure 34), as was also identified in the HBV genotype 
C plasmid used in the experiment. This site is however not as well conserved than 
that found in the HBVCP, as only little more than 30% of the aligned genomes 
possess it. Nevertheless, this is still noteworthy, as none of the other genotypes 
possess such a near-optimal PARP1 binding motif at the same locus (Figure 34). 
At this locus within the pre-S1 promoter, the 5’ “ACTT” of the PARP1 binding site, if 
present, is conserved. The low conservation of the 3’ end of the sequence and low 
similarity to the defined “CAAA” sequence defined to be important for the PARP1 
binding motif function (Figure 24) suggests that in most HBV genotypes, this locus is 
unlikely to be transcriptionally regulated by binding PARP1. However, in a significant 
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proportion of HBV genotype C, the PARP1 binding motif is well-conserved, thus 
PARP1 should be able to transcriptionally regulate the pre-S1 promoter in this subset 
of HBV. This would expectedly result in the enhanced generation of the pre-S1 
transcript hence protein, whose high expression, unlike HBs, is positively correlated 
for the synthesis of infectious virions20.  
It can be now be seen how PARP1 can affect the efficiency of HBV replication and 
associated disease outcome, especially for genotype C. PARP1 recognizes the 
PARP1 binding motif at both the HBVCP and the pre-S1 promoter, enabling large 
amounts of HBV transcripts to be synthesized, hence high efficiency of HBV 
replication associated with high viral load and viral DNA. This is enhanced if the host 
possesses one or more copies of the V762A allele, for which based on the 
prominence of HBV genotype C in the Asian continent (Illustration 2) the likelihood 
is very high because nearly 75% of Asians have at least a single V762A allele 
(Figure 23). The efficient HBV replication generates large amounts of cccDNA, which 
possesses two copies of the PARP1 binding motif that are spaced sufficiently far 
apart in the genome (Illustration 4) instead of one, rendering the cccDNA of 
genotype C more capable in impairing cellular PARP1 enzymatic activity than 
cccDNA generated from other HBV genotypes. The impaired PARP1 dependent 
DNA repair results in the accumulation of HBV insults at a faster rate, hence HCC. 
Contrary to its association with impaired DNA damage repair238-240, HBx is a safety 
mechanism to suppress the accumulation damaged DNA (Figure 31) in a bid to 
prevent the infected host from triggering the DNA damage checkpoint hence dying 
from apoptosis. Larger numbers of dying cells impairs liver function to a greater 
extent hence severe liver disease, and at the same time triggers continual liver cells 
regeneration to replace the dead cells hence diseases cirrhosis. Since dead cells 
cannot contribute to HCC, it is conceivable that the expression of HBx is associated 
with the development of HCC, as cells that express it have sub-lethal but sustained 









Figure 34 HBV genotype C has additional copy of PARP1 binding motif. Only HBV 
genotype C possesses another “ACTTCAAA” PARP1 binding motif within the pre-S1 
promoter. This motif is however not well conserved within the genotype. Gen A = 
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4.5 PARP1 MOTIF ENHANCES CYTOTOXICITY OF DNA DAMAGE INDUCERS 
 
Using the HBVCP as a model for PARP1 dependent transcription, the PARP1 
consensus motif for sequence dependent transcription was attained and described to 
be an octamer “RNNWCAAA” (Figure 24), such that the optimal sequence for 
PARP1 dependent transcription is “ACATCAAA” found in the HBVCP of genotypes F 
and H, and the near optimal “ACTTCAAA” was found to be highly conserved in all 
other HBV genotypes (Figure 27). Perplexed by the potential contradictory scenarios 
of having PARP1 enzymatic activity enhanced by the binding of DNA strand breaks 
necessary for DNA repair but decreased transcriptional activity with enzymatically 
active PARP1, it was discovered that the binding of the PARP1motif in fact results in 
the inhibition of its enzymatic activity instead (Figure 28). This lead to the hypothesis 
that exogenous PARP1 binding motif can inhibit PARP1 enzymatic activation in the 
cell, leading to the impairment of cellular processes such as DNA repair that require 
the active PARP1 enzyme (Figure 30), leading to the accumulation of damaged DNA. 
In the treatment of cancer, PARP1 enzymatic inhibitors are used to enhance the 
cytotoxic effects of DNA damage induction131-134, 136, 154, as the impairment of PARP1 
enzymatic activity would prevent DNA repair to enable the accumulation of cytotoxic 
DNA lesions produced by DNA damage inducers. These enzymatic inhibitors achieve 
therapeutic effects by using nicotinamide analogues to block catalytic site of PARP1, 
preventing NAD+ substrate from binding. However, as these nicotinamide analogues 
act on all members of the PARP family, they cannot achieve the aim to specifically 
inhibit PARP1.  
It has been shown that the PARP1 binding motif is unique for PARP1, as no other 
transcription factors or nuclear proteins are known to bind the PARP1 motif in the 
HBVCP (Figure 10). Taking into account the fact that PARP1 can be enzymatically 
inhibited by binding its recognition motif, and that this can affect PARP1 enzymatic 




activity dependent processes such as DNA repair, it suggests that the PARP1 motif 
can itself be developed into a novel therapeutic for achieving specific PARP1 
inhibition. In the context of cancer therapy, this DNA inhibitor would be useful in 
enhancing cytotoxicity associated with DNA damage induction, but be advantageous 
over conventional PARP inhibitors by being PARP1-specific, hence should be 
associated with fewer side effects. 
To demonstrate that the idea of a DNA PARP1 inhibitor is feasible, the accumulation 
of DNA damage with exogenous expression of the PARP1 binding motif was followed. 
HepG2 cells were transfected with HBV-RFP or the control RFP vector and 96 hours 
later, subjected to either etoposide or bleomycin treatment. As shown by the caspase 
3 and caspase 7 dependent cleavage of luminogenic substrates, apoptosis triggered 
as a result of severe and irreparable DNA damage was significantly elevated in the 
HBV-RFP transfected cells compared to RFP controls (Figure 35A).  Annexin V 
staining provide further evidence that a significant population of dying cells were 
induced with transfection of the replicative viral construct compared to controls 
followed by treatment with bleomycin or etoposide (Figure 35B). Since the HBV-RFP 
construct did not affect the percentage of viable cells that fluoresce red, taken 
together, these results indicate that the reduced cell viability, increased apoptosis 
and cell death are the consequence of increased irreparable DNA damage due to the 
accumulation of damaged DNA and not a consequence of the viral replication per se. 
Similar results could be obtained with wild-type PARP1 enzymatic inhibition, as Huh-
7 cells transfected with HBV-RFP and treated with etoposide 96 hours later could 
also result in enhanced cell death when compared to RFP controls as revealed by 
annexin V staining (Figure 36). Therefore, PARP1 enzymatic inhibition by HBV 
replication can impair PARP1 enzyme dependent DNA repair to result in enhanced 
sensitivity of the HepG2 and Huh-7 cancer cells to the cytotoxic effects of otherwise 
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cells transfected with the PARP1 motif were treated with etoposide or bleomycin.  
This confirms that the PARP1 binding motif can act as a specific inhibitor of PARP1 
enzymatic activity when exogenously introduced to impair the cellular functions of 
PARP1 that depend on ADP-ribosylation such as DNA repair. Thus, the PARP1 
binding motif is, in its own right, a novel class of PARP1 inhibitor which may one day 
prove useful in the clinical setting. 
 
4.6 THE PARP1 BINDING MOTIF AS A NOVEL CLASS OF PARP1 INHIBITOR 
 
PARP1 enzymatic activity is required for strand-break dependent DNA damage 
repair (Illustration 10), preventing the accumulation of cytotoxic DNA lesions. 
Cancer cells make use of this property to undo the damage caused by the induction 
of DNA damage with chemotherapeutic agents, increasing their chance of survival 
while rendering chemotherapeutic efforts futile. PARP enzymatic inhibitors are 
therefore useful in enhancing the cytotoxicity of DNA damage inducers in cancer 
cells, as impaired PARP1 dependent DNA repair enables the accumulation of DNA 
damage to trigger the apoptotic pathway, achieving the therapeutic goal of inducing 
cancer cell death108, 132-136, 169, 179. PARP1 enzymatic activity has also been associated 
with many more disorders associated with inflammation and ischaemic-reperfusion132, 
137, as the generation of reaction oxygen species induces large amounts of DNA 
strand-breaks, causing hyper-activation of PARP1 which consumes so much NAD+ 
that the stressed cells end up with necrotic death from energy depletion. Various 
experimental models have shown that PARP inhibition can also alleviate symptoms 
of such diseases, which include stroke and diabetes131, 197 (Table 3). The efficacy of 
PARP enzymatic inhibition in multiple diseases demonstrates the broad range of 
therapeutic outcomes with a single class of drugs, hence the immense interest in the 
development of PARP inhibitors. 




Interestingly, most PARP inhibitors mimic the nicotinamide moiety of NAD+ 
(Illustration 12), which when bound by PARP1, prevent the utilization of the NAD+ 
substrate by blocking its interaction with the catalytic site108, 132-136, 169, 179. However, as 
the PARP catalytic domain is highly conserved among members of the family109, 112, 
117, these inhibitors do not act specifically on PARP1. In fact, given the relative 
abundance of PARP1 and their lower affinity for the PARP1 catalytic domain133, large 
doses of inhibitors are also required to inhibit enough PARP1 enzymatic activity to 
achieve therapeutic efficacy. Furthermore, enzymatic inhibition enhances the 
functions of PARP1 that require it to be an inactive enzyme such as transcription. 
As was demonstrated, the application of PARP inhibitors enhanced PARP1 
dependent transcription at the HBVCP (Figure 16), resulting in enhanced HBV 
replication (Figure 17). The use of PARP inhibitors in patients with chronic HBV 
infection would therefore expectedly result in the development of severe liver disease. 
Given the potential of PARP1 activity modulation to be effective in the treatment of 
multiple disease states, it is worthwhile the effort to develop a PARP1 specific 
inhibitor that can overcome the hurdles of enhancing enzymatically inactive PARP1 
functions and producing unnecessary adverse effects associated with the inhibition of 
multiple PARP family members, producing a safer but more potent alternative.  
Through a screen for host binding factors, it was discovered that PARP1 specifically 
bound to the HBVCP, as no other candidate was shown to bind the “ACTTCAAA” 
sequence within (Figure 10). Furthermore, it was discovered that the PARP1 binding 
motif has an inhibitory effect on PARP1 enzymatic activity (Figure 28). When 
introduced into a cell by transfection or by HBV replication, the PARP1 binding motif 
was sufficient to inhibit PARP1 enzymatic activity dependent functions such as DNA 
repair to achieve enhanced cytotoxicity with the application of DNA damage inducers 
(Figures 35-37).  This phenomenon is synonymous with that of the general PARP 




inhibitors currently used for cancer therapy, suggesting that the DNA PARP1 motif is 
a novel class of PARP1 specific inhibitor capable of achieving therapeutic effects.  
To prove so, Huh-7 cells were treated with various PARP inhibitors and DNA damage 
induced 24 hours later. Figure 39 shows the viability of the cells treated with clinical 
PARP inhibitors compared to that of cells transfected with the PARP1 motif. 
Interestingly, the lower cell density of cells treated with the clinical inhibitors (ABT-
888, AG01469, AZD-2281, BSI201) compared with controls transfected with the 
empty vector without DNA damage induction by DMSO treatment indicates that these 
drugs on their own display some cytotoxicity, possible associated with the loss of 
function of other PARP family members. In contrast, cells transfected with the 
PARP1 binding motif and treated with DMSO displayed better survivability than the 
clinical PARP inhibitors. This demonstrates that the PARP1 motif is a safer 
alternative to the PARP inhibitors tested.  
As most vector transfected cells survived etoposide and NMU treatment, any 
cytotoxic effects observed with the use of PARP inhibitors or PARP1 motif are 
specific to the effects of general PARP or PARP1 inhibition and not due to the 
potential cytotoxicity associated with transfection or drug administration procedure. 
All tested inhibitors display enhanced cytotoxicity with etoposide treatment, of which 
transfection with the PARP1 binding motif resulted in maximal loss of cell viability. 
Similar observations were obtained with NMU treatment, which involves base-
excision DNA repair and thus might take longer time than etoposide for the cytotoxic 
effects of PARP1 inhibition to manifest. The viability of the cells treated with general 
PARP inhibitors were not greatly affected with NMU treatment whereas transfection 
of the PARP1 motif was still capable of achieving enhanced cytotoxicity with sub-
lethal NMU concentrations. The greater cytotoxicity observed in PARP1 motif 
transfected cells compared to cells treated with general PARP inhibitors demonstrate 



























































damage induction, it was more potent, presumably as a consequence of higher 
specificity of action on PARP1 than the clinical inhibitors. Since the PARP1 motif 
displayed less cytotoxicity than the general PARP inhibitors in the absence of DNA 
damage, the PARP1 binding motif is indeed a safer alternative to general PARP 
inhibitors with higher specificity for PARP1. 
General PARP inhibitors can enhance PARP1 dependent transcriptional activation at 
the HBVCP (Figure 16), resulting in the generation of large amounts of HBV 
transcripts (Figure 17). To determine if PARP1 specific enzymatic inhibition by the 
PARP1 binding motif can achieve similar effects, HBV-RFP was co-transfected with 
the plasmid bearing three tandem repeats of the PARP1 motif. Interestingly, the 
PARP1 specific enzymatic inhibition did not result in enhanced production of HBV 
transcripts (Figure 40A). Instead, the PARP1 binding motif suppressed, albeit to a 
small extent, HBV transcript generation. This suggests that, as opposed to general 
PARP inhibitors that act on the catalytic site of PARP1 and have little effect to the 
motif recognition domain of PARP1 per se, the PARP1 binding motif plasmid acts as 
a competitor of the HBVCP for PARP1 binding. This reduces the amount of 
competent PARP1 that can bind the HBVCP to carry out transcription activation 
hence reducing the amount of HBV transcripts generated. Therefore, the PARP1 
binding motif is indeed a much safer alternative for PARP1 specific inhibition, as it is 
not only less toxic on its own (Figure 39), it will also not enhance the activities of the 
inactive PARP1 enzyme. Furthermore, the reduction in HBV transcript generation, 
even though small in magnitude, suggests that the PARP1 motif can be the novel 
drug the entire study was aimed at designing for the suppression of HBV replication 
in the treatment of chronic HBV infection. This is because, given the smaller number 
of effective PARP1 binding sites associated with the PARP1 specific inhibitor at the 
point of transfection when compared to HBV-RFP(Figure 40B), the PARP1 specific 
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Therefore, HBV replication can in this experiment still be sustained due to the 
decreased pool of transcriptionally competent PARP1 at the HBVCP. The effects of 
PARP1 inhibition were more obvious at the protein expression level, where the 
decreased amounts of HBV transcripts generated resulted in a significant reduction 
of HBs expression at 60 hours post-transfection relative to cells transfected with 
empty vector (Figure 40C). This provides further evidence that HBV replication can 
be controlled by the introduction of the PARP1 binding motif alone. Surprisingly, at 96 
hours post-transfection, the PARP1 binding motif resulted in reduced viability of HBV-
RFP transfected cells compared with RFP transfected controls (Figure 40D) as the 
population of RFP expressing cells was significantly reduced. Perhaps the large 
amounts of effective PARP1 binding motifs present in the cell with HBV-RFP and 
PARP1 motif transfection resulted in the severe impairment of PARP1 dependent 
DNA repair, preventing the maintenance of the integrity of DNA that is exposed to 
otherwise sub-lethal background DNA damage, triggering the apoptotic cell death 
pathway of cells with effective HBV replication that are more likely to accumulate 
more damaged DNA as more nuclear PARP1 enzymatic activity would be impaired. 
This phenomenon might be useful for killing HBV infected cells early in HBV infection, 
limiting the spread of the virus. 
In conclusion, the PARP1 binding motif is useful as PARP1 specific inhibitor that on 
its own is associated with low cytotoxicity when compared to general PARP inhibitors 
that act on multiple PARP family members. When coupled with DNA damage 
inducers, the PARP1 binding motif is capable of enhancing cytotoxicity of cells, and 
is more potent than general PARP inhibitors because of its specific action on PARP1. 
On top of these, the PARP1 binding motif will not enhance the function of the 
enzymatically less active PARP1 such as sequence dependent transcription, 
reducing the possible side effects associated with enhanced transcriptional activities 
such as HBV replication. Furthermore, the PARP1 binding motif has potential to 




suppress HBV replication as observed by the reduced transcript and viral protein 
expressions. These qualities strongly support the development of the PARP1 binding 
motif as a novel class of PARP1 specific inhibitor that can achieve similar therapeutic 
effects of general PARP inhibitors in use today, with the added benefit of targeting a 




The definition of the PARP1 binding motif required for transcription has finally been 
resolved. In addition, PARP1 is now known to display two modes of action with DNA-
binding—strand-break recognition will activate its catalytic activity, while motif 
recognition will inhibit it. Since the HBV genome possesses functional PARP1 
binding motif(s), the phenomenon of enzymatic inhibition with motif binding accounts 
for the reduced capability of infected host cells to repair damaged DNA, providing a 
novel mechanism for the development of HCC in chronic carriers with persistently 
high viral DNA loads. The finding that PARP1 may be enzymatically inhibited by 
binding its recognition motif also indicates that the motif itself is a novel class of 
PARP1 specific inhibitors. Understanding how enzymatic inhibition can be achieved 
with motif binding would be useful for discovering new ways to inhibit PARP1 activity 























5.1 PARP1 ENZYMATIC ACTIVITY AND THE PARP1-HBVCP INTERACTION 
 
350 million people worldwide are afflicted with chronic HBV infection1. These people 
have increased risks of developing liver diseases, whose outcomes are dependent 
on the ability to establish functional host interactions. This study focuses a novel 
interaction between the DNA repair enzyme and transcription factor PARP1 and its 
binding motif at the HBV core promoter. The importance of PARP1 in HBV replication 
is reflected by its transcriptional activation function at the HBVCP for the production 
of multiple HBV transcripts including pgRNA, pcRNA and that of HBs. Consistent with 
the fact that the severity of disease outcome is dependent on host ethnicity14, it was 
shown that the host contributes to functional interaction between PARP1 and the 
HBVCP by the expression of PARP1 enzymatic activity variants, as exemplified by 
the less active V762A mutant associated with Asians enhancing transcriptional 
activation. The HBV pathogen in turn contributes to the establishment of functional 
interaction by the PARP1 binding motif it possesses, as revealed by enhanced 
transcriptional activity associated with the optimal PARP1 binding motif found in HBV 
genotype F associated with more severe disease outcomes such as fulminant 
hepatitis11, 12, 90. However, the PARP1-HBVCP interaction is not a closed system. It is 
subjected to multiple levels of regulation dependent on the way PARP1 activity is 
regulated in the infected host. The effects of PARP1 activity regulation on HBV 
replication will be discussed. 
 
PARP1 enzymatic activity shuts down constitutive transcription at the HBVCP  
Many transcription factors have been described to be associated with the HBVCP54, 
55, 63, 64, 67, 215-219, 225 (Illustration 5, 14 and 15), including HNF4α and c/EBPα/β and 
deemed to be important for ensuring efficient HBV replication. By studying how 





factors required for efficient HBV replication were identified (Illustration 16). 
Importantly, this approach revealed the relative contribution of each binding host 
factor to the efficiency of transcriptional regulation at the HBVCP, resulting in the 
establishment that in fact only a handful that have been described are critical 
regulators of transcription at the HBVCP. These included the transcriptional negative 
regulators NREBP and possibly FTF, and the transcriptional activators HNF1, SP1 




Illustration 16 PARP1 enzymatic activity shuts down transcription at HBV core 
promoter.  Important regulatory factors at the HBV core promoter whose binding sites 
result in significant change (>50% increase of >75% decrease in 2 or more cell lines) 
in luciferase gene reporter expression are represented, such that transcriptional 
repressors are black and transcriptional activators are in dark grey. PARP1 activation 
by other PARP family members or by post-translational modification (P) adds PAR (R) 
to itself, SP1 and hnRNP K. ADP-ribosylated PARP1, SP1 and hnRNP K have 
reduced affinity for DNA, resulting in decreased transcriptional activation at the HBV 
core promoter. The net outcome of PARP1 enzymatic activation is transcriptional 
repression by transcriptional repressors to prevent HBV replication. PARP inhibitors 
prevent PARP1 activation, thus enhance HBV replication.  
 
As cell lines such as Huh-7 and Sk-hep-1 shown to have low capability of supporting 
efficient HBV replication (Figure 4A) had an absolute requirement for the activities of 
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deemed to contribute to “basal” hence “constitutive” HBV replication. Of note, SP1 
and hnRNP K are ubiquitously expressed, indicating that these transcription factors 
do not account for the “liver-tropism” of HBV. In contrast, HNF1 is a liver-enriched 
transcription factor, potentially explaining the preference of HBV replication in the 
liver. However, as it is also expressed in other organs such as the kidney and 
pancreas70, HNF1 cannot itself fully account for efficient HBV replication in the liver.  
PARP1 is a multi-functional protein first described in this study to mediate 
transcriptional activation at the HBVCP. More importantly, it was found that the lower 
enzymatic activity of PARP1 in HepG2 and Huh-6 cells (Figure 19) due to the 
expression of PARP1 V762A mutants confer their better capability in supporting HBV 
replication than Huh-7. These suggest that, the minimally auto-modified PARP1 is 
the transcription activator at the HBVCP that confers the infected host cell its ability 
to enable efficient synthesis of HBV transcripts (Illustration 16). Auto-modified 
PARP1 attains high net negative charges, preventing sustained interaction with the 
HBVCP PARP1 binding motif necessary for transcription initiation, hence low 
efficiency of HBV replication. 
Transcription activators such as HNF4α were by comparison less important for 
establishing efficient HBV replication, as transcriptional activity at the HBVCP was 
not particularly affected by the deletion of its binding site in the URR (Figure 5) and 
the BCP (Figure 13) when compared to the effects of the deletion of PARP1, HNF1, 
SP1 or hnRNP K binding sites. HNF4α thus possibly plays the role of enhancing 
efficient transcription that may be established by other host binding factors. 
Interestingly, the expression of most major HNF4α isoforms at transcript and protein 
levels was similar in HepG2, Huh-6 and Huh-7. Only HNF4α3 was shown to be 
differentially expressed such that its higher expression could correlate with the 
capability of the three cell lines to enable efficient HBV replication (Figure 7). This is 





line incapable of supporting HBV replication as the synthesis of HBV transcripts 
cannot be sustained (Figure 3). Whether the preferential expression of larger 
amounts of HNF4α3 in HepG2 contributes to its ability to support efficient HBV 
replication needs further clarification. 
From the screen, it was revealed that two transcription factors, NREBP218 and 
presumably FTF216, negatively regulate transcription at the HBVCP, as deletion of 
their binding sites enhanced transcription at the HBV core promoter in HepG2, Huh-6 
and Huh-7 cell lines capable of producing HBV transcripts. Since no clear pattern of 
enhanced transcription could be demonstrated with the ability of each cell line in 
establishing efficient HBV replication, it is possible that these transcription factors act 
as constitutive repressors at the HBVCP.  
Taken together with the finding that HNF1, SP1 and hnRNP K are deemed 
“constitutive” transcription activators of the HBVCP required for basal transcription, 
the scenario is painted that in any given host cell, these five transcription factors can 
bind the HBVCP together. The net effect of such host factor binding to the HBVCP is 
not known. It is possible that transcriptional activation mediated by HNF1, SP1 and 
hnRNP K is the “default” pathway otherwise it would not have been possible to 
identify the contribution of these transcription factors to transcription at the HBVCP. 
Deletion of their binding sites would have otherwise resulted in no change in 
luciferase expression if the transcriptional repressors were instead constitutively 
exerting their effects at the HBVCP. This suggests that, transcription at the HBVCP is 
activated several fold by PARP1 when recruited and inhibited only when 
transcriptional repressors such as NREBP were instead recruited. How the 
recruitment of different transcription factors occurs is unknown. 
SP1 and hnRNP K are known to be modified by PARP1118, 190, where the association 
of PAR to these transcription factors prevents their association with DNA by 





not only account for the dissociation of auto-modified PARP1 from the HBVCP, but 
the dissociation of multiple transcription activators, all of which have been shown to 
be important for efficient HBV replication and even basal transcriptional activation at 
the HBVCP. Interestingly, the binding sites of PARP1, SP1 and hnRNP K are within 
very close proximity of one another (Illustrations 5 and 16). Thus, PARP1 
enzymatic activity within the proximity of the HBVCP results in the dissociation of 
nearly all the transcriptional activators at the HBVCP, perpetually shutting down 
transcription at the HBVCP as HNF1 is left on its own to mediate transcription. The 
binding of transcriptional repressors should be particularly useful at this juncture for 
suppressing active transcription at the HBVCP, preventing HBV replication. The 
converse is also true, as PARP inhibitors would prevent the modification of nearly all 
the transcription activators required at the HBVCP, enabling their prolonged 
interaction at the HBVCP necessary for transcription. This explains the large 
amounts of HBV transcripts generated with PARP inhibition that was observed 
(Figure 17), and clearly demonstrates why PARP1 enzymatic activity is key to 
determining the efficiency of HBV replication. 
 
HBV replicative phases and rhythmic PARP1 enzymatic activity 
PARP1, is involved in many cellular pathways including transcriptional regulation, 
DNA repair and cell death99-112. Many of its functions are ascribed to its enzymatic 
activity, where the activation of the catalytic domain results in the cleavage of NAD+ 
such that ADP-ribose may be added to protein acceptors (Illustration 8), conferring 
negative charges hence altering the protein’s function. The proteins that may be 
modified by ADP-ribosylation include histones H1 and H2B103, transcription factors 
such as SP1190 and p53151, as well as hnRNP K118, all of which themselves play 
important roles in transcriptional regulation (Illustration 9). PARP1 is itself the major 





modification domain, which act as a signaling cue for the recruitment and assembly 
of complexes involved in DNA repair (Illustration 10), transcription (Illustration 11) 
as well as DNA replication fork restart. These processes are all required for HBV 
replication (Illustration 17) although this study has focused only on sequence 
dependent transcription at the HBVCP by motif recognition that is distinct from the 
other PARP1 dependent functions in the requirement of a minimally auto-modified 
form of PARP1 for activity.  
PARP1 is a critical transcriptional activator that recognizes the near optimal 
“ACTTCAAA” PARP1 binding motif in the HBVCP of most HBV genotypes, or the 
“ACATCAAA” optimal motif to result in enhanced transcription initiation of pgRNA 
and pcRNA. In this respect, PARP1 enzymatic activity need not be required, as 
activation of its catalytic activity would result in PAR formation hence result in the 
accumulation of negative charges on PARP1 to force its repulsion from DNA, 
preventing transcription. The optimal PARP1 binding motifs serve dual functions. It 
makes the PARP1 recognition site more prominent when compared to less optimal 
motifs found in the host genome while achieving maximal PARP1 enzymatic 
inhibition as reflected by sequence dependent degree of histone H1 modification 
(Figure 28). Together, this is a powerful combination in sustaining PARP1-HBVCP 
interaction required for efficient transcriptional activation at the HBVCP, attaining 
maximal attainable amount of HBV transcripts. 
However, the possibility that PARP1 exerts its effects on HBV replication in many 
more ways cannot be excluded (Illustration 17). For example, the synthesis of 
cccDNA from rcDNA requires DNA repair, the mechanism of which this takes place 
remains to be resolved. Given the role of activated PARP1 and PAR formation in 
recruiting Mre11 and polymerase β upon recognition of gaps formed in stalled 
replication forks127, it is tempting to speculate that rcDNA may be recognized by 





required for the conversion of rcDNA to cccDNA. Furthermore, PARP1 enzymatic 
activity may be required for the relief of the minichromosomal structure by the 
modification of cccDNA associated histones or the recruitment of topoisomerase II-β 
to enable transcription. Moreover, modification of nuclear protein functions such as 
that of p53 may also be beneficial to HBV replication, as p53 has been reported to 
inhibit HBV replication241. Until these can be shown to be PARP1 enzyme 
independent, the possibility of having some PARP1 active enzyme being beneficial to 




Illustration 17 Potential roles of PARP1 enzymatic activity in HBV replication. Polβ—






























However, PARP1 enzymatic activity can shut down transcription at the HBVCP, 
preventing HBV replication (Illustration 16). By modification of the transcription 
factors crucial for basal transcription at the HBVCP such as SP1 and hnRNP K, and 
the minimally modified PARP1 transcription activator, PARP1 enzymatic activity 
would result in the decreased transcription of pgRNA, pcRNA and transcripts 
positively regulated by enhancer II function. Therefore, if PARP1 enzymatic activity 
were required for the conversion of rcDNA to cccDNA, and the inhibition of p53 
transcriptional repressor function, its enzymatic activity would impair pgRNA 
transcription hence new virion synthesis. The converse is also true, for when pgRNA 
transcription is required, PARP1 should be enzymatically inactive and disallow 
processes such as rcDNA conversion to cccDNA. In this model, PARP1 acts as a 
double-edged sword, where the synthesis of pgRNA and the conversion of rcDNA to 
cccDNA cannot co-exist.  
The activity of PARP1 has been reported to follow a rhythmic cycle to regulate the 
activity of proteins involved in the circadian cycle, although the cause for its rhythmic 
activity is currently unknown242. Indeed, while the relative protein expression of 
PARP1 is probably invariable, the efficient knockdown of PARP1 protein expression 
within 24 hours of siRNA treatment (Figure 14B) suggests that the turnover rate of 
the protein is dynamic, such that large amounts of PARP1 protein are synthesized 
and degraded within a short period of time. This presents a very enticing model, 
where the alternation of PARP1 form in the infected host cell may contribute to the 
efficacy of HBV replication at different stages of its replicative cycle (Illustration 18). 
When the HBV virion just infects a host cell, the primary goal of the virus is to 
establish stable cccDNA. This requires DNA repair, which might require PARP1 
enzymatic activity. During this time, inhibitors of viral transcript production such as 
p53 may be modified with the active PARP1 enzyme, preventing its association to its 





After cccDNA is generated, viral progeny need to be made by the transcriptional 
activation activity of PARP1, necessitating PARP1 to revert to its enzymatically 
inactive form. This can be achieved by the inhibitory effects of the PARP1 binding 
motif at the HBVCP. The transcription of large amounts of pgRNA by the 
enzymatically inactive PARP1 allows the synthesis of large amounts of core particles.  
The PARP1 transcriptional activator acting on enhancer II also results in the increase 
of envelope protein synthesis such as HBs. Together, the envelopment of core 




Illustration 18 Rhythmic cycling of PARP1 enzymatic activity and HBV replication. It 
is currently not known if PARP1 plays a role in rcDNA repair for the generation of 
cccDNA. 
 
When PARP1 enzymatic activity is once again high in the nucleus, the virus may take 
the opportunity to recycle some core particles, releasing the rcDNA synthesized for 
the conversion to cccDNA, maintaining a stable cccDNA pool in the nucleus to 
enable sustained HBV virion production. This model therefore predicts that the HBV 



























enzymatic activity of PARP1—a “maintenance” phase where regardless of the 
involvement of PARP1 enzymatic activity in the conversion of rcDNA to cccDNA, is 
the period of time where enzymatic activity of PARP1 is high such that pgRNA 
transcription is lower and transcription repressors are preemptively inactivated, and a 
“replicative” phase where PARP1 acts as a transcriptional activator at the HBVCP for 
the synthesis of pgRNA, pcRNA, and potentially as a positive regulator of enhancer II 
to increase transcription of HBV transcripts for the synthesis of other HBV products 
such as HBs.  
This model predicts that virion synthesis is timed, and therefore implies that, to 
achieve maximal therapeutic potential, drugs used to control or prevent HBV 
replication should be carefully administered and synchronized to the target “phases” 
of the rhythmic cycle of HBV replication. Take the example of IFNα treatment that 
boosts host immunity to aid viral clearance. Maximal therapeutic potential can be 
achieved when the viral load is low which should correspond to the “maintenance” 
phase of HBV replication. Drugs targeted at host factors binding at the HBVCP 
should conversely act at the “replicative” phase of the HBV replication cycle, 
achieving the goal of reducing virion synthesis. Understanding the circadian rhythm 
of the liver should prove useful in elucidating the establishment of functional PARP1-
HBV interactions, contributing further to the establishment of an effective treatment 
regiment with PARP1 transcriptional activator function inhibition for the treatment of 
chronic HBV infection. 
 
5.2 THE PARP1 BINDING MOTIF AS A NOVEL THERAPEUTIC 
 
PARP1 was identified as a potential therapeutic target for the treatment of chronic 
HBV infection as it satisfied several guidelines necessary for the development of a 





potential need of prolonged usage without causing too many undesired effects. 
PARP1 satisfied the criteria that it is a sequence dependent binder of the HBVCP 
required for efficient HBV replication, as removal of the PARP1 motif in the HBVCP 
reduced transcription at the HBVCP in HepG2 by more than 95% (Figure 5). It also 
displayed variability in individuals, revealing that it is the V762A mutant, or the 
minimally auto-modified form of PARP1 and not the wild-type PARP1 or 
enzymatically active form that is actively involved in HBV replication.  This not only 
accounts for the more effective cccDNA synthesis in HepG2 hence HBV replication 
when compared to the other cell lines tested, it also suggests that targeting the 
V762A PARP1 mutant alone would achieve the therapeutic goal of suppressing 
transcription of HBV products. This is beneficial for drug development, as the more 
specific the drug is, the greater its potency yet the milder its adverse effects.  
Furthermore, despite its multiple roles in important cellular processes such as 
transcriptional regulation and DNA repair, the viability and the relative healthy 
phenotype of several PARP1 knockout mice models157 have shown that the loss of 
PARP1 function is somewhat redundant, hence targeting the function of PARP1 
should be much safer than targeting other HBVCP binders such as HNF1. 
However, given the wealth of available PARP inhibitors, none are suitable for 
therapeutic modulation of PARP1 activity to inhibit HBV replication. One reason for 
this is that most act by the principle of inhibiting the conserved PARP catalytic site of 
the PARP1 enzyme. Thus, while they may differ in potency on various PARP family 
members, most serve the similar function of blocking the binding of NAD+ substrate 
from binding the catalytic site, hence preventing PARP1 auto-modification108, 132-134, 136, 
154, 169. Therefore, these drugs cannot be used in the treatment of chronic HBV 
infection, as minimally auto-modified PARP1 is the form of PARP1 involved in 





disease outcomes. An alternative approach of modulating PARP1 activity, switching 
it from a transcription competent to a transcription incompetent form is required. 
 
The PARP1 binding motif 
By testing the effects of single nucleotide substitutions on PARP1 dependent 
transcription at the HBVCP, it was unraveled that PARP1 binds the octamer 
“RNNWCAAA” sequence (Figure 24), such that “R” is “A” or “G”, and “W” is “A” or “T” 
and “N” may be any nucleotide to mediate transcription. This is the first description of 
a PARP1 binding motif that may be used to describe validated PARP1 binding sites 
(Figure 26). The binding motif should prove useful in the prediction of novel PARP1 
binding sites in promoter analyses.  
The PARP1 binding motif may be functionally split into the 5’ end and the 3’ end, of 
which the latter sequence is critical for transcriptional activation. Any single base 
substitution within the 3’ “CAAA” sequence results in the loss of 75% or more PARP1 
dependent transcriptional activity. In particular, nucleotide 6 is the most important for 
the PARP1 dependent transcription, for substitution from “A” to any other nucleotide 
results in the loss of 90% or more of transcriptional activity. In contrast, the 5’ end of 
the motif is less conserved. This is especially so for nucleotides at position 2 and 3, 
as few substitutions result in the loss of transcriptional activity by more than 50%.  
Nucleotide positions 1 and 4 play a more important role in the 5’ end of the motif, as 
the loss of transcriptional activity with at least 2 single base substitutions result in the 
loss of nearly 75% transcriptional activity. Putting all the data together, it was 
revealed that the optimal PARP1 motif required for transcription is “ACATCAAA”, 
which may be found in the HBVCP of HBV genotype F and H (Figure 27). 
Interestingly, infections with HBV genotype F tend to result in more severe disease 
outcome such as fulminant hepatitis11, 12, 90. Perhaps this is a reflection of the 





transcripts, as the “A” at nucleotide position 3 of the PARP1 binding motif was shown 
to increase luciferase expression in HepG2 by nearly 50%, hence resulting in 
excessively high viral load leading to severe liver injury. It follows then that the 
possession of the optimal PARP1 binding motif limits the spread of the virus, as it is 
potentially lethal to the host. This may explain why most HBV genotypes possess the 
“ACTTCAAA” near optimal PARP1 binding site instead, enabling sub-lethal but 
sufficiently efficient synthesis of virions. 
Indeed, the near-optimal PARP1 binding motif is important for transcription at the 
HBVCP, as the viral PARP1 binding site in the HBVCP needs to be more prominent 
than the other PARP1 binding sites carried on the host genome for HBV to 
successfully hijack transcriptionally competent PARP1. This is especially so, as many 
of the genes transcriptionally regulated by PARP1 are immune-modulatory, including 
the anti-viral IFNγ179 and the anti-viral receptor IFNAR1184. Sequestration of 
transcriptionally competent PARP1 at the HBVCP prevents the transcription of these 
anti-viral products while enabling HBV replication, achieving two goals at once. 
These cannot be achieved had the PARP1 binding motifs within the host genome 
been easily recognized by transcriptionally competent PARP1 instead.  
The description of the relative contribution of each nucleotide within the octamer in 
PARP1 dependent transcription is consistent with the contribution of each nucleotide 
within the octamer of the HTLV Tax RE towards PARP1 specific binding175 (Table 6), 
where it may be deduced from the relative affinity of EMSA probes bearing mutations 
of the octamer sequence that nucleotides 5 and 6 are most important for the binding 
of PARP1 but not nucleotides 2 and 3. Furthermore, it can be seen that nucleotide 
positions 1, 4 and 7 also play a part in the binding of PARP1 to its motif, albeit to a 
smaller extent than nucleotides 5 and 6. These reports therefore concur with the 






Table 6 Nucleotide positions critical for PARP1 motif binding 
EMSA probe Probe sequence  Binds PARP1 
HBV PARP1 motif A C T T C A A A  Yes 
HTLV Tax RE WT A C G A C A A C  Yes 
HTLV Tax RE M6 A C G A C A C C  Yes 
HTLV Tax RE M5  C A T C C A A C  Yes 
HTLV Tax RE M4 C C G C C A A C  Yes 
HTLV Tax RE M2 A C G A A C A C  Weak 
HTLV Tax RE M1 C C G C A C C C  No 
PARP1 motif R N N W C A A A   
Nucleotide position 1 2 3 4 5 6 7 8   
Mutations within the PARP1 recognition motif in the HTLV Tax RE EMSA probes 
were analyzed for their relative affinity to PARP1. Nucleotides in red depict 
nucleotide positions when mutated prevent PARP1 binding. Nucleotides in blue 
depict nucleotide positions when mutated have less effect on PARP1 binding. 
Nucleotides in grey denote nucleotide positions that have little effect on PARP1 
binding. 
 
Interestingly, the PARP1 binding motif was found to exhibit inhibitory effects to the 
enzymatic activity of PARP1, preventing effective ADP-ribosylation of its substrates 
such as histone H1 (Figure 28). This inhibitory effect on PARP1 enzymatic activity 
was sufficient to enhance cytotoxicity of cells towards DNA damage induction 
(Figure30), achieving the therapeutic outcome of apoptotic cancer cell death (Figure 
36) that general PARP inhibitors used in the clinical setting are meant to perform. 
Thus, the PARP1 binding motif is a PARP1 specific enzymatic inhibitor that may 
eventually also prove useful in the clinical setting for the treatment of cancer.  
 
Comparing the PARP1 binding motif and general PARP inhibitors 
The molecular mechanism of action of the PARP1 binding motif on enzymatic activity 
is not known. PARP1 has two zinc fingers at its N-terminus that recognizes DNA 





transcriptional repression194. Whether these two zinc fingers are responsible for motif 
recognition has not been ascertained. The third zinc binding domain acts as the link 
between the N-terminal events of DNA binding to the C-terminus events of enzymatic 
activation by organizing the PARP1-PARP1 homodimer interface114, 115. Perhaps 
PARP1 motif binding disrupts this interface, preventing catalytic enzymatic activation. 
Indeed, the PARP1 binding motif is not in the form of a repeat often observed in 
transcription factor complexes that are composed of homodimeric units such as 
HNF4α243, reflecting that the transcriptionally competent PARP1 is a monomer. 
Furthermore, the PARP1 binding motif acts by posing steric hindrance to prevent 
PARP1 binding to DNA strand-breaks (Illustration 19), thereby enabling the 
accumulation of damaged DNA when exposed to DNA damage inducers, triggering 
cell death by apoptosis. In contrast, general PARP inhibitors act by direct binding to 
the conserved catalytic domain of PARP family members, preventing ADP-
ribosylation as NAD+ is blocked from the catalytic site. 
   
 
 
Illustration 19 PARP1 binding motif as a novel class of PARP1 inhibitors. Proposed 
mechanism for PARP1 inhibition by a DNA duplex comprising the PARP1 motif 
compared with that of conventional chemical inhibitors. 
 
The difference in mechanism of PARP1 inhibition has significant impact on the 
application of the PARP inhibitors, as it determines the properties (Table 7) of the 
















Table 7 Comparing the PARP1 binding motif and general PARP inhibitors 
Property PARP1 binding motif General PARP inhibitors
Target PARP1 domain Zinc fingers I and II? Catalytic domain* 
Specific for PARP1 Yes No 
Cytotoxicity on its own Low High 
Cytotoxicity with DNA damage Yes Yes 
Half-life Long Variable 
Effect on HBV replication Suppressed Enhanced 
Gender specificity ? Males (Inflammation) 
*Most PARP inhibitors act on the catalytic domain. 
 
Administration of PARP general inhibitors enhances PARP1 dependent transcription 
at various gene promoters175, 178 and the HBVCP (Figure 16), implying that the 
inhibitor-PARP1 complex can still bind the PARP1 recognition motif to mediate 
transcription (Illustration 19). Conversely, the finding that transcription at the 
HBVCP is slightly reduced with introduction of the PARP1 binding motif indicates that 
it competes with other PARP1 binding sites in promoter regions for transcriptionally 
competent PARP1, preventing transcription. Thus, general PARP inhibitors have the 
effect of enhancing the manifestation of diseases associated with PARP1 sequence 
dependent transcription, such as enhancing HBV replication (Figure 17) and 
transcription of HTLV products175, restricting their use to the treatment of diseases 
with high morbidity such as cancer and stroke. However, by preventing 
transcriptionally competent PARP1 to mediate its effects, the PARP1 binding motif 
can achieve the therapeutic effects of general PARP inhibitors in cancer therapy, with 
the advantage of targeting a wider spectrum of diseases such as HBV infection. 
Besides its potential in the treatment of multiple diseases, the PARP1 binding motif is 
also safer as it is associated with lower levels of cytotoxicity when administered alone 
yet capable of achieving enhanced therapeutic outcomes (Figure 39). This is due to 
its specificity for PARP1 only, as no other protein was found to bind the HBVCP 





the inhibition of other PARP family members. In contrast, the general PARP inhibitors 
exhibited lower specificity for PARP1 hence was not only cytotoxic on its own (Figure 
39), higher doses of DNA damage are clearly needed for the therapy to be effective, 
defeating the purpose of achieving enhanced cytotoxicity in cancer cells with low 
levels of DNA damage induction.  
In line with the high turnover rate of PARP1 as reflected by efficient knockdown 
within 24 hours of specific siRNA treatment (Figure 14) and rhythmic cycling of 
PARP1 enzymatic activity242, general PARP inhibitors have been reported to have 
short half lives of 1-3 hours244 hence necessitating frequent dosage. This also 
accounts for the relatively lower cytotoxicity with DNA damaged induction when 
coupled with etoposide or NMU treatments compared to the PARP1 binding motif 
(Figure 39), as the enzymatic inhibition effects of the general inhibitors have partially 
worn off after 24 hours of PARP inhibitor treatment. It appears that the PARP1 
binding motif has a longer half-life, such that transcriptionally competent PARP1 may 
still be prevented from acting on the HBVCP 72 hours after transfection to result in a 
decrease in HBV transcript expression (Figure 40A). This is another advantage of 
the PARP1 binding motif, as it reduces the need of multiple doses to achieve similar 
therapeutic outcomes. 
Interestingly, males have been found to respond better to PARP general inhibitors for 
the treatment of inflammatory disorders relating to PARP1 enzymatic hyper-
activation155. It was proposed that the estrogen-bound estrogen receptor transcription 
factor complex anchors PARP1 to promoter regions, sequestering it from sites of 
DNA lesions so that the PARP1 enzyme may not be activated. This implies that 
males having a proportionately larger pool of PARP1 that may be enzymatically 
activated, accounting for the greater role of PARP1 hyper-activation in the 
development of disease in males. Whether the same applies for the PARP1 binding 





several shortcomings of the nicotinamide analogue class of general PARP inhibitors 
(Table 7), indicating it to be a novel class of PARP1 specific inhibitor with potential to 
treat multiple PARP1 dependent diseases. Furthermore, understanding how the 
PARP1 binding motif achieves enzymatic inhibition would shed light on allosteric 
regulation of the PARP1 enzymatic activity, paving the way for the development of 
novel therapeutics against PARP1. 
 
5.3 NOVEL THERAPEUTIC STRATEGIES AGAINST HBV INFECTION 
 
HBV replication is dependent on the establishment of functional host-pathogen 
interactions at the HBVCP that govern the synthesis of pgRNA (Illustration 3 and 5). 
However, current therapeutic strategies used in the treatment of chronic HBV 
infection do not make use of this (Illustration 21). Nucleoside and nucleotide 
analogues inhibit the activity of the HBV polymerase, disallowing the continued 
transcription of pgRNA from stable cccDNA templates. Therefore, HBV polymerase 
can still be synthesized from the pgRNA, enabling the selection of drug resistant 
mutants. IFNα treatment avoids the root of the problem altogether by boosting host 
immunity which can be easily overcome with the generation of large amounts of virus. 
Thus, there is a need to find new ways of treating chronic HBV infection. 
The PARP1-HBVCP interaction is a novel one that is critical for efficient HBV 
replication. This interaction can only be functional if the host PARP1 is in a 
transcriptionally competent form, and if the HBVCP has an easily recognizable 
PARP1 binding motif. It was shown that in all HBV genotypes, the PARP1 binding 
motif is highly conserved and favourable for transcriptional activation (Figure 27), 
thus the ability to produce a functional interaction depends mainly on the host PARP1. 
Only PARP1 with low enzymatic activity, such as that of the natural V762A mutant, 
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transcriptionally less competent PARP1. However, given the highly dynamic PARP1 
turnover, it is unlikely the effects of increasing the relative amount of auto-modified 
PARP1 will be sustained. 
The other approach is to use the PARP1 binding motif as a competitor of the HBVCP 
for transcriptionally competent PARP1, preventing it from exerting its effects on the 
HBVCP (Illustration 20). The feasibility of this approach was demonstrated with the 
slight reduction of HBV transcripts and amount of HBs generated, as well as the 
gradual loss of HBV-RFP transfected cells (Figure 40). To enhance the efficacy of 
the PARP1 binding motif in preventing HBV replication, an increase in the amount of 
optimal PARP1 binding motifs will be needed. General PARP inhibitors will not be 
suitable for preventing HBV replication, as they would increase the relative 
expression of transcriptionally competent PARP1, resulting in enhanced HBV 
replication (Figures 16 and 17) hence severe disease.  
Studying the host-pathogen interactions at the HBVCP has deepened the 
understanding of transcriptional regulation at the HBVCP. With the discovery of the 
PARP1-HBVCP interaction, a novel strategy of tackling the root of persistent HBV 
replication in HBV infection has been developed. By shutting down pgRNA 
transcription, the PARP1 binding motif should overcome the pitfalls of current 







5.4 PARP1 V762A POLYMORPHISM, HBV REPLIATION AND HCC 
 
It is well-established that chronic HBV infection accounts for more than half the cases 
of HCC2, 201, 245. High replication efficiency associated with high viral DNA and load 
are prognostic markers for poor disease outcomes and high risk of HCC in chronic 
carriers of HBV90. Other factors relating to infection outcomes include the gender of 
host, the genotype of the virus as well as being of Asian descent14. These point to the 
importance of functional host-pathogen interactions, such that specific combinations 
of host factors and pathogen elements produce HBV more efficiently than others 
(Illustration 22). The discovery of the PARP1-HBVCP interaction is significant, as it 
not only identifies a novel transcriptional activator required for HBV replication, it also 
demonstrates how HBV can make use of the host factor, contributing to HCC. 
The HBVCP has a novel “ACTTCAAA” PARP1 binding site that is highly conserved 
(Figure27). Importantly, this PARP1 binding motif is well-suited for PARP1 
dependent transcriptional activation, rendering it easily recognizable for 
transcriptionally competent PARP1 to exert its effects when compared to less 
conserved PARP1 binding sites in the host genome. The ability of HBV to efficiently 
transcribe pgRNA is enhanced when it possesses the “ACATCAAA” motif in 
genotype F and H, increasing HBV replication and viral load. Furthermore, a 
significant proportion of HBV genotype C possesses an extra copy of the 
“ACTTCAAA” PARP1 binding motif in the pre-S1 promoter. Taking the geographical 
prevalence of the HBV genotypes into account (Illustration 22), it can be seen that 
in most parts of the world, HBV possesses only a single “ACTTCAAA” PARP1 
binding motif. In East Asia, HBV can possess two copies of the “ACTTCAAA” PARP1 
binding motif. In Central and Southern Americas, HBV possesses a single 
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Enzymatically less active PARP1 is the transcriptionally competent form that 
establishes functional PARP1-HBVCP interaction. Natural SNPs such as the V762A 
mutation reducing the enzymatic activity of PARP1 would therefore contribute to 
effective HBV replication. Interestingly, the prevalence of the V762A allele is also 
similar to the distribution of HBV genotypes associated with sever disease outcomes 
(Illustration 22). While heterozygosity of the mutant allele is about 35% worldwide, 
most sub-Saharan Africans do not inherit this allele (Figure 23). Therefore, hosts of 
African descent are less capable of forming functional PARP1-HBV interactions. In 
contrast, approximately 75% of Asians have at least a copy of the V762A allele 
(Figure 23), accounting for the formation of functional PARP1-HBVCP interactions 
regardless of HBV genotype. This would explain why being of Asian descent is a 
prognostic marker for poorer disease outcomes associated with high viral load. 
Males are thought to have a larger pool of “free” transcriptionally competent 
PARP1155, as the lack of prevents the sequestration of PARP1 to genomic PARP1 
binding sites. The large amounts of transcriptionally competent PARP1 would 
increase the chance of establishing functional PARP1-HBVCP interactions, 
accounting for high HBV replication efficiency hence severe disease outcomes. 
The PARP1 binding motif is not just a recognition motif. It is also an enzymatic 
inhibitor of PARP1 with long half-life (Table 7). Functional PARP1-HBVCP interaction 
is therefore not only beneficial to HBV replication. It acts on the host to impair PARP1 
dependent function such as DNA repair. Several reports have shown that the long-
term loss of PARP1 function results in the development of HCC. For example, all 
mice fed on a diet to deprive liver NAD+ results in the development of HCC with 
age166. Furthermore, PARP1 mice knockout models have also shown that HCC 
develops spontaneously with age158, confirming that long-term loss of PARP1 
enzymatic activity would increase the risk of HCC development. On top of that, 





associated with the development of HCC246. Therefore, the long-term suppression of 
PARP1 enzymatic activity by the persistent expression of the HBV PARP1 binding 




Illustration 23 PARP1 V762A polymorphism, HBV replication and HCC. The V762A 
confers reduced PARP1 enzymatic activity, enabling efficient HBV replication. The 
PARP1 binding motif of HBV inhibits PARP1 enzymatic activity hence DNA repair, 
increasing susceptibility of an infected individual to accumulate DNA damage. This 
increases the risk of developing HCC. In tumour cells, large amounts of damaged 
DNA would lead to cell death by apoptosis. To prevent this, tumour cells up-regulate 
PARP1 expression to increased DNA repair capacity. This overall enhanced PARP1 
enzymatic activity is detrimental to HBV replication, accounting for the loss of HBV 
replication in HCC patients. 
 
Taking gender, prevalence of the V762A transcriptionally competent PARP1, as well 
as the type and number of PARP1 binding motifs in HBV into account, it is clear how 
HCC develops in high risk individuals (Illustration 23). Males have large amounts of 
transcriptionally competent PARP1, increasing the chance of establishing functional 
PARP1-HBVCP interaction. Expression of the V762A allele further increases the 
































dependent manner, accounting for high risk of males of Asian origins in developing 
severe disease. Efficient HBV replication generates large amounts of PARP1 binding 
motifs, of which the amount of functional motifs is doubled in HBV genotype C due to 
the presence of another PARP1 binding motif in the pre-S1 promoter. The large 
amounts of PARP1 specific inhibitors in the nucleus severely impairs PARP1 
enzymatic activity, creating a positive feedback loop to enhance HBV replication, 
while at the same time resulting in the loss of function of PARP1. Compromised 
PARP1 dependent DNA repair capability renders the infected host susceptible to 
DNA damage, enabling the accumulation of sub-lethal DNA lesions over years for the 
development of HCC. With this model, the functional PARP1-HBVCP accounts for 
how variability in host factors and viral genotypes contribute to efficient HBV 
replication. Furthermore, it provides the link explaining the relevance of high viral 
DNA and load towards the development of HCC. 
Interestingly, HBV replication is often reduced when HCC develops23. This further 
reflects the importance of the functional PARP1-HBVCP interaction (Illustration 23). 
As HCC tumour cells have large amounts of DNA lesions, to survive the cells up-
regulate PARP1 enzymatic activity167, 168 to repair DNA, keeping the amount of DNA 
lesions that trigger apoptotic pathways to sub-threshold levels. This inevitably 
weakens the PARP1-HBVCP interaction, as transcription at the HBVCP can no 
longer be effectively sustained. HBV replication thus is decreased, and viral load 
eventually cleared. 
The discovery of the PARP1 binding motif in the HBV core promoter has important 
implications. It demonstrates that PARP1 is a host factor critical for efficient HBV 
replication. Furthermore, it establishes the connection between HBV genotype and 
host ethnic origins in the contribution towards severe liver disease, and indicates that 
the V762A allele is a biomarker increased susceptibility to chronic HBV infection. On 





and chronic HBV infection is provided. The novel PARP1-HBVCP interaction has 
therefore contributed substantially towards the understanding of functional host-














Materials and Methods 
 
  




Cell culture and transfection conditions 
HepG2, Huh-6, Huh-7 and Sk-hep-1 were maintained at 37oC, 5% (v/v) CO2 in a 
humidified incubator with complete Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% (v/v) fetal bovine serum (Gibco) without antibiotics.  
 
RNA extraction and RT-PCR 
Cells were seeded to match for confluency in 10cm dishes as follows: HepG2 and 
Sk-hep-1—4.5 X 106 cells/well; Huh-6 and Huh-7—3 X 106 cells/well. Total RNA was 
extracted 30 hours later using the NucleoSpin® RNA II kit (Machery Nagel) and 
reverse transcribed using the Accuscript® High Fidelity 1st Strand cDNA Synthesis Kit 
(Stratagene) with 100ng total RNA and oligo-dT primers. RT-PCR primers for HNF4α 
isoform detection and the cloning of PARP1 are listed in Table 8. 
 
Table 8 List of RT-PCR primers 
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PCR conditions are outlined as follows: 1 round of 95oC for 2 minutes, 35 rounds of 
95oC for 20 seconds, 58oC for 20 seconds and 72oC for 20 seconds to amplify 
specific products, using the Expand High Fidelity PCR System (Roche). 
 
Table 9 List of primers for generating HBVCP deletion mutants 
Deletion Primer sequence (5’Æ 3’) 
URR1 
B-URR1 GGATCTGATGGGC CATGCAACG 











































































B-BCP4 TTAAAGGTCTTTGTGCATAAATTGGTCTGC G 















C-BCP9 ATGTACAAGAGATGATTAGTTGCATGG TGCT 
 
Single base substitutions in the HBV core promoter were generated with the 
QuickChange® II Site-Directed Mutagenesis Kit (Stratagene).  
Full-length replicative HBV genotype A (1.1X HBV genome, nt 1535-1930) was 
amplified from another construct203, 204 using the Expand Long Template PCR System 




(Roche). PCR conditions were as follows: 95oC for 2 minutes, 35 rounds of 95oC for 
2 minutes, 58oC for 30 seconds, 72oC for 4 minutes, 1 round of 72oC for 15 minutes. 
Primers used were HBVF and HBVR (Table 10), and the amplicon inserted into 
pcDNA3.1+ upstream of the CMV promoter via the MfeI and MluI restriction sites. 
The coding sequence for RFP was cut from the pTurboFP635N (Evrogen) and 
inserted via KpnI and NotI sites.  
The PARP1 motif construct was synthesized by annealing a pair of oligomers, 
PARP1motif-F and PARP1motif-R (Table 10), and inserting the product into 
pcDNA3.1+ vector via the MfeI and MluI restriction sites. To synthesize the PARP1 
over-expression vector, total RNA was extracted as described and the coding 
sequence amplified using the primers PARP1-F and PARP1-R (Table 8). The 
amplicon was inserted into pcDNA3.1+ via the NheI and XhoI restriction sites.  
 
Table 10 Sequences of cloning primers 








PARP1 specific knockdown was achieved with 10nM Silencer® Select Validated 
siRNA #s1098 (Ambion). The Silencer® Select Negative Control #2 siRNA (Ambion) 
was used as a non-specific siRNA control. 
 
 




Protein extraction and immunoblotting 
Nuclear or cytoplasmic lysates were obtained using the NE-PER kit (Thermo 
Scientific) as recommended.  Lysis was performed on ice in the presence of PMSF 
and protease inhibitor cocktail (Sigma-aldrich). Protein concentration was determined 
using the Bradford assay (Bio-Rad Laboratories). SDS-PAGE was performed with 10% 
gels under standard reducing conditions. Proteins were semi-dry electroblotted onto 
Immobilo-PSQ PVDF transfer membrane (Millipore) under standard conditions. 
Blocking was performed overnight at 4oC on a rotator with 5% milk in PBS with 0.01% 
Tween-20 (Sigma-Aldrich) as the blocking agent.  Antibodies for lamin B1 (sc-56145, 
1:400, Sant-cruz), PARP1 (sc-74469X, 1:1000, Santa-cruz), HBs (sc-52411, 1: 200, 
Santa-Cruz), HBx (sc-57760, 1:200, Santa-cruz), HBc (sc-71236, 1:200, Santa-cruz) 
HNF4α (PP-H1415-00, 1:1000, R&D Systems), albumin (ab-10241, 1:2000, Abcam), 
and Oct-1 (sc-8024, 1:200, Santa-cruz) were added into blocking reagent and 
incubated with the membrane on a rotator for 2 hours at room temperature. Blots 
were washed thrice, 10 minutes each with 0.01% Tween-20 in PBS. HRP-conjugated 
secondary antibodies (Dako) were diluted 20,000 times in blocking reagent, and 
incubated with the blot for 1 hour at room temperature on a rotator. After 3 washes 
for 10 minutes each, specific protein bands were detected with the SuperSignal West 
Femto Maximum Sensitivity Substrate (Thermo scientific) chemiluminscent substrate 
diluted 4 times in water.  
 
Luciferase assays 
Assays were performed using the Dual-Luciferase® Reporter Assay System 
(Promega). Cells were seeded in triplicates to match for confluency 18 hours prior to 
transfection in 24-well plates as follows: HepG2 and Sk-hep-1—1.5 X 105 cells/well, 
Huh-6 and Huh-7—1 X 105 cells/well. Transfection was performed with 2.2 μl of 
Lipofectamine 2000 (Invitrogen), 1μg of PGL3 Basic construct plasmid and 15ng of 




Renilla-luciferase construct per well. Transfected cells were lysed with 60 μl lysis 
buffer at 37oC on a shaking incubator for 20 minutes after washing thrice with ice-
cold PBS 30 hours post-transfection unless stated otherwise. 50μl of the lysate was 
then transferred on ice into 96-well black plates with clear bottoms (Corning), and 
luminescence measured with the GloMax® Multi-Microplate Multimode Reader 
(Promega). Luminescence is normalized to that of the empty PGL3 Basic vector, and 
expressed as a ratio relative to normalized luminescence of the wild-type HBV 
promoter. 
 
Electrophoretic mobility shifts assays (EMSA) 
EMSA was performed using the LightShift Chemiluminescent kit (Thermo Scientific) 
with 2μg HepG2 nuclear lysates and 1ng 5’ end biotinylated probes with sense 
strand sequence 5’-TTGAGGCCTACTTCAAAGACTGTGTG-3’, unless stated 
otherwise. Biotinylated EBNA probes provided in the kit were used as negative 
control. Binding was performed at 37oC for 45 minutes using a thermocycler in 20μl 
reactions. The binding buffer comprised of 1X binding buffer provided in the kit, 12.5% 
glycerol, 0.5mM EDTA, 0.3mg BSA, 0.05% NP-40 and 1μg poly-dIdC. 1μl PARP1 
antibody (sc-74469X, Santa-cruz) was used when indicated. Electrophoresis was 
performed at 4oC on pre-run 4% native polyacrylamide gels at 100 V for 1.5 hours. 
Subsequent steps were performed as per instructions. 
 
Streptavidin pull-down and MALDI-TOF/TOF 
10μl of Dynabeads® M-280 Streptavidin (Invitrogen) were washed as recommended.  
1μg of 5’ end biotinylated probe was incubated with 70μg HepG2 nuclear lysates in 
100μl reactions identical to that used in EMSA. Binding was performed for 45 
minutes on a bench-top thermo-mixer at 37oC with gentle agitation. Washing was 




performed with EMSA binding buffer. Bound proteins were eluted by boiling at 95oC 
for 20 minutes in 20μl of 2X reducing SDS-PAGE loading buffer. SDS-PAGE was 
performed using all the eluate in 10% reducing gels under standard conditions and 
the gel stained with coomassie overnight. Bands of interest were washed then 
excised and sent to the Protein and Proteomics Center in the National University of 
Singapore for MALDI-TOF/TOF analysis. 
 
Complete genome alignments 
Complete viral genomes were extracted from Entrez Nucleotide using the keyword 
search terms “HBV genotype X complete genome”, where “X” may be any of the 8 
genotypes of HBV. Sequences containing the word “clone” were excluded. Global 
alignments were performed with the software Clustal X version 2.0.5 with standard 
parameters247, 248.  
 
MATCHTM search for transcription factors 
MATCHTM was performed using the WeightMatrix library matrixTFP60, matrix groups 
for vertebrates and cut-off to minimize false negative matches. 
 
Assays for cccDNA, HBV transcripts, and HBs 
Cells were transfected with HBV-RFP in 6-well plates to match for confluency as 
follows: HepG2 and Sk-hep-1—7.5 X 105 cells/well, Huh-6 and Huh-7—5 X 105 
cells/well. Transfection was performed at the point of seeding with 5μg HBV-RFP and 
5.5μl Lipofectamine2000 (Invitrogen). Medium was changed 6 hours after 
transfection, and washed thrice with PBS before fresh medium was added. Total 
DNA was extracted from cultures in triplicaltes using the DNeasy Blood and Tissue 
kit (Qiagen) in the presence of RNase A (Qiagen). To determine th relative cccDNA 




fold-change, quantitative real-time PCR (qRT-PCR) was performed using the 
LightCycler® FastStart DNA MasterPLUS SYBR Green I (Roche) in 10μl reactions 
containing 1ng total DNA. cccDNA fold-change at indicated time-points relative to 6 
hours post-transfection was determined using the ΔΔCt method, with the relative 
amount of pcDNA3.1+ vector serving as the internal reference to account for 
differences in transfection efficiency. Primer sequences are provided in table 11.  
 
Table 11 Primer sequences for detecting HBV cccDNA and HBV transcripts 









Reverse 5’- ATGGCAACTGTGAGGAGGGGAGATTC-3’ 
 
HBV transcripts were extracted from total RNA as described, reverse transcribed and 
amplified using primers for cccDNA detection, and their relative expression 
normalized to the amount of Glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
Melting curve analysis was performed, and all primer pairs produced only a specific 
peak. Primer sequences for are provided in table 11. 
HBs assay was performed using the Monolisa® HBs Ag Ultra kit (Bio-Rad) as 
indicated with 100μl of culture medium. 
 
Histone H1 modification assay 
Assays were performed in triplicates using the PARP Universal Colorimetric Assay 
Kit (R&D Systems). 5μg of nuclear lysates in PARP buffer containing PMSF and 




protease inhibitor cocktail (Sigma-aldrich) was used with 1μl DNA duplexes formed 
by annealing equal amounts of 100μM DNA oligomers, whose sequences are 
provided in table 12. 
 
Table 12 Sequences of 20bp DNA duplexes used in histone H1 modification assays. 
DNA duplex Sequence (5’Æ3’) 
Wild-type PARP1 motif 
Sense ACGTCTACATCAAAGTTGCA 
Anti-sense TGCAACTTTGATGTAGACGT 
“CC” mutation flanking motif 
Sense CCGTCTACATCAAAGTTGCA 
Anti-sense TGCAACTTTGATGTAGACGG 
“CTA” mutation flanking motif 
Sense CTATCTACATCAAAGTTGCA 
Anti-sense TGCAACTTTGATGTAGATAG  
“C” mutation within motif 
Sense ACGTCTACATCCAAGTTGCA 
Anti-sense TGCAACTTGGATGTAGACGT 
“GC” mutation within motif 
Sense ACGTCTACATGCAAGTTGCA 
Anti-sense TGCAACTTGCATGTAGACGT 
“GGC” mutation within motif 
Sense ACGTCTACAGGCAAGTTGCA 
Anti-sense TGCAACTTGCCTGTAGACGT 
HBV PARP1 motif 
Sense ACGTCTACTTCAAAGTTGCA 
Anti-sense TGCAACTTTGAAGTAGACGT  
 
Alkaline comet assays 
Etoposide (Sigma-Aldrich) dissolved in DMSO, aqueous bleomycin (Sigma-Aldrich) 
or aqueous NMU (Sigma-Aldrich) were used at concentrations indicated in text. 
Alkaline COMET assays were performed using the CometAssay® kit as instructed 
(Trevigen).  At least 50 comets per treatment were analyzed and scored with the 
TriTek CometScoreTM version 1.5 software.  




Cell death and apoptosis assays 
Cells were transfected at the point of seeding in 24-well plates to match for 
confluency at 1.5 X 105 HepG2 cells/well and 1 X 105 Huh-7 cells/well with 1.1μl 
Lipofectamine2000 (Invitrogen). Culture medium was replaced with fresh medium 
containing DNA damage inducers etoposide (Sigma-Aldrich) dissolved in DMSO, 
aqueous bleomycin (Sigma-Aldrich) or aqueous NMU (Sigma-Aldrich) were used at 
concentrations indicated in text. PARP inhibitors ABT-888, AG014699, AZD2281 and 
BSI-201 were purchased from Selleck Chemicals and dissolved in DMSO, and used 
at 10μM. Annexin V staining was performed at indicated time-points. Culture medium 
was removed and annexin V-Fluos (Roche) was diluted in Hepes buffer and added to 
cells on ice in the dark for 10 minutes. Excess dye was removed and fresh culture 
medium gently added. Stained cells were analyzed immediately. 
Apoptosis was measured using the Caspase-Glo® 3/7 Assay (Promega) as 
recommended. Triplicates were performed in 96-well plates. 3 X 104 HepG2 cells 
were seeded per well and transfected with 200ng of plasmids using 0.22μl 
Lipofectamine 2000 (Invitrogen) at the point of seeding. Drugs were added in 100μl 
fresh culture medium and lysis was performed with equivalent volumes of reagent. 
Luminescence was measured with the GloMax® Multi-Microplate Multimode Reader 
(Promega) 25 minutes after lysis.  
 
Immunofluorescence 
Culture medium was removed and cells washed thrice with PBS, then fixed with 4% 
paraformaldehyde (Sigma) for 30 minutes at room temperature. Excess 
paraformaldehyde was quenched with 50mM NH4Cl for 10 minutes. Fixed cells were 
permeabilized with 0.1% (v/v) Triton-X in PBS for 30 minutes. Blocking was 
performed using 1% BSA (w/v) in PBS for 30 minutes at room temperature, and 
staining performed with anti-HBs (sc-52411, 1: 100, Santa-Cruz) in blocking buffer 




overnight at 4oC in a humidified chamber. After washing thrice in PBS at room 
temperature for 10 minutes each, DyLight-488 conjugated secondary antibody (1:100, 
Thermo Scientific) was added at room temperature in the dark for 1 hour. Nuclei are 
stained with 500ng/ml DAPI (Thermo Scientific) for 10 minutes before washing thrice 
in PBS and mounting. 
 
Statistical analysis 
F-test for equal variance was performed, and one-tailed student’s t-test with equal or 
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It is well-established that hepatitis B virus (HBV) infection is associated with the 
development of hepatocellular carcinoma (HCC) but patients with high viral DNA load 
have significantly higher risk. As host factors are required for efficient viral replication 
and may therefore contribute to high viral DNA load, we screened for host factors that 
can transcriptionally activate the HBV core promoter (HBVCP). We report here that poly 
(ADP-ribose) polymerase 1 (PARP1) which is known for its DNA repair activity binds 
prominently to an octamer motif in the HBVCP and increases transcriptional efficiency. 
By utilizing a series of single base substitutions at each nucleotide position of the 
octamer, the PARP1 binding motif can be defined as “RNNWCAAA”. Intriguingly, 
introduction of a vector construct bearing tandem repeats of the octamer motif was 
able to impair the DNA repair function of PARP1. This finding suggests that HBV viral 
DNA contains specific sequence motifs that may play a role in disrupting the DNA 
repair pathways of infected hepatocytes. Conclusion: This study has identified a novel 
octamer motif in the HBVCP which binds PARP1, and this interaction increases the 
replication efficiency of HBV. The presence of this octamer motif in hepatocytes was 
shown to inhibit the DNA repair capacity of PARP1, potentially contributing to the 
development of HCC. 
 
Chronic infection with the hepatitis B virus (HBV) contributes to more than half the world’s 
cases of hepatocellular carcinoma (HCC) (1). Several mechanisms have been proposed to 
account for HBV-associated HCC, including chronic inflammation and constant liver 
regeneration, oncogenic effects of viral proteins such as HBx and truncated pre-S2/S, as well 
as insertional mutagenesis of HBV genomes (2-4). However, occult HBV infection 
characterized by presence of HBV genomes in the absence of HBs expression can also lead 
to the development of HCC when chronic liver inflammation and viral DNA integration is 
minimal (5, 6). Furthermore, covalently closed circular DNA (cccDNA), a persistent replicative 
intermediate required for HBV replication is found in higher quantities in tumour tissues of 
HCC patients when compared to non-tumour tissues (7). Moreover, high HBV DNA load is a 
strong risk factor for the development of HCC (8-11). These suggest the possibility that HBV 






Chronic infection with HBV also leads to accumulation of genotoxic lesions such as oxidative 
DNA damage and DNA strand breaks (12). Many of these DNA lesions are repaired via 
pathways involving the poly (ADP-ribose) polymerase 1 (PARP1) (13, 14), where recognition 
of DNA strand breaks trigger its enzymatic activation, adding poly-ADP ribose (PAR) to 
protein acceptors required for the recruitment of DNA repair enzymes (15, 16). Consistent 
with the dependence on PAR for DNA repair, loss of PARP1 expression or enzymatic activity 
result in hypersensitivity to DNA damage inducers (17, 18) and spontaneous development of 
HCC (19-21). Interestingly, inhibition of PARP1 enzymatic activity has also been reported to 
increase HBV DNA integration (22), contributing further to the risk of developing HCC. 
 
Since high HBV DNA load leads to increased chance of HCC development, which is in turn 
associated with impaired DNA repair, we investigated whether the HBVCP-host interaction 
that regulates HBV genomic replication (23, 24) can alter the properties and function of 
nuclear proteins involved in the DNA repair pathways. Using a series of deletion mutants 
along the HBVCP to map host factor binding sites, PARP1 was uncovered to bind in a 
sequence-specific manner, exerting transcriptional activation effects to regulate HBV 
replication. Furthermore, by binding its recognition motif, its enzymatic activity was reduced, 
compromising cellular DNA repair.  
 
 
MATERIALS AND METHODS 
 
Cell culture. HepG2 was maintained at 37 oC, 5% (v/v) CO2 in a humidified incubator with 
complete Dulbecco’s modified Eagle’s medium supplemented with 10% (v/v) fetal bovine 
serum without antibiotics.  
 
Plasmids and siRNA. HBVCP deletions were generated using a multi-step strategy 





inserted via KpnI and HindIII restriction sites into the PGL3 Basic vector (Promega, Madison, 
WI). Using this as a template, sequences flanking either ends of the deletion (denoted “X”) 
were generated with primers PGLF and BX or primers PGLR and CX (Supporting Information 
Fig. 1B). Resultant products were annealed by complementary base-pairing, amplified with 
PGLF and PGLR then inserted into PGL3 Basic vector via KpnI and HindIII restriction sites. 
Single base substitutions were generated with the QuickChange® II Site-Directed 
Mutagenesis Kit (Stratagene, Santa Clara, CA). Full-length replicative HBV genotype A (1.1X 
HBV genome, nt 1535-1937) was amplified from another construct (25, 26) using the primers 
HBVF and HBVR, inserted into pcDNA3.1+ upstream of the CMV promoter via MfeI and MluI 
restriction sites. The coding sequence for RFP was cut from the pTurboFP635N plasmid 
(Evrogen, Moscow, Russia) and inserted via KpnI and NotI sites. The PARP1 motif construct 
was synthesized by annealing the oligomers PARP1motif-F and PARP1motif-R and inserted 
into pcDNA3.1+ vector via MfeI and MluI restriction sites. To synthesize the PARP1 over-
expression vector, total RNA was extracted using the NucleoSpin® RNA II kit (Machery Nagel, 
Germany) and reverse transcribed using the Accuscript® High Fidelity 1st Strand cDNA 
Synthesis Kit (Stratagene, Santa Clara, CA). The coding sequence was amplified with primers 
PARP1-F and PARP1-R, and inserted into pcDNA3.1+ via NheI and XhoI restriction sites. 
PARP1 specific knockdown was achieved with 10 nM Silencer® Select Validated siRNA 
#s1098 (Ambion, Austin, TX) while the Silencer® Select Negative Control #2 siRNA (Ambion, 
Austin, TX) was used as a non-specific control. Primer sequences are provided in Supporting 
Information Table 1.  
 
Protein extraction, immunoblotting, immunofluorescence. Lysates were extracted with 
the NE-PER kit (Thermo Scientific, Rockford, IL). Reducing SDS-PAGE and 
immunofluorescence were performed under standard reducing conditions. Cells were fixed 
with 4% paraformaldehyde (Sigma-Aldrich, St. Louis, MO). Primary antibodies (Santa-cruz, 
Santa Cruz, CA) for lamin B1 (sc-56145, 1:400), PARP1 (sc-74469X, 1:1000) and HBs (sc-






Luciferase assays. Dual-Luciferase® Reporter Assay System (Promega, Madison, WI) was 
used. 1.5 X 105 cells were seeded in 24-well plates and transfected with 2.2 μl Lipofectamine 
2000 (Invitrogen, San Diego, CA), 1 μg of PGL3 Basic construct plasmid and 15 ng of Renilla-
luciferase construct, then lysed 30 hours later with 60 μl buffer. Luminescence was measured 
using 50 μl lysate with the GloMax® Multi-Microplate Multimode Reader (Promega, Madison, 
WI) and normalized to that of the empty vector. 
EMSA, streptavidin pull-down and MALDI-TOF/TOF. EMSA was performed using the 
LightShift Chemiluminescent kit (Thermo Scientific, Rockford, IL) and 2 μg nuclear lysates, 1 
ng biotinylated probes (sense strand sequence 5’-TTGAGGCCTACTTCAAAGACTGTGTG-3’). 
Biotinylated EBNA probes provided were used as negative control. Binding was performed at 
37 oC for 45 minutes in 20 μl reactions with EMSA buffer (12.5% glycerol, 0.5 mM EDTA, 0.3 
mg BSA, 0.05% NP-40 and 1 μg poly-dIdC). 1 μl PARP1 antibody (sc-74469X, Santa-cruz, 
Santa Cruz, CA) was used. Streptavidin pull-down was performed with 10 μl of Dynabeads® 
M-280 Streptavidin (Invitrogen, San Diego, CA), 1 μg of biotinylated EMSA probe and 70 μg 
nuclear lysates in 100 μl reactions in EMSA buffer. Bound proteins were eluted by boiling and 
sent to the Protein and Proteomics Center in the National University of Singapore for MALDI-
TOF/TOF analysis. 
 
cccDNA assay. DNA was extracted using the DNeasy Blood and Tissue kit (Qiagen, 
Germany). Quantitative real-time PCR was performed using LightCycler® FastStart DNA 
MasterPLUS SYBR Green I (Roche, Switzerland) in 10 μl reactions containing 1 ng total DNA. 
cccDNA was amplified with primers cccF and cccR (Supporting Information Table 1), and 
normalized to the relative amount of pcDNA3.1+ amplified by primers pcDNA-F1 and pcDNA-
R1 (Supporting Information Table 1).  
 
PARP1 function, DNA damage and cell death assays. Histone H1 modification assay was 
performed with the PARP Universal Colorimetric Assay Kit (R&D Systems, Minneapolis, MN) 
and 5 μg nuclear lysates. 1 μl DNA duplexes (Supporting Information Table 2) formed by 





performed with the CometAssay® kit (Trevigen, Gaithersburg, MD) and scored using the 
TriTek CometScoreTM version 1.5 software. Annexin V staining was performed with annexin 
V-Fluos (Roche, Switzerland). Apoptosis was measured using the Caspase-Glo® 3/7 Assay 
(Promega, Madison, WI). 
 
Statistical analysis. F-test for equal variance followed by one-tailed student’s t-test with 





PARP1 is a novel transcriptional activator at the HBVCP 
 
To determine the host factors interacting specifically with the HBVCP that may be involved in 
transcriptional activation, DNA probes spanning the HBVCP were biotinylated and subjected 
to affinity pull-down assays. A strong band of approximately 120 kDa was selectively enriched 
from HepG2 nuclear lysate by the probe nt 1696-1722 of enhancer II (23, 24) within the 
HBVCP (Fig. 1A). MALDI-TOF/TOF analysis revealed that the bound protein was PARP1 (Fig. 
1A and Supporting Information Fig. 2). In agreement, nuclear lysates derived from PARP1 
siRNA treated cells were EMSA negative when tested with biotinylated nt 1696-1722 probe 
(Fig. 1B). The HBVCP-PARP1 interaction was further affirmed when both PARP1 specific 
antibody and excess unlabeled competitor probes significantly diminished complex formation. 
It is important to demonstrate that the HBVCP-PARP1 interaction was not due to binding of 
PARP1 to the free ends of the DNA probes. Addition of a 1000-fold excess of poly-dIdC failed 
to abolish complex formation whilst 100-fold excess of unlabeled HBVCP was sufficient to do 
so (Supporting Information Fig 3), providing confirmation for the sequence specific nature of 






PARP1 is also an important transcriptional regulator (27, 28) as studies of fibroblasts from 
PARP1-/- mice have altered expression of a large number of genes (29). To determine if the 
novel PARP1 binding site is transcriptionally functional, the effect of its deletion on HBVCP 
activity was investigated by a luciferase reporter assay in HepG2 cells (Fig. 1C). Consistent 
with enhancer II function (23, 24), all deletions resulted in the loss of luciferase expression. Of 
these, two overlapping deletions covering nt 1701-1721 that share the “TTCAAA” sequence 
had significantly reduced luciferase expression, indicating that this is the minimal motif 





PARP1 motif is well conserved in HBVCP 
 
To define the PARP1 recognition motif and map its precise site on the HBVCP, we generated 
scanning mutations of the “TTCAAA” sequence and 3 flanking nucleotide positions at either 
ends. All four base substitutions were tested at each position. The results indicate an absolute 
requirement for the “CAAA” sequence as any change would cause significant (>75%) 
reduction in luciferase expression (Fig. 2). The effect of nucleotide substitutions was seen to 
extend two positions 5’ of the “TTCAAA” motif such that an 8 nucleotide sequence 
“ACTTCAAA” was defined by the boundary where nucleotide substitutions flanking it had little 
effect on luciferase expression. Interestingly, only substitutions at position 3 of the octamer 
motif resulted in increased luciferase expression while all other substitutions were either 
neutral or deleterious. The PARP1 sequence dependent transcription motif can therefore be 
described as “RNNWCAAA”, where “R” is either “A” or “G”, “N” is any nucleotide, and “W” is 
either “A” or “T”, and the optimal sequence for PARP1 sequence dependent transcription is 
“ACATCAAA”. The data also suggests that the wild-type HBVCP PARP1 binding motif 
“ACTTCAAA” is a near-optimal PARP1 recognition motif. Curiously, HBV genome alignments 





HBV genotypes possess the “ACTTCAAA” PARP1 motif, whereas genotypes F and H 
possess the optimal “ACATCAAA” motif. This high degree of functional PARP1 motif 
conservation in the HBVCP reflects the importance of PARP1 to HBV replication. 
 
HBV replication is dependent on PARP1 
 
The HBVCP transcriptionally regulates synthesis of pgRNA which converts to cccDNA 
required for persistent HBV replication (30-32). To determine if HBV replication is dependent 
on PARP1, the effects of reduced PARP1 expression on cccDNA and HBs expression were 
investigated. HBV replication was established with a full-length genomic replicon (HBV-RFP) 
(25, 26) that is driven by native HBV promoters (Supporting Information Fig. 5) which enables 
HBs and cccDNA accumulation in transfected HepG2 cells (Fig. 3A). The effects of the loss of 
PARP1 expression was then tested in HepG2 cells pre-treated with PARP1 specific siRNA 24 
hours prior to HBV-RFP transfection when PARP1 expression was significantly reduced 
(Supporting Information Fig. 6). As anticipated, the loss of PARP1 resulted in the failure to 
accumulate cccDNA whereas cells treated with control siRNA were still able to do so (Fig. 3B). 
Furthermore, the expression of HBs was also significantly diminished in transfected cells pre-
treated with PARP1specific siRNA (Fig. 3C). These results concur with the loss of 
transcriptional activity by deletion of the PARP1 motif (Fig. 1C), providing evidence that HBV 
replication is dependent on HBVCP-PARP1 interaction.        
 
PARP1 motif inhibits PARP1 dependent ADP-ribosylation 
 
As PARP1 enzymatic activity is known to be activated by binding DNA strand breaks (15, 33), 
we investigated whether the same could be induced by the PARP1 binding motif. Using an in 
vitro histone H1 modification assay, we detected the amount of ADP-ribosylation activity in 
the presence of damaged DNA and 20 bp DNA duplexes bearing the “ACATCAAA” motif with 
endogenous PARP1 from HepG2 nuclear lysates (Fig 4).  Surprisingly, instead of increasing 





ribosylated histone H1 when compared to buffer control. The effect of the PARP1 motif was 
sequence-dependent, as mutations within the octamer core “ACATCAAA” sequence 
significantly diminished the capacity to block PARP1 dependent histone H1 modification. 
Furthermore, mutations to sequences flanking the motif showed no difference from the wild-
type sequence in ability to ADP-ribosylate histone H1, validating the PARP1 binding 
properties of the defined motif. These results suggest that, in contrast to damaged DNA which 
activates PARP1, binding the “ACATCAAA” sequence results in PARP1 inhibition. It is not 
clear at this point whether the PARP1 binding motif competes with damaged DNA for the 
same PARP1 binding site, but it appears that upon binding an optimal motif sequence, the 
PARP1-motif complex is stable and negates the activation of PARP1 to ADP-ribosylate 
targets. To demonstrate the relative potency of motif mediated PARP1 inhibition, nuclear 
lysates from HepG2 cells treated with PARP1 specific siRNA was shown to reduce histone 
H1 modification by 40% when compared with lysates from non-specific siRNA controls (Fig. 
4). This indicates that small amounts of active PARP1 is sufficient for histone H1 modification 
in vitro, thus the 25% reduction of ADP-ribosylated histone H1 achieved with the addition of 
wild-type PARP1 motif reflects that the bulk of PARP1 molecules was inhibited.  
 
Exogenous PARP1 motif impairs DNA repair 
 
Consistent with its ability to bind PARP1 for transcriptional activation, the “ACTTCAAA” 
HBVCP PARP1 binding motif could also interfere with histone H1 ADP-ribosylation (Fig. 5A). 
This raises the possibility that HBVCP-PARP1 interaction not only supports HBV replication, 
but also impairs PARP1 enzyme dependent functions such as DNA repair in vivo. If this were 
true, the ability of cells to effectively carry out DNA strand break repair when challenged by 
DNA damaging agents would be compromised. To verify this, a construct bearing the HBV 
PARP1 binding motif in three tandem copies (Fig. 5B) was tested for its capacity to inhibit 
cellular PARP1 enzymatic activity by determining the degree of DNA damage induced with 
etoposide (DNA single and double strand break inducer) or bleomycin (DNA double strand 
break inducer). Alkaline comet assays reveal that HepG2 cells transfected with the PARP1 





vector (Fig. 5C), reflecting enhanced DNA damage. This suggests that the ability of PARP1 to 
ADP-ribosylate protein targets required in DNA damage repair pathways was reduced, 
supporting the inhibitory role of HBVCP PARP1 motif expression on nuclear PARP1 
enzymatic activity. The effect of the PARP1 motif was further assessed for its ability to 
sensitize cells to induced cytotoxicity caused by DNA damaging agents. Consistent with 
accumulation of damaged DNA, etoposide or bleomycin treated HepG2 cells transfected with 
the PARP1 motif had a significantly larger population of annexin V positive cells (Fig. 5D). In 
contrast, DMSO treatment or vector control did not show significant changes in annexin V 
staining. The enhanced cytotoxicity towards sub-lethal amounts of etoposide and bleomycin 
in cells transfected with the motif is reminiscent of the hyper-sensitivity of PARP1 knockout 
and haploinsufficient mice towards DNA damaging agents (18, 20), reflecting compromised 
DNA repair with the loss of PARP1 enzymatic function. The ability of the PARP1 motif to 
specifically disrupt cellular PARP1 function was also demonstrated by diminished HBs 
expression in HepG2 cells co-transfected with HBV-RFP (Supporting Information Fig. 7). 
 
To confirm that the effects of the HBVCP PARP1 motif are specific to PARP1, rescue 
experiments were performed in which PARP1 was over-expressed to compensate for the loss 
of DNA repair. Excess PARP1 cannot avert the accumulation of cytotoxic DNA lesions if 
alternative DNA repair pathways were instead compromised. Using apoptotic cell death as 
the end-point of extensive irreparable DNA damage, the effect of etoposide or bleomycin on 
HepG2 cells co-transfected with the HBVCP PARP1 binding motif and PARP1 or RFP 
expression vectors was determined by apoptotic caspase dependent cleavage of luminogenic 
substrates.  As anticipated, increased sensitization to apoptosis was overcome by specific 
over-expression of PARP1 (Fig. 6), greatly reducing the enhanced caspase activities of cells 
transfected with the PARP1 binding motif when compared to vector controls. Conversely, 
over-expression of RFP had little effect on the sensitivity of transfected cells towards DNA 
damage induced apoptosis, demonstrating that the reduction in apoptosis towards induced 
DNA damage was PARP1 specific. Therefore, the HBVCP PARP1 binding motif is a specific 








A number of clinical epidemiological studies have demonstrated that patients with high viral 
DNA loads have significantly enhanced risk of developing HCC (8-11) although the reason for 
this remains unclear. To understand the regulation of HBV viral replication, we focused on the 
interaction of host transcription factors that influence HBVCP activity. A surprising finding is 
the specific recognition of a DNA binding motif in the HBVCP by the PARP1 DNA repair 
enzyme. Interestingly, HBV is not the only oncogenic DNA virus with a functional PARP1 
binding motif. Similar PARP1 binding sequences have been found on the human T-cell 
leukemia virus Tax responsive element (HTLV Tax RE) and shown to be required for 
transcriptional activation (34). The Kaposi’s sarcoma-associated virus has also been shown to 
bind PARP1 via its DNA for genomic maintenance and replication (35). Consistent with the 
suppression of PARP1 dependent poly-ADP ribosylation by motif recognition, inhibition of 
PARP1 has been shown to enhance PARP1 motif-dependent transcription resulting in 
increased viral transcripts and genome copies (34, 35). The inhibition of PARP1 thus could be 
a pre-requisite for motif recognition and transcriptional activation, as inhibiting auto-
modification prevents PAR-mediated electrostatic repulsion from DNA (16, 36) to enable 
PARP1 retention on its recognition motif for the transcriptional apparatus to assemble. 
Besides transcriptional regulation, viruses such as the human immunodeficiency virus and 
HBV itself also make use of PARP1 for genomic integration, the process in which is also 
enhanced by enzymatic inhibition (22, 37). The requirement for enzymatically inactive PARP1 
for transcription and genomic integration suggest that PARP1 inhibition may be a common 
mechanism utilized by viruses for replication and in doing so impairs DNA repair, leading to 
enhanced risk of developing malignancy. This is supported by evidence that individuals with 
decreased PARP1 enzymatic activity have increased risks of developing cancers (38, 39). 
Perhaps low PARP1 enzymatic activity is also a risk factor for chronic infections and renders 
chronic carriers of PARP1 dependent viruses susceptible to cancer development.  
 
Even though PARP1 can bind DNA in a sequence-dependent manner to carry out 





studying the effects of single base substitutions on PARP1 dependent transcription, the 
octamer “RNNWCAAA” was shown to be the minimal motif required for transcriptional activity 
(Fig. 2). Importantly, in agreement with our data, substituting “A” with “C” at position 1 of the 
SMARCB1 promoter had been associated with decreased PARP1 dependent transcriptional 
activity (41). Within the PARP1 binding site of the HTLV Tax RE, mutating nucleotides 5 and 
6 from “CA” to “AC” abolished PARP1 binding while substitutions at positions 2 and 3 were 
less important for the functional specificity of the motif (34). Furthermore, in line with the 
deleterious effects of nucleotide substitution, changing position 5 from “C” to “T” at the Bcl-6 
PARP1 binding site resulted in abrogation of PARP1 dependent transcription (42). These data 
are congruent with our findings that nucleotide positions 5 and 6 are critical for PARP1 
dependent transcriptional activation while nucleotide positions 2 and 3 of the octamer are less 
so. Thus, the “RNNWCAAA” octamer may be used to describe the PARP1 motif that also 
reflects the relative contribution of each nucleotide position to bind PARP1 required for 
transcription. 
 
PARP1 hyperactivity has been associated with various disease states such as cancer (43, 44). 
A survey of 37 HCC patient tumor samples with its matched non-tumor tissue showed that 
PARP1 mRNA is on average 1.11-fold (range 0.98-1.21) above the mean of non-tumor 
tissues (Supporting Information Table 3) and therefore indicate that the PARP1 levels in 
HepG2 liver cell line does not deviate significantly from physiological levels. Suppression of 
PARP1 enzymatic activity by general PARP inhibitors is thought to have therapeutic potential 
as they have been shown to enhance the cytotoxic potential of DNA damaging agents in 
clinical trials (43, 44). In contrast to binding DNA strand breaks for DNA repair, the capacity 
for PARP1 to ADP-ribosylate histone H1 surprisingly decreased when bound by the PARP1 
motif (Fig. 4). Similar to how HBV DNA impairs cellular PARP1 functions, we propose that 
exogenous DNA bearing the PARP1 binding motif can function as a cognate ligand for 
PARP1 that interferes with its ability to carry out DNA repair, enhancing synthetic lethality of 
chemotherapeutic agents. Indeed, transfection of a synthetic construct bearing tandem 
repeats of the HBVCP PARP1 binding motif was able to increase cytotoxicity of HepG2 HCC 





binding motif produced PARP1 as the only interacting protein (Fig. 1), the specificity of the 
PARP1 binding motif for PARP1 would be advantageous over current PARP inhibitors, 
potentially reducing adverse effects associated with inhibition of other PARP family members 
targeted by general PARP inhibitors (28, 45). Understanding how PARP1 inhibition is 
achieved by engaging a specific DNA binding motif would also shed light on how the enzyme 
is allosterically regulated.  
 
In conclusion, this study describes the identification of a specific PARP1 binding site in the 
HBVCP and its role as a recognition motif for PARP1 dependent transcription. The PARP1 
motif also possesses enzymatic inhibitory properties, resulting in impaired DNA repair and the 
accumulation of damaged DNA when exogenously expressed in cells. This finding suggests 
that HBV DNA impairs PARP1 cellular functions, which may contribute to genomic instability 
over time. Taken together, the results indicate that the HBV PARP1 binding motif is not only 
important for HBV replication, but also suppresses PARP1 dependent DNA repair, providing a 
novel mechanism to explain the association between high HBV DNA loads and the increased 
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Fig. 1. PARP1 is a novel transcriptional activator at the HBVCP. (A) Selective enrichment of 
an approximately 120 kDa protein using 1 μg of the biotinylated HBVCP probe (5’-
TTGAGGCCTACTTCAAAGACTGTGTGT-3’) in affinity pull-down assays from 70 μg HepG2 
nuclear lysates. The MALDI-TOF/TOF result identifies PARP1 as the specific binder. 
Sequenced peptides are underlined and bold. (B) 1 ng of biotinylated HBVCP probe was 
incubated with 2 μg HepG2 nuclear lysates treated with non-specific siRNA. The binding 
complex formed in the presence of 1 μg poly-dIdC could be removed with 100-fold excess of 
unlabeled probe, PARP1 specific antibody or with the use of nuclear lysates with PARP1 
specific knock-down (K/D). The relative amounts of PARP1 in the nuclear lysates used are 
shown. (C) Deduction of the putative PARP1 binding site by luciferase reporter assays. The 
HBVCP fragment (nt 1600-1860) was cloned upstream of a luciferase reporter construct; five 
constructs were generated in which each contained a 15 bp deletion that overlaps to span nt 
1689-1727. Results show normalized mean luminescence ± SE relative to the wild-type 
promoter of three independent experiments performed in triplicates. The exact nucleotides 
deleted in each construct are represented by gray lines. 
 
Fig. 2. The PARP1 recognition motif. The effect of all possible single base substitutions on the 
predicted PARP1 core motif “TTCAAA” and the 3 bases flanking either of its sides were 
determined by examining altered luciferase expression. Results show mean normalized 
luminescence ± SE of triplicates relative to that of the wild-type promoter. Relative positions of 
each nucleotide with respect to the defined PARP1 binding motif are indicated.   
 
Fig. 3. HBV replication is dependent on PARP1. (A) HBV replication in HepG2 is indicated by 
the production of HBV surface antigens in cytoplasmic lysates and the accumulation of 
cccDNA with time. (B) Effect of PARP1 specific knock-down on HBV replication as indicated 
by cccDNA fold-change relative to 6 hours post-transfection. Values represent mean fold-





student’s t-test. (C) Effect of PARP1 specific knock-down on enhancer II function as 
determined by immunofluorescence (IF) staining for HBs expression 60 hours after siRNA 
treatment. HBV-RFP transfected cells fluoresce red.  
 
Fig. 4. PARP1 motif reduces PARP1 enzymatic activity in vitro.  The effect of PARP1 binding 
to 20 bp DNA duplexes containing the PARP1 motif “ACATCAAA” (highlighted) on PARP1 
enzymatic activity was investigated by histone H1 modification assays. Mutations to the 
duplex sequence are shown in bold. The effect of PARP1 specific knock-down (K/D) on 
PARP1 activity is also shown for comparison to demonstrate that the near absence of PARP1 
expression reduces in vitro histone H1 modification by 40%. Means of an experiment ± SE 
performed in triplicates are shown. **P < 0.01 using one-tailed student’s t-test.  
 
Fig. 5. Exogenous PARP1 motif impairs cellular DNA repair. (A) Inhibition of PARP1 
dependent histone H1 modification by short DNA duplexes containing the “ACTTCAAA” 
HBVCP PARP1 binding motif. The mean ± SE reduction in histone H1 modification of 
triplicates with the viral PARP1 motif relative to buffer control was analyzed using one-tailed 
student’s t-test with equal variance. ***P < 0.001. (B) Construct containing the HBVCP 
PARP1 binding motif “ACTTCAAA” in tandem repeats. (C) The extent of DNA damage 
visualized by alkaline comet assays induced with 50 nM etoposide and 20 ng/ml bleomycin in 
HepG2 cells transfected PARP1 motif construct of independent experiments is as plotted and 
analyzed using one-tailed student’s t-test. Cells transfected with empty vector were used as 
controls. Bars indicate the median extent of DNA damage. ***P < 0.001 with one-tailed t-test 
(D) HBVCP PARP1 motif sensitizes cells to apoptosis by DNA damaging agents. Dying cells 
stain positive by annexin V staining resulting from irreparable DNA damage induced by 50 nM 
etoposide or 20 ng/ml bleomycin. 0.01% DMSO and empty vectors were used as controls. 
 
Fig. 6. PARP1 motif dependent enhanced cytotoxicity to induced DNA damage is PARP1 
specific. Exogenous PARP1 was readily detectable in 10 μg of HepG2 nuclear lysates within 





PARP1 binding motif and 500 ng of the PARP1 over-expression plasmid were co-transfected 
into HepG2 cells, and the mean percentage ± SE increase in caspase activity associated with 
the PARP1 motif relative to the empty vector was compared to that of RFP over-expression. 
DNA damage was induced by 100 nM etoposide or 10 ng/ml bleomycin of independent 





Supporting Information Fig. 1. Generation of luciferase assay constructs with 15 bp deletions. 
(A) Schematic of relative positions of primers used to generate 5’ and 3’ sequences flanking 
of each deletion. (B) Primer sequences used to generate each flanking sequence. 
 
Supporting Information Fig. 2. A second, independent experiment of an affinity pull-down 
assay to identify the bound complex was analyzed by MALDI-TOF/TOF. The results provide 
additional confirmatory data (Fig. 1A) demonstrating the specificity of PARP1 for the HBVCP 
probe. 
 
Supporting Information Fig. 3. PARP1 binds the HBVCP in a sequence dependent manner. 
Large excess of 1000-fold poly-dIdC cannot diminish the PARP1 specific complex, whereas 
100-fold of unlabeled HBVCP probe was sufficient to do so.   
 
Supporting Information Fig. 4. The PARP1 binding motif is conserved in the HBVCP. Gen A = 
Genotype A; n = number of aligned sequences. 
 
Supporting Information Fig. 5. The HBV-RFP construct. 1.1-fold of the viral genome was 
inserted upstream of the CMV promoter, thus viral replication depended only on host factors 
that bind the HBVCP (CP). A short stretch of the replicon, including the HBVCP and the poly-





Constitutive expression of red fluorescent protein (RFP) driven by the CMV promoter was 
used to show transfection into cells.  
 
Supporting Information Fig. 6. PARP1 specific knockdown can be achieved within 24 hours of 
transfecting PARP1 specific siRNA. The effects of the PARP1 specific siRNA can last at least 
48 hours. 
 
Supporting Information Fig. 7. Inhibition of PARP1 function by exogenous PARP1 binding 
motif. Co-transfection of 1 μg of the HBV-RFP with 500 ng of the plasmid containing the 
HBVCP PARP1 binding motif results in a reduction of enhancer II function as shown by a 
reduction in HBs expression in HepG2 cells 60 hours post-transfection. Cells co-transfected 





















Supporting Information Table 1.  Primer sequences for cloning and quantitative real-time PCR. 
 

























DNA duplex  Sense strand  Antisense strand  
Wild-type 
PARP1motif  
5’-ACGTCTACATCAAAGTTGCA-3’  5’-TGCAACTTTGATGTAGACGT-3’  
“CC” mutation 
flanking motif  
5’-CCGTCTACATCAAAGTTGCA-3’  5’-TGCAACTTTGATGTAGACGG-3’ 
“CTA” mutation 
flanking motif  
5’-CTATCTACATCAAAGTTGCA-3’  5’-TGCAACTTTGATGTAGATAG-3’  
“C” mutation 
within motif  
5’-ACGTCTACATCCAAGTTGCA-3’  5’-TGCAACTTGGATGTAGACGT-3’ 
“GC” mutation 
within motif  
5’-ACGTCTACATGCAAGTTGCA-3’  5’-TGCAACTTGCATGTAGACGT-3’ 
“GGC” mutation 
















Supporting Information Table 3.  Relative PARP1 mRNA expression in paired tumor and non-
tumor samples. 
 
Paired sample 
PARP1 expression 
Tumor/ Non-tumor 
HCC93 0.98 
HCC171 0.99 
HCC188 1.00 
HCC100 1.01 
HCC159 1.04 
HCC174 1.05 
HCC182 1.05 
HCC98 1.06 
HCC112 1.06 
HCC111 1.06 
HCC63 1.07 
HCC128 1.08 
HCC13 1.08 
HCC155 1.09 
HCC130 1.09 
HCC69 1.10 
HCC107 1.11 
HCC85 1.12 
HCC86 1.12 
HCC154 1.12 
HCC77 1.12 
HCC124 1.13 
HCC103 1.13 
HCC102 1.14 
HCC83 1.14 
HCC163 1.14 
HCC101 1.14 
HCC99 1.15 
HCC105 1.16 
HCC67 1.17 
HCC168 1.18 
HCC96 1.18 
HCC110 1.19 
HCC81 1.19 
HCC118 1.19 
HCC90 1.20 
HCC64 1.21 
Mean 1.11 
SD 0.06 
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